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Abstract
The objective of this work was to develop materials for continuous low-dose delivery of
cisplatin directly into the abdomen, also known as intraperitoneal (IP) chemotherapy. IP
chemotherapy can help treat peritoneal metastasis in many advanced gynecologic and
gastrointestinal cancers and has shown particular promise in treating advanced ovarian
cancer. It is however tremendously underutilized because it requires a lot of resources
and the current technology and maximum tolerated dose regimen cause complications
and severe toxicity to patients.
We previously showed that continuous low-dose IP cisplatin delivery via an
implanted diffusion-based reservoir device can be as effective as and less toxic than
intermittent maximum tolerated dose IP injections. To translate this work to a clinically
relevant implantable system, we developed composite materials that can deliver
cisplatin at a continuous low dose that is tunable. The materials were mechanically well
suited for placement in the abdomen and were evaluated for in vitro bioactivity, in
vivo tolerability and in vivo ability to deliver platinum to key abdominal organs with
promising results. Dosing studies with different material dimensions helped identify a
dose to pilot treatment of ovarian cancer in human xenograft-bearing mice.
The implications of more accessible and affordable IP chemotherapy are
especially important in countries with limited resources. Design reviews and a clinician
survey in India reveal eagerness for early adoption of new technologies and dosing
regimens to treat peritoneal metastasis and show promise for utilization of our implant in
the developing world.
The work described in this thesis carries implications for the treatment of
advanced ovarian cancer and peritoneal metastasis of other tumors affecting millions of
patients worldwide and may help with the management of nonmalignant conditions with
abdominal involvement.
Thesis Supervisor: Michael J. Cima, PhD
Title: David H. Koch Professor of Engineering
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Chapter 1: Background
1.1 Intraperitoneal Drug Delivery
1.1.1 Background and Rationale
Intraperitoneal (lP) drug delivery is the administration of drugs directly into the
peritoneal cavity. The peritoneal cavity is a potential space defined by the peritoneum -
a serous membrane that surrounds the abdominal organs - that has been used widely
for metabolite removal and drug administration because of its large surface area (-2 m 2
in adult humans) and the extensive blood flow through the tissues around it.1 ,2 The
peritoneal cavity of healthy individuals contains between 5 - 20 mL of serous exudate,
which can reach up to 200 mL in women at different phases of the menstrual cycle.
Certain pathologic conditions may lead to excessive accumulation of peritoneal fluid,
called ascites.
The peritoneal cavity is a frequent site of localized disease, is in intimate
contact with many important abdominal organs and is an anatomically privileged
compartment because the peritoneal-plasma barrier doesn't allow intracavitary
partitioning of systemically administered drugs.2 Solutes introduced intraperitoneally are
metabolized in the cavity or leave it either via the lymphatics by bulk flow or via the
tissue by convection and diffusion (Figure 1.1).5 Solutes that leave the cavity via the
visceral peritoneum that drains in the portal circulation may be inactivated by first-pass
liver metabolism. This reduces systemic drug exposure while maximizing therapeutic
advantage to treat localized disease. Solutes that reach the capillaries in the interstitium
surrounding and supporting the peritoneum may enter the general circulation via
12
exchange with the plasma. The major resistances to transport are the capillary
endothelium and cell-matrix system around the capillaries. Water and low molecular
weight solutes are absorbed mainly via diffusion from the peritoneum with convection
becoming increasingly important as the solute molecular weight increases. Lymphatic
flow is negligible for small molecules.7 High molecular weight solutes are removed
primarily via lymphatic drainage.7
IP drug delivery has been used to treat both localized and systemic diseases.
Insulin is added to the dialysate of diabetic patients who undergo peritoneal dialysis
while continuous IP insulin infusion has been found to be superior to subcutaneous
insulin therapy in type 1 diabetes mellitus.8'9 IP administration of antibiotics to combat
dialysis-related peritonitis and IP chemotherapy to palliate malignant ascites are two of
the earliest applications of IP therapy against regional disease.1 011 IP drug delivery to
treat peritoneal tumors received renewed interest in 1978 after Dedrick et al. published
a paper presenting a pharmacokinetic rationale for the regional treatment of peritoneally
metastasized ovarian cancer.10,1
Chemotherapeutic agent
Lung
Peritoneal cavity -- Liver cictione
K* (Liver)
Figure 1.1: Pharmacologic rationale of IP chemotherapy
administration. Adapted with permission.
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1.1.2 Intraperitoneal Chemotherapy for Ovarian Cancer Treatment
Peritoneal metastasis is the spread of cancer to the peritoneal cavity and can affect
patients who suffer from cancers primarily of the abdomen and pelvis (e.g. ovarian,
gastrointestinal) but also cancers of the breast, skin or lung.13 Peritoneal metastasis
seeds the cavity with tumors and fills it with malignant fluid called ascites (Figure 1.2).
The prognosis of patients with peritoneal metastasis is very grim as it is usually a sign of
terminal disease.
IP delivery of chemotherapy improves treatment outcome for patients with
peritoneal metastasis and has found particular application in the management of
ovarian cancer. Ovarian cancer is the main cause of gynecologic cancer death in the
developed world.14 The disease will affect an estimated 22,240 women and kill 14,070
women in the US in 2018.'1 Patients face an average five-year survival of 47.4% but
survival statistics are a lot better when the disease is diagnosed early (stage 1-1).'5 Only
about 35% of ovarian cancer patients are however diagnosed at an early stage.' 5
Advanced-stage ovarian cancer patients face a five-year relative survival lower than
30%.16 IP treatment with platinum agents has been the single biggest breakthrough for
more than 20 years.10 12" 7
The superiority of ovarian cancer treatment with IP chemotherapy compared to
intravenous (IV) chemotherapy alone has been demonstrated both in clinical trials
(improving overall survival by 16 months)' 8 and in clinical practice (improving 3-year
survival by 10%).19 This led the National Cancer Institute to make a clinical
announcement in 2006 supporting IP chemotherapy to treat advanced ovarian cancer.
More than a decade later, academic and media publications have repeatedly highlighted
14
extremely poor adoption statistics for IP chemotherapy against ovarian cancer despite
evidence supporting its use.19-22
Adoption barriers facing IP chemotherapy stem primarily from the way that it is
administered. The patient receives six cycles of high-dose chemotherapy infusions
spaced three weeks apart to allow recovery from drug toxicity. The drug is dissolved in
2 L of saline and administered through an indwelling catheter that is connected to a port
implanted on the patient's abdominal wall. More than 50% of ovarian cancer patients in
clinical trials and 20% of ovarian cancer patients in clinical care discontinue IP therapy
before completing all six cycles.18 19 These patients drop out primarily because of
toxicity from the high-dose infusions and complications from the catheter and port
(infections, blockages, leaks among others).1 8'1 9 IP chemotherapy is extremely
underused as a result, despite its demonstrated advantage in clinical trials and in the
clinic (Figure 1.3A). It was given to fewer than half of eligible ovarian cancer patients
treated across six National Comprehensive Cancer Network centers from 2003 to 2012
(Figure 1.3B).19 Adoption variability ranged from 4% to 67% of eligible patients between
these centers.' 9 Adoption statistics are expected to be worse in non-elite cancer
centers. Most ovarian cancer patients receive care at such non-specialized facilities,
and therefore lack access to IP chemotherapy even though they could benefit from it.
Adoption statistics are also bound to be worse for cancers that have shown a smaller
advantage with IP chemotherapy making it even less appealing as a treatment option
given the toxicities and complications associated with its administration.
15
Surgical
debulking
0 0
~ 2L
IP
chemot herapy
Every 3 weeks for 6
cycles:
- 1OOmg/m2 bodySA
IP cisplatin (day 2)
. 60 mg/M 2 body SA IP
paclitaxel (day 8)
0 Tumors = Malignant ascites Chemotherapy solution
Figure 1.2: IP chemotherapy treatment regimen. The patient undergoes tumor debulking
surgery to remove as much of the tumor burden as possible that commonly also removes the
omentum, the ovaries and uterus, parts of the bowels and other affected organs that can be
safely removed. A peritoneal catheter and port are also placed in the patient's abdomen to
allow future access of the peritoneal cavity for IP chemotherapy administration. Surgery is
followed by a break to allow the patient to recover and then six cycles of IP chemotherapy
usually comprising a platinum and a taxane agent. The regimen shown here is the
recommended dosing regimen following the Gynecologic Oncology Group (GOG) clinical trial
172. Modified dosing is frequently used to tailor the treatment to the patient's health status or
when given in clinical trials evaluating dosing to maximize treatment while reducing toxicity.
The chemotherapy is given as a two-liter infusion over the course of multiple hours and the
patient is asked to change positions and rotate frequently to better distribute the drug solution.
This regimen leads to many debilitating side effects including catheter and port infections,
blockages or leaks, nausea and vomiting, tissue perforation and bowel obstruction.1 ,23-25
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Figure 1.3: Use and outcomes of IP chemotherapy against ovarian cancer
in the clinic. (A) Overall patient survival for ovarian cancer patients treated
with a combination of IP and IV chemotherapy (blue line) or IV
chemotherapy alone (yellow line) in six national cancer hospitals between
2003 and 2012. (B) Percentage of eligible ovarian cancer patients
receiving combination IP/IV chemotherapy (blue) vs. IV chemotherapy
alone (yellow) in the same hospitals between 2003 and 2012. Adapted
with permission.19
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1.1.3 Existing Tools and Other Solutions for Sustained IP Chemotherapy
The first peritoneal access systems were devices such as rubber catheters and sump
drains that were borrowed from other fields like general surgery to use in peritoneal
dialysis.26 Serious complications resulting from those borrowed access systems and a
growing interest in peritoneal dialysis led to the development of dedicated access tools,
which improved patient outcomes and increased adoption of peritoneal dialysis.2728
Drug delivery to the peritoneal cavity has been employed for centuries but there exist no
peritoneal access tools specifically designed for the purpose of IP drug administration,
which is instead carried out using devices borrowed from peritoneal dialysis. The
catheter and port used for IP chemotherapy require specially trained nursing staff for
infusions.2 9 They are prone to infections, blockages and leaks. 29 Every infusion can
cause respiratory distress, nausea, diarrhea, and other immediate side effects because
of the mutliliter fluid that is rapidly instilled into the peritoneal cavity.2 9 The tools currently
available therefore play a critical role in limiting clinical adoption of IP chemotherapy.
Sustained exposure to chemotherapy is hypothesized to improve antitumor
efficacy by limiting treatment-free periods during which resistant tumor cells are given
the opportunity to multiply.30,' There have been previous attempts to achieve localized
and sustained chemotherapy delivery to the peritoneal cavity but they face several
challenges related to the control of their drug release profile and the safety of their use
in patients. The most notable examples are polymeric nanoparticles and microparticles
as well as injectable gels and films that are placed at the desired site and release the
contained drug over a period of time. 32-39 These modalities rely on bulk degradation to
release drug and can therefore achieve only short-lasting, non-linear release .40 41 They
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also lose their mechanical integrity as they degrade, which would compromise the
surgeon's ability to revise or remove them safely. Particles for targeted drug delivery
face the additional challenge of achieving adequate concentrations near the site of
disease often requiring local administration.42 Nanoparticles are rapidly cleared from the
peritoneal cavity via the lymphatics and so require frequent readministration.39,4 3
Microparticles have longer retention times but suffer from documented material-
associated toxicities.35 ,39 ,4 3 Gels and films developed in the literature to date would
scale up to dimensions that would be unrealistic for implantation in human patients in
order to carry the required drug payload and often exhibit material properties like
increased viscosity that make them untenable for injection.3 1374446 Many of the existing
studies of sustained-release IP chemotherapy systems have additionally limited the
duration of treatment to 3 weeks or less making their findings less clinically relevant in
comparison to the 18-week duration of the current IP chemotherapy standard of
care. 4
5
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1.1.4 Proposed Solution
Nondegradable diffusion-based reservoir devices for controlled zero-order cisplatin
release were previously created in our lab and used for continuous low-dose IP delivery
of cisplatin in mouse models of ovarian cancer over a period of six weeks. The
antitumor efficacy of the devices was comparable to that of periodic high-dose IP
injections of cisplatin while toxicity was reduced.45 Continuous chemotherapy is
additionally thought to reduce the incidence of drug-resistant cancer clones by
preventing their proliferation during treatment-free periods.47
19
The goal of this thesis was to translate these mouse findings to an implant for
continuous low-dose IP cisplatin delivery in humans that is relevant to the clinical setting
in specialized cancer centers as well as more resource-constrained facilities. The
proposed solution is based on a composite nonresorbable material that can accomplish
continuous low-dose cisplatin delivery to the peritoneal cavity while mechanically
matching the properties of the surrounding tissues and maximizing the surface area for
drug release to treat microscopic metastases left behind after surgical debulking. Solid
drug is incorporated into the composite matrix without undergoing dissolution to
maximize the payload while minimizing implant dimensions. A sacrificial excipient is
added with the aim to create interconnected paths within the composite cross-section
and so enable removal of the incorporated drug. The composite material is envisioned
to form the basis for deployable thin sheets designed for IP placement by minimally
invasive laparoscopy. The design of these deployable implants draws inspiration from
origami tessellations (e.g. v-pleats, Miura ori) to create a drug-eluting collapsible sheet
that can be placed and removed using laparoscopic tools. The sustained low-dose
delivery of cisplatin from the implant is expected to maximize patient tolerability of the
full course of IP chemotherapy due to the reduced morbidity expected from this dosing
regimen and from eliminating catheter-and-port complications. The number of hospital
visits required for treatment will be reduced to just two with no need for periodic
infusions while full control of treatment will be given to clinicians in the operating room
making the implant an attractive solution for resource-constrained settings. The clinical
significance of the proposed solution may extend to treatment of peritoneal metastasis
20
of other cancers and even to peritoneal drug delivery for treatment of non-malignant
conditions.
1.1.5 Selection of Intraperitoneal Chemotherapy Agent for Ovarian Cancer
Treatment
The pharmacologic rationale behind IP drug administration is based on both drug
uptake by the systemic circulation and drug intracavitary localization to achieve
therapeutic concentrations at the site of regional disease. The antitumor effectiveness of
IP chemotherapy to treat ovarian cancer is driven by: (1) the activity of the drug against
ovarian cancer; (2) direct drug penetration into peritoneal tumors via the tumor surface;
and (3) diffusion into the inner core of vascularized tumors as well as treatment of any
distant metastases by entering the systemic circulation. Drug absorption from the
peritoneal cavity is faster with increasing lipophilicity while increasing molecular weight
leads to intracavitary sequestration.7 ' 48 Drug inactivation by first-pass liver metabolism if
absorbed into the systemic circulation via the visceral peritoneum may be problematic
for treating distant metastases and for diffusing into the inner tumor core but beneficial
for reducing systemic side effects. Drugs that are vesicants or major irritants when
administered intraperitoneally can cause peritoneal inflammation with significant pain
and adhesion formation that may affect intracavitary drug distribution and lead to more
serious toxicity like bowel obstruction.49 The ideal agent for IP chemotherapy has thus
been described as one that: (1) is not toxic to the peritoneal lining; (2) has documented
and concentration-dependent activity against the targeted malignancy; (3) is highly
effective systemically against the malignancy; (4) can penetrate deep into the tumor;
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and (5) is removed slowly from the peritoneal cavity but rapidly from the systemic
circulation to maximize the IP pharmacologic advantage. 12 '23 49
High peritoneal-to-plasma concentration ratios can be achieved for many
commonly used chemotherapeutics with IP administration. Table 1.1 summarizes the
chemical properties and pharmacokinetic advantage of IP administration of commonly
used chemotherapeutic agents. Selection of the drug to be incorporated into the
composite matrix must take into account barriers to adoption of the proposed implant
along with chances of success of the proposed dosing mechanism and regimen. The
only agents currently approved for IP administration are cisplatin and paclitaxel.46
Platinum chemotherapy is a cornerstone in ovarian cancer treatment and is one of the
most extensively studied types of chemotherapy for IP administration. The platinum
agents cisplatin and carboplatin both achieve a comparable pharmacokinetic advantage
of 10-20-fold when given intraperitoneally but the bulk of data in support of superior
treatment efficacy has come from trials using IP cisplatin . 5051 An early study of IP
carboplatin vs. IP cisplatin in rats by Los et al. found that the former required
administration of a 6-10 - fold higher concentration than the latter to achieve
comparable levels within peritoneal tumors. Markman et al. then looked retrospectively
at the response rate of patients with small-volume residual ovarian cancer treated on
salvage cisplatin- or carboplatin-based IP chemotherapy regimens. They found that
patients with microscopic residual tumors had an identical surgically documented
complete response rate regardless of drug. Patients with small-volume residual
macroscopic tumors (< 0.5 cm) in contrast responded significantly better to IP cisplatin
(41% and 71% complete and overall response rate respectively) than to IP carboplatin
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(11 % and 32% complete and overall response rate respectively). It has been pointed
out however that the dose Markman and coauthors looked at may have been too low
since they assumed dose equivalency between carboplatin and cisplatin that may have
been erroneous, while the accuracy of the peritoneal tumor penetration in rats reported
by Los et al. has been questioned and has not been replicated successfully.49 51 It is
also important to note that carboplatin has been found to cause less toxicity and side
effects both via the IV and the IP route and the availability of encouraging clinical trial
data for IP carboplatin has been increasing making it a promising candidate for future
work in this project. Paclitaxel has a tremendous pharmacokinetic advantage of 1000-
fold when given intraperitoneally but is water-insoluble requiring special formulations for
IP administration and suffers from dose-limiting local side effects like abdominal pain
that necessitate reduced systemic exposure compared to IV administration.12
Cisplatin was the chemotherapeutic agent previously used in our lab to
demonstrate the viability of sustained low-dose IP chemotherapy as a treatment
regimen in mouse ovarian cancer models. These previous data along with the extensive
body of findings in support of IP cisplatin administration for ovarian cancer treatment
and the fact that cisplatin has been approved for IP delivery make this drug an
appropriate first choice for development of the proposed chemotherapy-eluting material
for an IP implant. The implant is however intended to function as a platform that can be
modified to release other chemotherapeutic agents as well. Table 1.1 illustrates that,
beyond the potential of carboplatin for continuous low-dose IP delivery, the peritoneal-
to-plasma concentration ratios for other common chemotherapeutics are even more
striking than those for platinum agents suggesting an even greater potential
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pharmacokinetic advantage. Some of these agents suffer from significant and obvious
drawbacks making them less attractive for incorporation into the implant described in
this thesis while others seem to hold promise for future studies
Agent
Cisplatin
Carboplatin
Gemcitabine
Topotecan
Mitomycin
Doxorubicin
5-fluorouracil
Paclitaxel
Mitoxantrone
Melphalan
Methotrexate
Docetaxel
Molecular
weight
300.05
371.25
263.20
421.45
334.33
543.53
130.08
853.92
517.40
305.20
454.44
807.88
Log P
(T 250C)
-2.27
-1.89 0.41
-2.216 0.487
0.318 1.142
-0.298 0.542
0.239 1.028
-0.649 0.237
3.950 0.808
1.548 1.475
0.536 0.428
-0.446 0.869
2.456 0.657
Water
solubility
+
+
+
+
-+
expanding this work.
Peritoneal cavity /
plasma drug level ratio
Peak AUC
20 12
24 10-18
759
54
71
474
298
93
92
367
1000
1400
65
100
181
Table 1.1: Chemical properties and pharmacokinetic advantage of chemotherapeutic agents
when delivered intraperitoneally. AUC = area under the concentration-time curve. Partition
coefficient log P values are obtained using SciFinder. Water solubility indices and peritoneal
cavity / plasma drug level ratios are adapted from Fujiwara et al. (2007).
Doxorubicin, 5-fluorouracil, mitoxantrone, methotrexate and docetaxel are less
attractive candidates for expansion of this work. Doxorubicin has showed limited
penetration into the outermost four to six cell layers of peritoneal tumors in mice as well
as into multicellular tumor spheroids in vitro, 3 Methotrexate similarly suffers from limited
penetration into avascular tumors.2 3 5-fluorouracil has shown more promising data
regarding penetration into tumor nodules but commonly causes chemical peritonitis.54
Mitoxantrone has been reported to suffer from dose-limiting local toxicities similar to
those seen with doxorubicin and paclitaxel while docetaxel has been found to cause
gastrointestinal toxicity following IP administration.55
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Gemcitabine, topotecan or perhaps even mitomycin may warrant further
exploration to make the implant a platform for IP chemotherapy delivery. Gemcitabine
demonstrated an impressive peritoneal/plasma AUC ratio of 759 in phase 1/2 studies
and has a high total body clearance and little evidence of local toxicity in animals.56' 57 IP
gemcitabine has already been used with success against peritoneal metastasis
primarily of pancreatic and ovarian cancers although some have reported significant
local toxicities including peritoneal irritation and adhesions in patients.57-60 Topotecan is
also an interesting candidate that has already been deemed tolerable for IP
administration in ovarian cancer patients and tested as consolidation IP chemotherapy
in phase 2 trials in ovarian and primary peritoneal cancer with good results.6 1-63 A 2015
paper by Previs et al. highlighted promising preclinical findings of dual metronomic
chemotherapy with IP nab-paclitaxel every other day and daily oral topotecan against
ovarian cancer in mice.64 Mitomycin is the most extensively used drug in the clinic as
hyperthermic IP chemotherapy (HIPEC) to treat peritoneal spread of colorectal,
appendiceal, ovarian and gastric cancer as well diffuse malignant peritoneal
mesothelioma with good results but no data on its use as postoperative catheter-based
IP chemotherapy without hyperthermia were found in the literature to-date. 65 '66
The choice of cisplatin as the first agent used in developing the sustained-
release implants in this thesis is warranted given the body of findings in support of IP
cisplatin to treat ovarian cancer both in the literature and in our lab. The future of this
project however will likely involve exploration of other chemotherapeutic agents either
as monotherapy or as combination therapy to maximize the anticancer efficacy of this IP
treatment regimen.
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1.2 Effect of Tumor Size on IP Chemotherapy Outcome*
1.2.1 Clinical Evidence
The majority of ovarian cancer patients are diagnosed with tumors spread throughout
the peritoneal cavity. Debulking surgery to remove as many of these tumors as possible
followed by chemotherapy is the clinical standard of treatment and a critical step to
lengthen patient survival. The Gynecologic Oncology Group (GOG) has recommended
that optimal debulking surgery translate to no residual tumors greater than 1 cm in size.
There is however ongoing debate over the size of residual tumors required for good
prognosis with suggested sizes ranging from 0.1 - 1.5 cm. 67'68 Skilled surgeons that can
perform optimal debulking surgery can drastically improve patient survival but less than
half of ovarian cancer patients have access to such care.69 Microscopic residual tumors
have regardless overall been shown to result in the best long-term treatment outcomes
especially for patients receiving IP chemotherapy.7'68' 70
The outcome of debulking surgery may have played a critical role in the most
recent GOG 252 phase 3 clinical trial comparing IP and IV platinum chemotherapy. The
trial released preliminary results in 2016 that have thrown the ovarian cancer community
into renewed disagreement regarding the benefits of IP therapy. The GOG 252
preliminary results revealed no significant difference in progression-free survival (PFS)
among patients receiving IV or IP chemotherapy and no significant increase in PFS in
women with microscopic residual tumors.71 73 Previous phase 3 GOG trials including
GOG 172, GOG 114 and GOG 104 had found that IP chemotherapy led to longer PFS
* Parts of this chapter were reproduced or adapted from Tanenbaum and Mantzavinou et al.
(2017).7
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and overall survival (OS) when given to women with no visible residual tumors
compared to women with visible residual tumors < 1 cm who received IP chemotherapy
or to women who received IV chemotherapy.1 8' 70' 74' 75 The GOG 252 trial was intended
to resolve the IP/IV debate by recruiting a larger number of patients and evaluating a
lower IP cisplatin dose (75 mg/M 2 of patient surface area compared to the 100 mg/M 2 of
patient surface area used in GOG 172). The GOG 252 trial also added bevacizumab 15
mg/kg IV to all treatment arms. It is these design parameters precisely that may
ultimately have played a confounding role in its findings. 18,71,76 GOG 252 recruited 1560
patients from 500 sites compared to 415 eligible patients from 40 sites included in the
GOG 172 analysis. Variability in subjective surgeon-reported debulking outcomes is
bound to be greater with an order of magnitude more centers included in the GOG 252
trial compared to the GOG 172.46 This variability makes it hard to determine with
certainty the cases where optimal cytoreduction was actually achieved.46'77 The trial
authors themselves pointed out the importance of IP cisplatin dose reduction in
interpreting the GOG 252 results.78 The addition of bevacizumab modifying the overall
treatment regimen is also regarded as a major confounding factor in the GOG 252
trial.72 A more complete assessment of GOG 252 will have to wait for OS data that will
become available in a few years but these confounding factors must be taken into
consideration when attempting to interpret the GOG 252 findings to date.
1.2.2 Experimental Findings and Mechanism of Tumor Size-Dependent Response
Experimental findings in animal models of human ovarian cancer similarly support the
notion that microscopic residual disease leads to better treatment outcomes. Jandial et
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al. used mice with peritoneal tumor xenografts to show that platinum levels following IP
cisplatin administration decrease significantly with increasing tumor size.79 Helland et al.
demonstrated that mice receiving debulking surgery followed by IP
carboplatin/paclitaxel chemotherapy had longer average survival than those treated with
either debulking surgery or chemotherapy alone . 80
We were previously able to match the efficacy of high-dose weekly IP cisplatin
injections in mice with human ovarian cancer xenografts using peritoneally implanted
reservoir devices to continuously deliver low doses of cisplatin.81 These devices caused
lower toxicity than the injections but an average of 4.7 X more total cisplatin was
needed to match the injection efficacy. There was no attempt to control the size of
tumors in the mice before the start of treatment and it is very likely that multiple animals
had tumors > 1 cm in their abdomen at the start of chemotherapy. This tumor size
consideration may help explain the need for an increased total amount of cisplatin in the
device treatment arm by looking at the mechanism of tumor kill by locally administered
cisplatin.
Local exposure of tumors to intraperitoneally given chemotherapy aims to take
advantage of direct chemotherapy penetration into the tumor. Penetration is affected by
diffusion down the drug concentration gradient and by convection driven by fluid flow
from vessels to the surrounding tissue and balanced by drainage into lymphatics. 82
Convection controls macromolecule transport as it affects fluid flow from blood vessels
into the interstitium but transport of small molecules like cisplatin is primarily controlled
by diffusion into tissue.82 Diffusion depends on drug partitioning, drug diffusivity in the
tissue and the diffusion length scale.83 Cisplatin is a small molecule for which direct
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diffusion into tumors appears to be limited to the outer 1.5 - 3 mm of the tumor.5,1 4 This
limitation of cisplatin diffusion may be improved by sustained exposure of tumors to
cisplatin. The continuous presence of active cisplatin around a tumor may allow killing of
each successive outer tumor cell layer and so enable the chemotherapy to reach
deeper into the tumor.84 This may however only be true up to a certain tumor size.
Taking into account cisplatin toxicity the cisplatin concentration that can be safely
maintained around tumors in a sustained-dosing regimen is necessarily going to be
lower than that accomplished immediately after intermittent IP cisplatin administrations
with breaks for recovery. This reduced concentration gradient between the peritoneal
fluid and the tumor center may carry efficacy implications for larger tumors despite the
fact that sustained exposure may allow layer-by-layer tumor cell kill.
Multicellular ovarian cancer aggregates called spheroids were used in in vitro
studies in this project to help understand any relationship between tumor diameter and
the efficacy of sustained low-dose cisplatin. The choice of spheroids for these studies
was made on the basis of their relevance to both ovarian cancer metastatic potential
and its response to treatment. Multicellular aggregates similar to spheroids are shed
from the primary tumor in ovarian cancer patients and are carried by peritoneal fluid flow
around the abdominal cavity seeding it with metastases.5 '86 These tumor spheroids are
considered the greatest obstacle to effectively treating late-stage epithelial ovarian
cancer.86 ,87 The seeding process requires remodeling of surface proteins (e.g. integrins,
cadherins) that is not recapitulated in traditional two-dimensional cultures of metastatic
ovarian cancer cells.85 ,88 Cells grown as spheroids in vitro not only express similar
surface proteins as metastatic nodules in vivo but also develop extracellular matrix and
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upregulate ovarian cancer biomarkers not observed in two-dimensional monolayer
culture. 2 ,88 90 Poor response of unresected tumors to chemotherapy is attributed to
limited drug penetration into the tumors and the ability of cells at the tumor core to
develop resistance.87 Multiple studies have shown that both in vitro and in vivo ovarian
cancer spheroids require higher chemotherapy doses than those same cells grown in a
monolayer to accomplish a similar response.85 -87 ,89 Loessner et al. found that ovarian
cancer cell spheroids exhibited a 50% greater survival compared to their monolayer
counterpart when exposed to the same treatment regimen with paclitaxel.88 These
finding support the use of spheroids in vitro to better model the structure, biological
markers and predicted in vivo treatment response of metastatic ovarian cancer and so
reach conclusions that are more clinically relevant.9192
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1.2.3 Implications for Animal Model Appropriateness to Study Treatment Efficacy
The implications of tumor size for assessing drug penetration extend beyond in vitro
models to affect the preclinical animal models of disease used to study the response of
human ovarian cancer to various dosing agents and regimens. Preclinical drug
screening in ovarian cancer is predominantly performed in immunocompromised mice
with orthotopic human cancer xenografts, as those are most clinically relevant to study
the chemosensitivity of new agents and replicate the early stages of tumor
development.80 The mice are inoculated with large numbers of cancer cells (order of
magnitude of 106 - 107 cells/animal) that are free-floating in solution. Investigators
usually wait for a sufficiently long period after cell inoculation before start of
treatment. 38,80 Generation of mouse models with this technique in this project has
resulted in diffuse and massive tumor nodules of irregular size throughout the peritoneal
cavity. Helland et al. pointedly emphasized the obvious disconnect between such
mouse models and the actual clinical presentation of debulked ovarian cancer patients
before the start of adjuvant chemotherapy. 80
Surgical debulking to leave minimal residual disease behind is one of the most
critical components of ovarian cancer treatment. The benefit of IP chemotherapy has
been demonstrated in patients after optimal debulking, and there is ongoing debate
around (i) the benefit, if any, of IP chemotherapy in patients with larger residual disease
and (ii) the impact of experience and performance in surgical debulking on the outcome
of ovarian cancer treatment. It is difficult to rationalize dose-finding studies in mice with
enormous tumors bearing no resemblance to residual disease in a debulked patient,
especially when exploring low-dose therapy. Surgical debulking in mice has been
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attempted but the procedure is highly invasive and very challenging for animal
survival.80 Laparoscopic debulking in mice is not possible due to size limitations and
back-to-back larger incisions would result in confounding loss of many animals.
Creation of a novel xenograft mouse model inoculated with ovarian cancer cell
spheroids of specific dimensions instead of free cells is likely to offer two benefits: (i)
better control of tumor nodule size and spatial nodule distribution; and (ii) more accurate
representation of the human disease by three-dimensional cell growth that mimics the
tumor microenvironment and promotes peritoneal metastasis.93 It remains to be
understood whether tumor size affects chemosensitivity via drug transport through
larger tumor nodules or via surface area-to-volume ratio for drug exposure. The in vivo
spheroid model studies along with the in vitro spheroid cisplatin exposure studies
described in this thesis may help shed light into this issue.
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1.3 Application of This Technology to Cancer Care in Low- and Middle-
Income Countries
The global cancer burden has shifted, and most new cancer cases and deaths now
occur in low- and middle-income countries (LMICs).94 Gynecologic and gastrointestinal
cancers are two of the most prevalent cancer types in LMICs estimated to affect more
than 2 million individuals and to kill more than 1 million patients every year.95 The
overall objective of this project is to develop implants for sustained delivery of IP
chemotherapy to treat peritoneal metastasis of cancer. Peritoneal metastasis is a
primary cause of morbidity and mortality in advanced-stage gynecologic and
gastrointestinal cancers and approximately 60-80% of cancer patients present with
advanced- or end-stage disease in LMICs. 96 The burden of disease of peritoneal
metastasis in those countries is therefore high. Management of advanced cancer is
largely unfeasible in the LMIC setting due to high cost, treatment unavailability, poor
infrastructure, and personnel limitations.96 Management of advanced gynecologic and
gastrointestinal malignancies with peritoneal metastasis is even grimmer as it requires
costly, technologically advanced or resource-heavy modalities such as surgical tumor
removal and frequent rounds of radiation therapy or chemotherapy to kill the remaining
cancer cells. IP chemotherapy has shown promise for better patient outcomes but has
faced limited clinical adoption in high-income countries in large part driven by the
complications and toxicities of the current infusion system and dosing regimen. 19
Adoption statistics are bound to be direr in non-elite cancer centers that are not well
equipped to handle the resource- and expertise-intensive technology currently used for
IP chemotherapy in the US and abroad. 2021
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A collaboration with the MIT Tata Center for Technology and Design was
established to explore the potential of bringing the sustained-release chemotherapy
implants developed in this project to the Indian setting. Drugs such as platinum-based
agents used in IP chemotherapy for peritoneal metastasis are on the WHO list of
essential medicines and are currently off-patent, making them more available and
affordable in LMICs. 96 Metronomic chemotherapy - chronic and frequent
chemotherapy administration at low, minimally toxic doses with no prolonged drug-free
breaks - has been championed as a cancer treatment strategy in resource-limited
settings because of its low cost, ease of access, and potential for improved cancer
control.94'97 Informal interviews with physicians throughout India were conducted as
preliminary research and revealed that catheter-based IP chemotherapy use, which
never really took off in the first place, has now dropped to almost zero in specialized
cancer centers. Indian physicians faced with the need to provide care to vast numbers
of cancer patients flocking to central hospitals from across the country are instead
performing high-temperature IP chemotherapy (HIPEC) and piloting pressurized IP
aerosol chemotherapy (PIPAC) during debulking surgery in the operating room. HIPEC
and PIPAC are getting embraced by Indian providers because they give them full
control of the treatment in the operating room with no infusion system maintenance and
no associated complications and have no loss to follow-up. The costs of HIPEC and
PIPAC are tremendously high compared to catheter- based IP or systemic
chemotherapy and very few patients are eligible to go through their extremely
aggressive regimens. Chemotherapy rarely ends at the HIPEC or PIPAC stage and the
patient will most likely require further treatment at a later point.
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These considerations create a vacuum for care of patients with peritoneal
metastasis that presents itself as a potential opportunity to affect the lives of millions of
patients globally by using fully implantable sustained-release systems for localized
chemotherapy. A clinician survey was distributed to centers across India using the
Indian National Cancer Grid to collect information on the current state of peritoneal
metastasis care in India, the use of surgical debulking, IP chemotherapy and
metronomic dosing, and the potential for adoption of the sustained-release implants
developed in this project by Indian physicians. The results show promise for use of this
technology in resource-constrained settings to give physicians autonomy of treatment
and help relieve the burden of follow-up care and of debilitating toxicity affecting patient
livelihood particularly for cancer patients seeking care from remote regions of the
country.
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Chapter 2: Ovarian Cancer Treatment with an Intraperitoneally
Implantable Cisplatin-Eluting Composite Material
2.1 Introduction
Ovarian cancer patients commonly present with peritoneal metastasis and can benefit
from IP delivery of chemotherapy after optimal surgical debulking. IP chemotherapy is
tremendously underused because it must be delivered as periodic high-dose infusions
through a catheter, causing severe toxicity and catheter complications. A better way to
perform IP chemotherapy is urgently needed. A supersoft silicone elastomer was
impregnated with cisplatin and lactose as a sacrificial excipient at different proportions
to create nonresorbable composite materials that mechanically match the properties of
abdominal tissues. Cisplatin and lactose crystals were uniformly distributed throughout
the composite materials and no crystal dissolution was apparent. Cisplatin was released
from the materials in vitro at a sustained rate over a period greater than three months
and following a triphasic linear release profile. A formulation was selected for further
development based on its in vitro cisplatin release profile and the bioactivity of the
released cisplatin against ovarian cancer cells was confirmed in vitro. The ability of
material samples to deliver cisplatin throughout the abdomen after intraperitoneal
implantation was confirmed in vivo in mice. Preliminary tolerability assessment of the
material in vivo in mice showed promising results. These findings suggest that this
cisplatin-eluting composite material is a good candidate to create implants for sustained,
controlled IP chemotherapy delivery against ovarian cancer.
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2.2 Materials and Methods
2.2.1 Chemicals and materials
Ecoflex 00-30 was purchased from Smooth-On Inc. (Macungie, PA, USA). Phosphate-
buffered saline (PBS) was purchased from VWR (Radnor, PA, USA).
Diethyldithiocarbamate trihydrate (DDTC), nickel (11) chloride, sodium hydroxide, high-
performance liquid chromatography (HPLC)-grade water, HPLC-grade methanol, 70%
nitric acid, cisplatin powder and lactose monohydrate powder were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Erbium 1,000 pg/mL standard solution was
purchased from Agilent Technologies (Santa Clara, CA, USA). Platinum 1,000 pg/mL
standard solution in nitric acid was purchased from Inorganic Ventures (Christiansburg,
VA, USA). Roswell Park Memorial Institute (RPMI) 1640 medium, McCoy's 5A medium,
0.25% trypsin-EDTA, 10OX penicillin-streptomycin-glutamine and fetal bovine serum
(FBS) were purchased from Thermo Fisher Scientific (Waltham, MA, USA). MTT
formazan powder was purchased from Santa Cruz Biotechnology (Dallas, TX, USA).
Medical injection-grade cisplatin solution (100 mg/100 mL) for bolus injections was
purchased from McKesson Medical-Surgical (Richmond, VA, USA).
2.2.2 Composite material fabrication
A matrix-type cisplatin-eluting composite biomaterial was fabricated by mixing cisplatin
and lactose powders with a supersoft silicone elastomer. Ecoflex 00-30, a two-part
platinum-catalyzed supersoft silicone elastomer, was manually mixed with cisplatin
powder and lactose monohydrate powder to create a composition containing 50%
w/wtotal powder. The 50% w/wtotai final solid powder content was determined based on
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preliminary experiments to achieve a matrix with interconnected pore paths allowing for
continuous release of its contents in an aqueous environment over a period of multiple
weeks. Ecoflex 00-30 was selected because of its mechanical properties that closely
resemble those of soft tissue. Lactose monohydrate was selected as a sacrificial
excipient to help create interconnected paths in the composite matrix and modulate the
rate of cisplatin release because it is a commonly used excipient with no adverse side
effects in the pharmaceutical industry, is readily available off-the-shelf, is very soluble in
water (lactose solubility in water = 100 mg/mL) and its molecular weight (360.31 g/mol)
is close to that of cisplatin (300.01 g/mol). Four different formulations containing
different proportions of cisplatin and lactose powders were tested to assess their in vitro
cisplatin release profile and determine the best candidate for sustained zero-order
cisplatin release: (1) CDDP5: 5% w/wtotai cisplatin - 45% w/wtotal lactose; (2) CDDP10:
10% w/wtotai cisplatin - 40% w/wtotal lactose; (3) CDDP25: 25% w/wtotai cisplatin - 25%
w/wtotai lactose; (4) CDDP40: 40% W/wtotai cisplatin - 10% w/wtotal lactose. A mass of 1.5-
2 g of the cisplatin-lactose-silicone mixture was poured into circular plasma-treated
polystyrene molds measuring approximately 35 mm in diameter and 18 mm in depth.
The mixture was spread evenly across the surface of the circular molds and allowed to
degas completely in vacuum for 15 min followed by overnight curing at room
temperature and pressure. This yielded composite material pieces measuring 35 mm in
diameter and approximately 1.2-1.7 mm in height, depending on the mass of material
poured in the mold. Cisplatin-containing samples were kept away from light for all
experiments. An additional composite formulation containing only lactose 50% W/Wtotal
(LAC50) was prepared to use in in vitro cytotoxicity studies and for mechanical testing,
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where material porosity was the critical parameter. The LAC50 formulation was
prepared in the same way as the cisplatin-containing formulations. A 5 mm-diameter
disposable biopsy punch was used to punch out disks from the cured material pieces for
in vitro cisplatin release quantification, in vitro cytotoxicity assessment and in vivo
implantation. The resulting disks measured 5 mm in diameter and 1-1.5 mm in
thickness. All disks used for cytotoxicity assessment and in vivo implantation were
sterilized by ethylene oxide gas and allowed to degas for 48 hours in a hood before use.
Ecoflex 00-30 and LAC50 samples for mechanical testing were prepared by pouring
uncured Ecoflex 00-30 or uncured LAC50 respectively into dog bone-shaped Teflon
molds measuring 1.5 mm in depth then allowed to degas completely in vacuum for 15
min and cure overnight at room temperature and pressure.
2.2.3 Chemical and structural characterization
Ecoflex 0030, LAC50, CDDP5, CDDP10, CDDP25 and CDDP40 disks were sectioned
through the axis of the disk using a razor to create lateral cross-sections of the disk
thickness. The cross-sections were examined by scanning electron microscopy (SEM;
Zeiss Merlin SEM, Jeol 5910 SEM and Jeol 5600LV SEM) and energy-dispersive X-ray
spectroscopy (EDS; Bruker) to study the presence and distribution of cisplatin and
lactose in the silicone matrix. A 10-pm gold-palladium coating was applied to the cross-
sections prior to SEM imaging to prevent charging of the sample.
2.2.4 Mechanical characterization
Tensile testing of dog bone-shaped Ecoflex 00-30 and LAC50 samples was performed
on an Instron 5943 testing machine with a 500 N load cell and steel grip platens.
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Specimens were subjected to elongation at a rate of 15 mm/min until failure. To
examine the mechanical properties of the composite material after prolonged release of
impregnated solid powder, dog bone-shaped LAC50 samples were immersed in PBS
for 6 weeks, allowed to fully dry in an oven at 800C for 48 hr and subsequently
underwent the same tensile test. Force was converted to stress using the cross-
sectional surface area of the sample and elongation was converted to strain using the
initial length of the sample. Stress-strain diagrams were plotted and the modulus of
elasticity, ultimate tensile stress and elongation at break were calculated and compared
to those of Ecoflex 00-30 and of representative tissues in the human abdominal cavity.
2.2.5 In vitro cisplatin release
CDDP5, CDDP10, CDDP25 and CDDP40 disks were immersed in PBS in scintillation
vials and incubated at 370C on a shaker oscillating at 60 cycles/min to quantify the
amount of cisplatin released in vitro at regular intervals for a total period of 109 days.
Each disk was lodged within the turns of a thin stainless steel spring similar to the
method described by Keskar et al. (McMaster-Carr, Elmhurst, IL, USA) to prevent the
disk from settling on the bottom of the vial or floating to the top of the liquid.98 A piece of
thin nickel wire was threaded through the spring and brought near the top of the vial to
allow movement of the setup to a new vial containing fresh PBS at regular time
intervals. The PBS was renewed at an amount equivalent to 2 mL of fresh PBS every
24 hours to maintain sink conditions for the dissolution of lactose (lactose solubility in
water = 100 mg/mL) and cisplatin (cisplatin solubility in water = 2.53 mg/mL). The
interval between PBS renewals was kept to 6 days or shorter to minimize cisplatin
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degradation. The amount of cisplatin present in the solution was measured at each
prescribed time point by HPLC with a nickel (II) chloride internal standard and the
method described previously by our group. A solution containing lactose alone was
also assessed by HPLC to confirm that lactose-associated peaks did not interfere with
the cisplatin peak and so their presence would not affect the perceived measured
amount of cisplatin in the sample, to ensure that the HPLC method would be cisplatin-
specific.
2.2.6 Cell culture
The cisplatin-sensitive UC1101 human ovarian cancer cell line (Dr. G. Scott Rose,
University of California, Irvine) and cisplatin-resistant SKOV3 human ovarian cancer cell
line (ATCC, Manassas, VA, USA) were used. Cells were pathogen tested in 2015 by the
Comparative Pathology Laboratory at MIT and in 2018 by the High-Throughput
Screening Core at the MIT David H. Koch Institute for Integrative Cancer Research and
tested negative for mycoplasma. The UC1101 cell line was authenticated in 2012 using
whole-genome copy number variation analysis comparing the pattern of variants to
those of other serous ovarian cancer cell lines. UCl101 cells were grown and
maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS)
and 1% penicillin-streptomycin-glutamine. SKOV3 cells were grown and maintained in
McCoy's 5A medium supplemented with 10% FBS and 1% penicillin-streptomycin-
glutamine. Cells were grown as monolayers at 370C with 5% CO 2 and were subcultured
with 0.25% trypsin-EDTA at regular time intervals to maintain cell densities below 80%
confluence. Cells were not used after passage number 13.
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2.2.7 In vitro material cytotoxicity
The CDDP25 formulation was deemed the most appropriate for use as the material for
a human implant based on its in vitro cisplatin release profile. The in vitro cytotoxicity of
the CDDP25 formulation was evaluated against both UC1101 cisplatin-sensitive cells
and SKOV3 cisplatin-resistant cells. The LAC50 formulation and Ecoflex 00-30 alone
were also tested as controls to evaluate any cytotoxic effect of the lactose excipient or
the silicone elastomer. Sterile CDDP25, LAC50 and Ecoflex 00-30 disks were incubated
for 24 hours in 2 mL of PBS at 370C on a shaker oscillating at 60 cycles/min prior to cell
culture use. This allowed elimination of the cisplatin burst observed in the first 24 hours
of CDDP25 release and use of the disks during their near-zero-order release phase.
The five treatment groups tested in vitro were: (1) untreated control; (2) CDDP25 disk;
(3) equivalent cisplatin solution; (4) LAC50 disk; (5) Ecoflex 00-30 disk. The equivalent
cisplatin solution group exposed the cells to the amount of cisplatin released by a
CDDP25 disk over 24 hours, calculated using the average in vitro cisplatin release rate
from the cisplatin release profile of the four different composite formulations. Cells were
seeded as a monolayer in 24-well plates at a density of 2 x 104 cells/well one day before
the start of the in vitro cytotoxicity study and allowed to adhere to the well bottom
overnight. The disks for groups 2, 4 and 5 were subsequently placed in Transwell cell
culture inserts featuring polyester membranes with an 8.0 pm pore size (Corning,
Corning, NY, USA) and immersed in the cell culture medium within each well without
coming in contact with the cell monolayer at the bottom of the well. Cisplatin at the 24-
hour equivalent amount was added as a solution in PBS in the cell culture medium of
each of the group 3 wells at that time. The cell culture medium in each well across all
five groups was refreshed every 24 hours, including the cisplatin-containing medium in
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group 3 wells to prevent any cisplatin degradation. Cell viability was evaluated using the
MTT assay after 24, 48 and 72 hours of treatment read at 570 nm (measurement) and
720 nm (background) using a BioTek Synergy 4 plate reader (BioTek, Winooski, VT). All
chemicals and materials for the in vitro cytotoxicity studies were sterile and maintained
under sterile conditions.
2.2.8 Surgical and euthanasia procedures for in vivo experiments
All listed procedures were in accordance with the Massachusetts Institute of Technology
Committee on Animal Care guidelines, as well as the NIH Guide for the Care and Use
of Laboratory Animals. Animal surgeries to implant CDDP25 and Ecoflex 00-30 disks
were performed within a sterile field and all surgical equipment was autoclaved.
Inhalation anesthesia was maintained throughout surgeries with isoflurane. Slow-
release buprenorphine was used as pre- and post-surgical analgesia per
recommendation by the animal care committee. The incision site was sterilized with
iodine and isopropyl alcohol. A small abdominal incision of about 5 mm was made
through the skin and peritoneum to implant the disks. The disks once implanted were
allowed to freely move within the peritoneal cavity. Mice were weighed regularly to
monitor overall health and euthanized upon weight loss greater than 20% or poor body
condition. Euthanasia was carried out by carbon dioxide inhalation at a steadily
increasing flow rate to minimize distress.
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2.2.9 In vivo composite toxicity study
The in vivo toxicity of the CDDP25 formulation was assessed in healthy
immunocompetent mice and compared to the toxicity of a single IP cisplatin injection. All
chemicals and materials for this study were sterile and maintained under sterile
conditions. Female BALB/c immunocompetent mice bearing no tumors and weighing
20-25 g were used (Charles River Laboratories, Wilmington, MA, USA). Blood was
sampled via the saphenous vein of all mice prior to the start of the experiment to obtain
baseline complete blood count (CBC) values with auto differential. The mice were
allocated in three different treatment groups: (1) intraperitoneal (IP) implantation of a
single CDDP25 5 mm-diameter disk (n=2); (2) IP administration of a single 4 mg/kg
cisplatin injection (n=2); or (3) untreated control (n=1). The single animal of group 3 was
included in the study to serve as a healthy control in the blood workup and histological
examination of the two treatment groups. Sterile CDDP25 disks were incubated in 2 mL
of PBS at 370C on a shaker oscillating at 60 cycles/min for 24 hours to eliminate their
cisplatin burst. The disks were then implanted intraperitoneally in the mice of group 1.
The mice of group 2 received a 4 mg/kg IP cisplatin injection at the same time as the
implantation surgery given as a 1 mL injection using 0.9% w/v saline as a diluent and
injected via a 28G needle. The mice of group 2 were euthanized 48 hours after the start
of treatment. The mice of groups 1 and 3 were euthanized 15 days after the start of
treatment. Blood was collected from all mice at euthanasia by cardiac puncture for CBC
with auto differential and serum platinum quantification. Blood samples for CBC with
auto differential were collected in EDTA-coated 100 pL microvettes (Sarstedt,
Numbrecht, Germany) as per manufacturer instructions to prevent clotting and were
processed on a Hemavet 950FS Auto Blood Analyzer (Drew Scientific, Miami Lakes,
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FL, USA) within 24 hrs after collection. Samples that were not processed immediately
after collection were stored in the refrigerator to maintain sample integrity. Blood
samples for serum platinum quantification were collected in 1.1 mL Z-Gel microtubes
(Sarstedt, Numbrecht, Germany) containing serum gel with clotting activator and were
centrifuged at 13,000 g for 5 minutes. The serum was collected following blood
centrifugation and ultrafiltered using an Amicon Ultra-0.5 mL centrifugal filter
(MilliporeSigma, Burlington, MA, USA) as per manufacturer instructions to collect both
the serum ultrafiltrate and the serum concentrate. The serum ultrafiltrate is free of
proteins, primarily albumin, and therefore does not contain protein-bound cisplatin that
is no longer therapeutic. Serum ultrafiltrate and concentrate samples were stored at -
800C until further processing. The platinum concentration in serum ultrafiltrate was
measured by inductively coupled plasma mass spectroscopy (ICP-MS) on an Agilent
7900 lCP-MS (Agilent, Santa Clara, CA, USA). The liver, spleen, kidneys, stomach,
sections of the small and large intestine, ovaries, uterus, femurs, fat pad tissue - if
present - and implant along with any surrounding fibrous capsule were harvested from
the euthanized mice. All harvested tissues were prepared for histological analysis to
assess toxicity using the following protocol. The implant and tissues with the exception
of the femurs were placed in 10% neutral buffered formalin immediately after harvesting
and allowed to fix for 48-72 hours. The femurs were placed in Bouin's solution and
allowed to decalcify for at least two weeks and until they could be bent by applying a
small amount of force to each end of the bone. The fixed tissues with the exception of
the femurs were sectioned with a razor blade and half of each sample was placed in
histology cassettes. The femurs were placed in histology cassettes without any
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sectioning. The implants were carefully sectioned with a razor blade along their axis to
ensure any fibrous capsule remained on the sample and placed in histology cassettes
such that the implant cross-section and capsule would be visible on the paraffin section.
Care was taken to ensure that all five liver lobes and half of each kidney as well as
different representative sections of the small and large intestines were included in the
respective cassette. The cassettes were placed in 70% ethanol followed by paraffin
embedding and hematoxylin & eosin (H&E) staining of slides for pathology review with a
veterinary pathologist consultant at the Hope Babette Tang Koch Institute Histology
Core.
2.2.10 In vivo abdominal platinum distribution study
The abdominal platinum distribution accomplished by intraperitoneally implanting a
single CDDP25 disk was assessed in healthy immunocompetent mice and compared to
that achieved with a single IP cisplatin injection. Any platinum leaching of Ecoflex 00-30
disks after intraperitoneal implantation was also assessed since the elastomer is
platinum-catalyzed. All chemicals and materials for the in vivo platinum distribution
study were sterile and maintained under sterile conditions. Female BALB/c
immunocompetent mice bearing no tumors and weighing 20-25 g were used (Charles
River Laboratories, Wilmington, MA, USA). The mice were allocated in three different
treatment groups: (1) intraperitoneal (IP) implantation of a single CDDP25 5 mm-
diameter disk (n=6); (2) IP administration of a single 4 mg/kg cisplatin injection (n=12);
or (3) IP implantation of a single Ecoflex 00-30 5 mm-diameter disk (n=3). Sterile
CDDP25 and Ecoflex 00-30 disks were incubated in 2 mL of PBS at 370C on a shaker
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oscillating at 60 cycles/min for 24 hours to eliminate the cisplatin burst from the
CDDP25 disks. The disks were then implanted intraperitoneally in the mice of groups 1
and 3. The mice of group 2 received their IP cisplatin injection at the same time given as
a 1 mL injection using 0.9% w/v saline as a diluent and injected via a 28G needle. The
euthanasia time points were as follows: group 1 - two mice euthanized at each of days
3, 8 and 15 after implantation; group 2 - two mice euthanized at each of 0.5hr, 1hr, 2hr,
3 days, 8 days and 15 days after injection; and group 3 - one mouse euthanized each
of 3, 8 and 15 days after implantation. The earlier time points at 1 .5hr, 1 hr and 2hr after
injection were added for group 2 to ensure that the cisplatin levels in serum and tissue
would be adequately quantified at the peak following injection and before the drug was
cleared from the systemic circulation and peritoneal cavity. The liver, spleen, kidneys,
stomach, small and large intestine, ovaries, uterus and fat pad tissue - if present - of
the euthanized mice were harvested. The harvested tissues were prepared for platinum
quantification using the following protocol. The tissues were collected in Eppendorf
tubes and placed immediately on dry ice followed by storage at -80*C until further
processing. To quantify the amount of platinum in the harvested tissues, the organs
were homogenized using a Bertin Precellys CK14 soft tissue homogenization kit (VWR,
Radnor, PA, USA) and digested using 70% nitric acid. Briefly, each organ was weighed
and then divided into pieces weighing at most 200 mg. Each piece was placed in a
tissue homogenization tube containing inert 1.4 mm zirconium oxide beads and 1 mL of
RIPA lysis and extraction buffer (Invitrogen, Carlsbad, CA, USA) was added. The tubes
were placed in a Precellys 24 homogenizer (Bertin, Montigny le Bretonneux, France)
and the samples were homogenized at 6,000 RPM for 4 x 20 s cycles. The tubes were
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then centrifuged at 10,000 g for 10 min to remove any foam buildup and placed
uncapped on a thermoblock at 950C for at least 48 hours until all the supernatant had
evaporated. The lysed tissue pellets were digested by adding 1 mL of 70% nitric acid to
each tube, loosely capping it and placing it in the hood on a hot plate at 550C for 24
hours. The platinum concentration of the digested samples was quantified by ICP-MS.
Samples were serially diluted to a final dilution of 10-3 using 2% nitric acid before ICP-
MS measurement. An internal erbium standard was used to monitor the performance of
the ICP-MS run for any drift and the bounds for rejecting readings were defined at +/-
20% of the erbium internal standard recovery. A platinum calibration curve was
prepared using eight platinum concentrations ranging from 0 to 500 ppb to convert the
ICP-MS platinum-to-erbium count ratio to a platinum concentration for each sample.
The platinum calibration curved was a straight line through the origin with R 2 = 0.9999.
The platinum concentration values obtained for each sample were multiplied by the
dilution factor to obtain the platinum concentration in the original sample and the
calculated platinum mass was divided by the tissue sample mass in each tube to obtain
a normalized pg Pt / g tissue content for each sample.
2.2.11 Data analysis
All data are expressed as a mean +/- standard deviation. All error bars represent
standard deviations from the mean. All samples were examined in triplicate unless if
otherwise noted. The GraphPad Prism software was used for all statistical analyses
(GraphPad Software, CA, USA). In vitro cytotoxicity results were compared across the
five groups (CDDP25 disk, equivalent cisplatin solution, LAC50 disk, Ecoflex 00-30 disk,
untreated control) using a one-way ANOVA with Tukey's multiple comparisons test. The
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two cisplatin treatment groups 'CDP25 implant' and 'Equivalent cisplatin solution' were
further compared using an unpaired student's t-test. Tissue platinum content values
were compared for each organ across the two treatment groups (IP injection, CDDP25
implant) using an unpaired student's t-test. Differences with p-value < 0.05 were
considered to be statistically significant. Statistical significance is indicated as: ns p >=
0.05; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
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2.3 Results
2.3.1 Chemical and structural characterization
Secondary electron SEM imaging of the Ecoflex 00-30, LAC50, CDDP5, CDDP10,
CDDP25 and CDDP40 disk cross-sections was performed to assess the topography of
the cross-sections and confirmed the presence of two distinct phases, with the minor
phase appearing as crystals of various shapes and sizes dispersed homogeneously
within a flat-appearing major phase across the height of the cross-section (Figure 2.IA-
C). Backscatter electron SEM imaging of the CDDP25 disk cross-section was
performed to assess the composition of the cross-sections. Cisplatin crystals were
expected to appear as brighter on backscatter electron SEM due to the higher atomic
number of platinum that backscatters electrons more strongly than the other elements.
Backscatter SEM of the CDDP25 disk cross sections confirmed the presence of brighter
and darker crystals across the silicone matrix thickness attributed to cisplatin and
lactose respectively and appearing homogeneously distributed throughout the thickness
with no apparent dissolution (Figure 2.1D). EDS spectra of the CDDP25 disk cross-
section revealed that the flat-appearing major phase comprised mainly silicon while the
crystal-appearing minor phase contained crystals with either the presence of carbon
corresponding to lactose or the presence of platinum and chlorine corresponding to
cisplatin (Figure 2.2A-B).
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Figure 2.1: SEM images of composite cross sections. (A)-(C) Secondary electron SEMimages of cross-sections of (A) Ecoflex 00-30; (B) LAC50; and (C) CDDP25; (D) BackscatterSEM image of cross-section of CDDP25. The cross-sections are oriented such that the top
surface of the cast sample is at the top of the SEM image and the bottom surface that is in
contact with the mold is at the bottom. A uniform distribution of crystals throughout the Ecoflex00-30 matrix is seen in both LAC50 and CDDP25 cross-sections. Cisplatin crystals are
expected to appear brighter in the backscatter electron SEM than lactose crystals because ofthe heavier Pt nuclei that more effectively scatter electrons compared to low-atomic-number
elements. Scale bars are 200 pm.
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Figure 2.2: EDS analysis of CDDP25 cross section. (A) CDDP25 cross-section
with points # 1-5 analyzed by EDS marked. (B) Plot of the EDS spectrum of the
points indicated in (A). Intensity of the measured X-rays emitted from each point
is plotted against X-ray energy. Peaks corresponding to the elements of interest
are identified. Pt and Cl were used to identify cisplatin in the sample while Si was
used to identify the Ecoflex 00-30 matrix and C was used as an indicator of the
52
350 -
300
C/)
c 250 -
0
200
150 -
ca 100 -
50 -
0*
presence of lactose. The colors in (A) and (B) are matched to help visualize which
line in the EDS spectrum corresponds to which point in the cross-section. Points
#1 and 3 were identified as cisplatin crystal while points #2,4 and 5 were identified
as lactose crystals. Slight peaks corresponding to Si were present in all points
analyzed and this is reasonable given that all crystals are encased in a silicone
matrix. The EDS spectrum confirmed that cisplatin and lactose crystals are
present and randomly distributed throughout the material.
2.3.2 Mechanical characterization
Ecoflex 00-30 and LAC50 dog bone-shaped samples underwent tension testing to
evaluate their elastic modulus, ultimate tensile strength and elongation at break and
compare them to the values reported by the Ecoflex manufacturer as well as those of
tissues commonly found in the abdominal cavity. This mechanical characterization was
used as a metric of the composite material's mechanical appropriateness for
intraperitoneal placement. Two types of LAC50 samples were tested to fully recapitulate
the intended multi-week composite implantation for in vivo cisplatin release: (1) fully
cured LAC50 samples after production and (2) fully cured LAC50 samples entirely
immersed in PBS for six weeks followed by drying completely in an oven. The complete
results along with values obtained from the literature for Ecoflex 00-30 and
representative human tissues found in the abdomen (esophagus, stomach, liver, small
and large bowel and colon) are shown in Table 2.1.
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Material Elastic modulus Ulti(MPa) stre
Ecoflex 00-30 0.027-0.12599-101
(literature)
Ecoflex 00-30 0.031(experimental)
LAC50 0.226
LAC50 after 42 0.128
days in PBS
Esophagus 0.018103
Stomach 0.0021 05
Liver 0.0061 05 - 0.27 106
Small bowel 0.00291 08
Large bowel 0.0029108
Colon 5.18109
Table 2.1: Mechanical properties of Ecoflex 00-30,
tissues.
The elastic modulus of Ecoflex 00-30 was found experimentally to lie within the range
reported in the scientific literature (0.031 MPa compared to 0.027 - 0.125 MPa
respectively). The ultimate tensile strength of Ecoflex 00-30 was found to be
approximately 40% of the value reported by the manufacturer (0.550 MPa compared to
1.379 MPa respectively) meaning that the material was actually 60% less strong than
the manufacturer-reported specification. The Ecoflex 00-30 elongation at break was
found to be approximately 92% of the value reported by the manufacturer (832%
compared to 900% respectively), meaning that the material tolerated a strain almost as
high as expected according to the manufacturer specifications.
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I
mate tensile
ngth (MPa)
1.379102
0.550
0.356
0.401
1.2104
0.7104
0.023107
0.5104
0.9104
0.87109
LAC50 and rE
Elongation at
break (%)
900102
832
590
317
140104
190104
46107
140104
180104
62.81109
presentative abdominal
The elastic modulus of LAC50 samples after 42 days of leaching in PBS was
found to be approximately 40% smaller than that of LAC50 samples tested without
further manipulation after curing (0.128 MPa compared to 0.226 MPa respectively),
suggesting a less stiff material. This is expected since the material has at this point lost
lactose content and the increased porosity should lead to a decrease in its modulus.110
112 The ultimate tensile strength of LAC50 samples was found to be approximately 65%
of that calculated for Ecoflex 00-30 alone experimentally (0.356 MPa compared to 0.550
MPa respectively), while the ultimate tensile strength of LAC50 samples after 42 days of
leaching in PBS was found to exceed 70% of the ultimate tensile strength calculated for
Ecoflex 00-30 alone (0.401 MPa compared to 0.550 MPa respectively). These values
suggest that the LAC50 composite material maintains the majority of the strength seen
with Ecoflex 00-30 despite being impregnated with 50% powder w/wtotai and its strength
is not compromised by releasing its powder content over six weeks immersed in PBS.
LAC50 in fact contained only lactose powder, which is much more readily soluble in
water compared to cisplatin powder. The amount of powder that leached out of the
LAC50 dog bone-shaped samples in the six-week leaching period is therefore expected
to be larger than the amount of powder expected to leach out of samples made of the
CDDP25 composite material, creating a more porous material at 42 days. The ultimate
tensile strength of CDDP25 after leaching would be expected to be larger than that
determined experimentally for LAC50 after leaching, and so any change in the ultimate
tensile strength of CDDP25 after six weeks of immersion in an aqueous environment is
anticipated to be even smaller than that seen with LAC50. The elongation at break of
LAC50 was found to be approximately 71% of that of Ecoflex 00-30 alone (570%
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compared to 832% respectively), but it markedly decreased after six weeks of leaching.
The elongation at break of LAC50 after six weeks in PBS was less than 60% of the
value for LAC50 without further manipulation after curing (317% compared to 590%
respectively), meaning that the composite material is able to withstand much less
stretching after the start of plastic deformation before it breaks once it has been
immersed in an aqueous solution and leached lactose powder over six weeks. This
effect is similarly expected to be less dramatic with CDDP25 compared to LAC50
because of cisplatin's lower water solubility.
The elastic modulus of Ecoflex 00-30 was confirmed comparable to the
elastic modulus of key organs in the abdominal cavity like the liver and bowels based on
values reported in the literature.99-1 09 The elastic modulus of LAC50 both intact (0.226
MPa) and after the 42-day leaching period (0.128 MPa) was larger than that reported for
all abdominal organs examined with the exception of the colon (5.18 MPa), suggesting
a stiffer material than those tissues. The modulus values however fall within 1-2 orders
of magnitude of the modulus reported for the softest tissues (liver, stomach) and are an
order of magnitude smaller than the modulus of colon. The ultimate tensile strength and
elongation at break of the LAC50 formulation both before and after leaching are both
comparable to the values reported in the literature for the examined abdominal organs.
The LAC50 composite material, both before and after leaching, can thus be considered
mechanically matched to key organs in the abdominal cavity and is therefore expected
to be mechanically well tolerated in vivo upon contact with abdominal tissues. These
mechanical properties also suggest that routine surgical manipulation of the composite
material in vivo will be safe since it will involve forces similar to those used when
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manipulating surrounding tissues. Further assessment of the composite material's
response to forces specifically experienced during laparoscopic placement, removal and
more extreme manipulation is necessary to ensure implantation safety and should be
carried out as a next step in material development.
2.3.3 In vitro cisplatin release
A multiphasic cisplatin release profile was observed for the CDDP5, CDDP10, CDDP25
and CDDP40 samples in vitro over the 109-day release period. An initial burst during
the first 24 hours of release was followed by three phases of near-linear cisplatin
release that were distinct and occupying the same time intervals for all formulations.
The time intervals for each phase were as follows: Phase 0 (burst) on day 0; Phase 1
on days 1-12; Phase 2 on days 17-44; Phase 3 on days 49-109. The intermediate days
between the end and start of phases 1-3 were not sampled for all release studies, and
so cannot be assigned to either the preceding or succeeding phase with confidence. No
peaks attributed to lactose were found to interfere with the peak attributed to cisplatin in
the HPLC method, ensuring its specificity to quantifying active cisplatin in solution.
The cisplatin release profiles for the four composite material formulations are
shown in Figure 2.3. Cisplatin release for each formulation during each phase 1-3 can
be approximated by a distinct zero-order release profile. Linear best-fit trendlines having
R2 > 0.98 were therefore used to quantify the average cisplatin release rates during
each of the phases 1-3 for each of the four formulations, and the results are shown in
Figure 2.4 and Table 2.2. Two methods were used to calculate an average in vitro
cisplatin release rate for each formulation for the entire duration of the 109-day release
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period. The first method fit a linear trendline to the entire data set for each formulation
without forcing the line to pass through the origin (R 2 > 0.9 for all trendlines fitted to the
data) and used the slope of the resulting line as an estimate for the average cisplatin
release rate for each formulation. The second method calculated a weighted average of
the release rates of phases 1-3 for each formulation using the relative duration of each
phase in comparison to the total period of release as a weight. The average and
weighted average in vitro release rates are shown in Table 2. The values for each
formulation were similar overall for the average and weighted average in vitro release
rates, with the largest difference observed for the CDDP40 formulation (8.6% faster in
vitro release rate computed when using a weighted average) and the smallest
difference observed for the CDDP25 formulation (0.9% slower in vitro release rate
computed when using a weighted average). The initial 24-hr burst was not taken into
account in calculating in vitro release rates as it was eliminated for all formulations after
24 hours. The initial 24-hour burst could similarly be eliminated in the actual clinical
embodiment of these composite materials for an intraperitoneal implant, for instance by
pre-treating the implant before placement in the patient.
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Figure 2.3: In vitro cisplatin release from various composite formulations. (A) In vitro cisplatin
release rate over time in days and (B) normalized in vitro cisplatin release rate per square
centimeter of sample area over time in hours. Values are average of four studies with n=2
each. Error bars represent standard deviation from the mean.
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The initial cisplatin burst displayed by all four formulations is attributed to the
dissolution of cisplatin crystals found on the surface of the composite samples. The
dissolution of these readily accessible cisplatin crystals by the aqueous solvent, PBS, is
governed exclusively by the solubility and dissolution rate of cisplatin in the solvent. The
three-phase zero-order release profiles displayed by all four formulations after this initial
burst are hypothesized to arise from the swelling process happening in the composite
samples, similar to the mechanism of cisplatin release from ureasil-poly(ethylene
oxide)-cisplatin matrices proposed by Molina et al. and to the swelling and potassium
dichromate release from silicone matrices described by Golomb et al. 113- 15 The swelling
is driven by the influx of the aqueous solvent in which a composite sample is immersed
both through pores generated by dissolution of the excipient crystals and through the
polymer backbone rendered more hydrophilic by the hydrophilic excipients incorporated
in the silicone matrix.' 15
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Figure 2.4: In vitro cisplatin release rate estimation for various composite
formulations. Linear best-fit trendlines for (A) phases 1-3 and (B) the entire 109-day
release for each formulation used as two different methods to estimate the average in
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vitro cisplatin release rate. Trendline equations and R 2 values tabulated in Table 2.
Formulation
CDDP5
Phase
1
2
3
Cisplatin release
rate (pg/cm2lhr)
0.855
0.719
0.282
0.995
0.998
0.995
Entire release 0.492 0.930(linear best-fit trendline)
Entire release 0.471 
-(phase...........1-3 .. wi h e ................. e)047
CDDP1 0 1
2
3
2.058
0.924
0.446
0.999
0.999
0.997
Entire release 0.746 0.917(linear best-fit trendline)
Entire release 0.772 
-
CDDP25 1 1.143 0.988
2
3
Entire release
0.932
0.628
0.999
0.993
(linear best-fit trendline)
Entire release 0.773CDDP .(phase 1-3 weighted avera.e)0
CDDP40 1 0.625 0.998
2
3
0.249
0.376
0.998
0.999
Entire release
(linear best-fit trendline)
Entire release 0.372(phase 1-3 weighted average)
Table 2.2: In vitro cisplatin release rates for CDDP5, CDDP10, CDDP25 and CDDP40
formulations. The rates are calculated using zero-order models based on linear best-fit
trendlines for phases 1-3 for each formulation or for the entire 109-day release period.
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Dissolution of the cisplatin crystals on the surface of the composite sample
creates a high cisplatin concentration near the sample surface. The dissolved cisplatin
is extracted away from the surface and toward the solution, driving an inverse PBS flux
into the composite.113 This flux is thought to be the driver behind phase 1 in the in vitro
cisplatin release profile of all four formulations. The passage of PBS into the composite
is aided both by the creation of pores by excipient dissolution as well as by PBS
diffusion directly into the polymer backbone. Plain silicone is highly hydrophobic and
does not swell when immersed in an aqueous solvent. The addition of lactose and
cisplatin (both hydrophilic) likely alters the hydrophobicity of the composite material,
allowing passage of PBS through the polymer backbone and subsequent swelling."'
The presence of excipient crystals inside the composite matrix is necessary to act as
the driving force for water uptake into the composite generating an osmotic pressure.
The more lactose a sample contains the faster it is expected to release cisplatin in
phase 1. Lactose is readily soluble in aqueous solvents and so a network of
interconnected pores will form sooner in samples containing a greater proportion of
lactose. Lactose is also significantly more hydrophilic than cisplatin (logP -5.4 vs. -2.27
respectively) and so a composite containing a larger proportion of lactose is likely
rendered more hydrophilic and allows passage of PBS into its polymer backbone faster.
This rate dependence on lactose content is indeed observed in the phase 1 cisplatin
release profile of the CDDPI, CDDP25 and CDDP40 formulations: the less cisplatin
(and so more lactose) the sample contained, the faster it released the drug. The CDDP5
formulation however did not follow the trend, its phase 1 rate falling in between those of
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CDDP40 and CDDP25. This may be attributed to the fact that CDDP5 contains too little
cisplatin and the availability of the drug is what causes this formulation's slower release.
As excipient crystals - both lactose and cisplatin - are dissolved away from
the composite, the hydrophobic nature of the silicone matrix encourages the composite
surface to try and shrink in order to minimize exposure to the aqueous solvent.1 3 This
shrinking force opposes the PBS flux into the matrix, but the osmotic pressure between
the cisplatin- and lactose-rich composite and the surrounding PBS allows the solvent to
continue entering the composite, swelling it and dissolving more cisplatin and lactose.' 1 3
The cisplatin release rate however slows down due to the shrinking of the composite
surface, the increasing swelling of the sample and resulting elastic contraction forces
and the osmotic flow of solute into the matrix, giving rise to the slower phase 2 for all
four formulations. Phase 2 corresponds to the intermediate stage described by Molina
et al.11 3 The trend is now reversed in terms of cisplatin release rate vs. lactose content
for CDDP5, CDDP10 and CDDP25: the higher the lactose content the slower the
cisplatin release in phase 2. This is attributed to an increased swelling of the composite
with increased lactose content that results in increased elastic contraction forces within
the composite opposing the osmotic pressure generated by the undissolved excipients.
Osmotic solvent flow into the composite and further cisplatin and lactose
dissolution continues in phase 3, the last phase evident in the 109-day release. Phase 3
is expected to last until the expanded network inside the swollen composite is able to
exert an elastic contraction force equivalent to the osmotic pressure and so hinder
further solute diffusion.' 3 The CDDP5, CDDP10 and CDDP25 formulations all
displayed a decreased cisplatin release rate during phase 3 as compared to the release
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rate during phase 2, and the rate decrease was more dramatic with decreasing cisplatin
content. The CDDP40 formulation on the contrary displayed a slight acceleration in
cisplatin release during phase 3. The behavior of the four formulations during phase 3
can be explained as follows. The total solid powder content in all formulations was
constant at 50% w/wtotai and so the formulations with lower cisplatin content had higher
lactose content. Lactose is readily soluble in water and its dissolution upon exposure to
an aqueous solvent like PBS is not rate limiting. The rate of swelling across formulations
upon immersion in PBS is expected to increase with increasing lactose content as a
result. The elastic contraction force and subsequent network rigidity occurring during
swelling as described previously will follow a similar trend, becoming effective at
hindering cisplatin diffusion and counterbalancing the osmotic gradient earlier on in the
in vitro release process as the lactose-to-cisplatin proportion is increased across
formulations. The CDDP40 formulation, containing more cisplatin than lactose, is most
likely accelerating cisplatin release during phase 3 because the swelling of the sample
is not sufficient to fully counterbalance the osmotic solute gradient and diffusion of the
now-dissolved cisplatin from within the pores of the composite to the outside solution.
The cisplatin release rates during each phase are plotted as a function of lactose
content in Figure 2.5 to illustrate this point further.
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Figure 2.5: Cisplatin release rate plotted as a function of formulation lactose content. As
the lactose content increases the phase 1 release rate (pink circles) increases until a
certain percentage of lactose after which the amount of cisplatin in the sample is too little
to continue the trend and the cisplatin release rate drops (CDDP5 formulation at 45%
lactose content). This observation is due to the fact that the total solid powder content in
each formulation is kept constant while ratios of cisplatin and lactose are varied. A
similar trend is observed for phases 2 (blue rectangle) and 3 (yellow triangle) although
less pronounced than in phase 1 likely due to the fact that sample swelling is
counteracting aqueous solution entry into the matrix and slowing down cisplatin release
universally. The release rate consistently drops from phase 1 to phase 3 for all but the
CDDP40 formulation. The CDDP40 formulation instead exhibits a slightly faster release
rate in phase 3 compared to phase 2. This formulation contains more cisplatin than
lactose and so during phase 3 the swelling of the sample is likely no longer sufficient to
counteract the osmotic solute gradient and diffusion of the now-dissolved cisplatin from
within the pores of the composite.
It is important to note that the total excipient content of 50% w/wtota, was
selected based on preliminary experiments as well as the existing literature in an effort
to create interconnected pores throughout the thickness of a composite sample. Having
such a network of interconnected pores would theoretically allow the entire excipient
load to be released once immersed in an aqueous solvent assuming sink conditions are
maintained around the sample. It may be however that the excipient content is not
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enough to fully connect all the excipient crystals to each other, leaving some crystals
undissolved inside the sample. This is not expected to be an issue as long as enough
crystals are in contact to sustain cisplatin release at the desired rate for the desired
amount of time and so deliver the intended cumulative cisplatin dose to the patient. The
porosity and pore interconnectivity of the composite material could be assessed
quantitatively by various methods including analysis of z-stacks of SEM images,
mercury porosimetry, permeability tests based on Darcy's law, gas adsorption and the
Brunauer-Emmett-Teller equation as well as three-dimensional imaging such as micro-
computed tomography, magnetic resonance imaging and confocal or multiphoton
microscopy.' 1 6
The in vitro cisplatin release data were used to determine which of the four
formulations would be best suited to use as the basis for a clinically relevant implant,
including material fine-tuning, in vitro anticancer toxicity assessment and in vivo
evaluation in animal models. The CDDP25 formulation was selected for further
development based on (i) its near-zero-order cisplatin release profile for the entire
duration of the 109-day release studies that exhibited small changes in release rate
from one phase to the next and (ii) its average cisplatin release rate (0.780 pg/hr/cm 2,
weighted average 0.773 pg/hr/cm 2) that was the largest of the four initial formulations.
The average disk sample mass and estimated cisplatin content for each
formulation tested in these in vitro release studies are listed in Table 3, along with the
amount of cisplatin released over 109 days in vitro calculated as a percentage of the
sample payload. These calculations illustrate that only a fraction of the total cisplatin
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payload was released over 109 days, suggesting that these composites can continue
releasing drug for a much longer period of time if necessary.
Formulation Average
sample mass
Estimated
cisplatin
Total cisplatin
released after 109
Fraction
released
(mg) content (mg) days (mg) (%)
CDDP5 27.82 1.39 0.797 57
CDDP10 31.64 3.16 1.292 41
CDDP25 34.10 8.53 1.286 15
CDDP40 25.95 10.38 0.598 6
Table 2.3: Cisplatin content release characteristics for the four composite formulations over
109 days in vitro. Average sample mass, estimated cisplatin content per sample based on the
% Wcispiatin/Wtotai formulation ratio, average total cisplatin released as determined quantitatively
by HPLC in studies 1-4 of Figure 6 and calculated fraction of total cisplatin content per sample
that was released over the 109-day in vitro release period are given for each of the four
formulations. All formulations released less than 60% of their estimated cisplatin content with
CDDP5 releasing the most (57%) and CDDP40 releasing the least (6%) of their respective
payloads. CDDP40 contains primarily cisplatin that dissolves over a much longer timescale in
aqueous solvents compared to lactose and therefore is expected to be the slowest-releasing
formulation. These values suggest that all formulations could continue release past the 109
days until they had released their entire payload or until the only cisplatin remaining was
trapped in spots not accessible to the interconnected network of pores created through
dissolution of cisplatin and lactose by PBS.
2.3.4 In vitro cytotoxicity
CDDP25 samples were as effective as an equivalent in vitro cisplatin solution in killing
both cisplatin-sensitive and cisplatin-resistant human ovarian cancer cells in vitro. No
cytotoxicity was observed as a result of exposure to Ecoflex 00-30 alone or the lactose-
only composite LAC5K. Cells treated with cisplatin were exposed to either a single 5
mm-diameter CDDP25 disk (total surface area 0.628 cm 2 , average release rate 0.777
pg/cm 2/hr) or a cisplatin solution containing 11.7 pg of cisplatin (the equivalent amount
of drug released over 24 hours). Cell viability for each group is plotted in Figure 2.6. It is
important to note that the CDDP25 disk released cisplatin gradually while the equivalent
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cisplatin solution group was exposed to the entire 24-hour cisplatin amount from the
start of treatment. The CDDP25 disk was still able to accomplish greater cell toxicity
against both the cisplatin-sensitive UC1101 cell line and the cisplatin-resistant SKOV3
cell line compared to the equivalent cisplatin solution. The difference was not
statistically significant when compared across all groups with a one-way ANOVA with
Tukey's multiple comparisons test. This difference in cell kill may however be explained
in part by the fact that cisplatin loses its activity over time in solution. 1 7', 18 The drug's
half-life in vitro at 370C has been reported to range from less than 2 hours (in human
blood, plasma or ultrafiltrate)'1 9 to almost 12 hours (in RPMI 1640 cell culture medium
supplemented with 10% FBS) 0. Media changes in this study were performed every 24
hours. The CDDP25 disk releases freshly dissolved drug steadily over the 24-hour
period. The equivalent cisplatin dose accomplishes a high-dose cisplatin exposure that
may then start to diminish after a few hours as the drug degrades whereas the disk
continues to release fresh, active cisplatin over time. The drug more readily kills
cisplatin-sensitive cells and so this effect of a high transient dose vs. a low continuous
dose is more dramatic with cisplatin-resistant cell lines like SKOV3 that are harder to kill
with cisplatin. Dose-dense chemotherapy has been championed as an approach to help
address drug resistance in many types of cancers including ovarian cancer and this
phenomenon may be attributed to a similar mechanism. 121-12' The findings of the in vitro
cytotoxicity studies confirm .that the drug released from the CDDP25 composites is
active against both cisplatin-sensitive and cisplatin-resistant cancer cells as expected
and that no other component of the composite material (the silicone matrix or the
lactose sacrificial excipient) is causing any of the observed cytotoxicity.
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Figure 2.6: Cytotoxicity of the CDDP25 composite formulation against
cisplatin-sensitive (UC1101) and cisplatin-resistant (SKOV3) human
ovarian cancer cell lines. Cells were cultured as monolayers. (A) and
(B) present the normalized viability after 72hrs of exposure to either a
CDDP25 disk in a Transwell insert (red, n=3), an equivalent cisplatin
solution in cell culture media (blue, n=3), regular cell culture media
(green, n=3), a LAC50 disk in a Transwell insert (pink, n=2) or an
Ecoflex 00-30 disk in a Transwell insert (yellow, n=2). LAC50 and
Ecoflex 00-30 caused no cytotoxicity to either cell line while the
CDDP25 disk resulted in greater cell kill compared to an equivalent
cisplatin dose but the difference was not statistically significant based
on one-way ANOVA with Tukey's multiple comparisons test across all
groups.
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2.3.5 In vivo composite toxicity
CDDP25 5 mm-diameter disks implanted intraperitoneally in mice were well tolerated
and did not cause any toxicity as confirmed by animal weight tracking, CBC and
histological examination of key abdominal organs known to suffer toxicity as a result of
cisplatin treatment (liver, kidneys, spleen, small and large intestine, bone marrow)
(Figure 2.7). All examined organs appeared normal and a thin capsule was seen around
the CDDP25 implant displaying very little fibrosis after 15 days of implantation (Figure
2.8), which helps address any concern about fibrous capsule formation around the
implant hampering cisplatin release from its surface. No remarkable histological
differences were noted in any of the organs examined in the IP injection group. CBC
with differential showed that the white blood cell (WBC), lymphocyte (LY) and red blood
cell (RBC) counts were largely within normal bounds (dashed lines in Figure 2.71B-D) for
all mice at euthanasia. Platelet (PLT) count was within normal bounds for mice
implanted with the CDDP25 formulation but was slightly below normal for mice that
received a single 4 mg/kg IP injection of cisplatin, suggesting possible
thrombocytopenia (Figure 2.7E). Thrombocytopenia is a known side effect of platinum
chemotherapy that is commonly addressed by supplementing with thrombopoietic
agents like thrombopoietin, reducing the chemotherapy dose or, in extreme cases,
stopping chemotherapy altogether.12 4 The reduction in platelet count in the IP group is
small and the value is still close to the normal lower bound. It is possible that 48 hours
are not enough to actually see meaningful changes in platelet survival based on the cell
half-life (7-10 days in human patients).12 4 This finding however may be indicative of
hematopoietic toxicity caused by the bolus IP cisplatin injection that is absent when
treating with the CDDP25 formulation.
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Figure 2.7: In vivo toxicity results of 15-day implantation with
a CDDP25 disk. (A) is a plot of average mouse weight
normalized to its value at the start of treatment and tracked
starting five days before start of treatment and through the
treatment period for CDDP25-implanted mice (red line) and
mice receiving a single 4 mg/kg IP cisplatin injection (blue
line). The latter group was euthanized 48 hours after injection
to observe any toxicity caused by the cisplatin before the
tissues had a chance to regenerate so weight tracking stops
on day 2, the last day of the group's treatment period. Both
groups showed relatively stable weights with the CDDP25
group animals experiencing a slight weight loss after surgery,
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which is expected, and recovering from it by day 7. (B)-(F)
are plots of the average cell density of white blood cells,
neutrophils, lymphocytes, red blood cells and platelets
respectively for each of the two treatment groups. Values
were obtained by CBC with auto-differential from samples
collected at euthanasia. A healthy animal was included to
provide a normal control as an extra security check against
the normal bounds given by the CBC analysis software. All
values were within normal bounds for all groups with the
exception of platelet counts for the mice receiving a singe
4mg/kg IP injection, which were low. Dashed lines indicate
normal value bounds.
76
4-- - _- --.- --- -m- -0--------...
40 - 'M
lk nI V
A
77
10 iPm
'1000
B
Figure 2.8: Representative histology with H&E staining from mice implanted with a CDDP25
disk for 15 days. (A) Clockwise from top left: liver, kidney, bone marrow and spleen sections
showed no tissue pathology. (B) Representative implant and surrounding capsule sections from
the two mice in the toxicity study. A thin capsule was noted around the implant displaying a very
small amount of fibrosis. Arrows point to capsule.
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2.3.5 In vivo abdominal platinum distribution
The CDDP25 disks resulted in a higher concentration of platinum (Pt) in pg Pt/g tissue
compared to a 4 mg/kg IP injection of cisplatin after 15 days of implantation in all organs
examined while the blank Ecoflex 00-30 implants resulted in a negligible concentration
of Pt in all organs examined (Figure 2.9). The difference in Pt concentration was
statistically significant for the liver (3.265 pg/g vs. 0.313 pg/g, p < 0.0001), the kidneys
(5.247 pg/g vs. 0.403 pg/g, p < 0.0001), the small intestine (0.970 pg/g vs. 0.170 pg/g, p
< 0.0001), the large intestine (1.198 pg/g vs. 0.145 pg/g, p = 0.006) and the ovaries and
uterus (1.320 pg/g vs. 0.191 pg/g, p = 0.0118). There was no statistical significant
difference in Pt levels for any tissue between the single IP injection and blank Ecoflex
00-30 implant groups. All the values for all organs across the three groups are tabulated
in Table 2.4.
The average in vitro cisplatin release rate for the CDDP25 implant was 0.488
pg/hr (using an average of 0.777 pg/cm 2/hr from Table 2 and multiplying by the implant
surface area). This translates to a weekly cisplatin dose of approximately 82 pg. A 4
mg/kg IP cisplatin injection delivers approximately 80-100 pg of cisplatin to an average
mouse weighing 20-25 g. The total amount of cisplatin delivered by an implant over a
two-week period would therefore be approximately 1.6-2X the amount delivered by a
single 4 mg/kg IP injection based on in vitro release data. The in vivo release rate, even
though not quantified yet, is expected to be lower due to any small amount of fibrosis
encasing the implant, the presence of tissues and in particular of fat in direct contact
with the implant surface as well as due to the higher protein content of the peritoneal
fluid compared to PBS that is likely to slow down fluid uptake into the implant and
cisplatin dissolution. The difference, if any, in total cisplatin delivered over the intended
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treatment period for each group is nevertheless not sufficient to explain the significantly
higher levels of platinum in all abdominal tissues after implantation with the CDDP25
sample compared to an IP cisplatin injection. This difference points to the fundamental
issue of drug clearance from the peritoneal cavity following bolus administration that
results in a transient drug concentration spike that may not necessarily translate to
elevated penetration of the drug into the tissues of interest in the abdomen. A
continuous low-dose releasing implant can however accomplish such an elevated
platinum content in these tissues and may thus be able to more effectively and
consistently expose microscopic metastases throughout the peritoneal cavity to
cisplatin.
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Figure 2.9 Platinum distribution results of in vivo 15-day CDDP25 disk
implantation. (A) Average mouse weight normalized to its value at the start of
treatment for each treatment group and each time point. Weights are notincluded for the %A hr, 1 hr and 2hr IP injection time points since their weight did
not change from the start of treatment. None of the groups experienced anydramatic loss in weight suggesting that their overall health remained good
throughout the treatment period. Error bars indicate standard deviation from the
mean. (B)-(D) Normalized tissue platinum (Pt) content in ppb for each of the
abdominal organs examined in the Ecoflex 00-30, single 4mg/kg IP injection
and CDDP25 implant group respectively. The Ecoflex 00-30 group exhibited
almost negligible Pt content as expected while the IP injection group exhibited
a spike in Pt content soon after injection that wore off to almost negligible levels
for all organs by 15 days after injection. The CDDP25 implant group exhibited
Pt content that was higher than that of the IP injection group on all time points
examined for the liver and spleen and was higher than the IP injection group for
all organs on the 15-day time point. Error bars indicate standard deviation from
the mean. (E) Box-and-whiskers plots of the average normalized tissue Pt
content in ppm for the two cisplatin treatment groups only (IP injection andCDDP25 implant) 15 days after the start of treatment. The ends of the box in
plot E are the upper and lower quartiles of the data, the lines outside the boxindicate the highest and lowest values and the median is marked by the vertical
line inside the box. The CDDP25 group had higher normalized Pt content in all
organs compared to the IP injection group. The difference was statistically
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significant for the liver, kidneys, small intestine, large intestine and
ovaries/uterus/fallopian tubes when compared with an unpaired student's t-test.
These data support the hypothesis that the CDDP25 implant, even though
releasing cisplatin at a much lower dose than that accomplished briefly by the 4
mg/kg IP injection can achieve a higher total exposure of tissue to platinum.
The high levels of Pt in the liver, kidneys, spleen and intestines achieved by the
CDDP25 implant may however also be cause for concern for toxicity even
though mouse weight remained relatively constant throughout the study. A
follow-up toxicity study was carried out to confirm that these ppm values were
not toxic to the tissues.
Pt level
(pg / g tissue)
CDDP25 IP
implant injection
Ecoflex
00-30
implant
CDDP25
vs.
injection
Comparison
p-value
CDDP25
vs.
Ecoflex
00-30
Liver
Kidneys
Spleen
Stomach
S Intestine
L Intestine
Ovaries +
Uterus
Fat pad
3.265
5.247
1.514
1.491
0.970
1.198
1.32
1.136
0.313
0.403
0.522
0.259
0.170
0.145
0.191
0.104
0.139 <0.0001 <0.0001 0.841
0.018 <0.0001 <0.0001 0.764
0.049
0.035
0.724
0.181
0.643
0.207
0.945
0.944
0.015 <0.0001 <0.0001 0.298
0.013
0
0.037
0.0005 0.0009
0.013
0.181
0.014
0.279
0.758
0.809
0.992
Table 2.4: Platinum levels in tissues for all animal groups in the 15-day Pt distribution
study. The p-values of comparing the mean of each group to the mean of every other
group using one-way ANOVA with Tukey's multiple comparisons test are also tabulated.
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Tissue
Injection
vs.
Ecoflex
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2.4 Discussion
The objective of this work was to develop a material as the basis for an IP implant that
could release cisplatin in a controlled, sustained manner while being safe for
implantation and effective against ovarian cancer in vitro. A matrix-type drug delivery
system was created to take advantage of the high level of control in drug release that it
allows and load the drug in solid form to minimize implant dimensions and preserve
drug activity.2 ,45'98 The implant is intended for placement in the peritoneal cavity, a
complex space that may change in volume depending on the amount of accumulated
peritoneal fluid that fluctuates with time and with a person's health status. The
peritoneal cavity is also in intimate contact with critical organs of the abdominal viscera
like the liver, kidneys, spleen and part of the digestive tract, which can be injured upon
contact with a mechanically mismatched implant. A matrix-type system is preferred over
a reservoir-type system because it can lead to smaller implant dimensions and offers
more tunable mechanical properties than a reservoir filled with solid drug powder.
Mechanical matching to surrounding tissue is a critical component of what
makes an implant safe and well tolerated in vivo. Mechanically mismatched implants
can trigger a foreign body response: an immune response to the implant that attempts
to encapsulate it in a fibrous sheath and therefore isolate it from the surrounding tissues
and the rest of the body. Mechanically mismatched implants may, beyond the foreign
body response, directly irritate and traumatize tissues that they come in contact with
inside the abdominal cavity. This can lead to the formation of adhesions - fibrous tissue
bands bonding abdominal organs and tissues together and causing side effects that
range from pain and discomfort to potentially life-threatening complications like bowel
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obstruction.125 127 Adhesions not only reduce a patient's quality of life but have also
been stipulated to affect effectiveness of IP-delivered chemotherapy in cancer treatment
due to the obstructive effect of the scar tissue in the distribution of the chemotherapy
solution in the peritoneal cavity. 128 , 129 A silicone elastomer was used to create
composite cisplatin-eluting materials because silicone elastomers have well-
documented biocompatibility and minimized fibrotic response as long-term implants. 13 0
133 Ecoflex 00-30 was used in particular because it is readily available off-the-shelf, has
mechanical properties similar to those of soft tissue, has been certified as safe for skin
contact and has previously been implanted in vivo in animals over the course of multiple
weeks with no adverse biocompatibility findings. 99,1 02 ,134
Cisplatin was used as the chemotherapeutic agent of choice because it is part
of the first-line standard of treatment for many cancers that metastasize to the
peritoneal cavity including ovarian cancer. Cisplatin is slightly hydrophilic (logP -2.27)135
while Ecoflex 00-30 is hydrophobic being a silicone elastomer. Lactose was used as the
sacrificial pore-generating excipient of choice because it is an excipient commonly
found in the pharmaceutical industry that poses very low risk of adverse patient side
effects, is readily soluble in water and has a molecular weight similar to that of cisplatin.
Structural examination of the composite materials developed in this work
confirmed that they comprised a polymer matrix with solid powder crystals uniformly
distributed throughout the sample thickness. EDS examination confirmed that the solid
powder crystals comprised lactose and cisplatin randomly distributed in the silicone
matrix with no evidence of dissolution or partition.
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Preparation of the composite materials developed in this work involves a
straightforward and simple mixing and casting method that ensures ease of fabrication
and of scale-up to produce both larger-sized implants and batches of multiple implants
at a time. The pot life of Ecoflex 00-30 is 45 minutes according to the manufacturer but
it becomes much shorter for Ecoflex 00-30-based composites with 50% Wpowder/wtotai. No
attempt was made to measure the pot life of these composites per se but experience
casting them places their pot life closer to 15 minutes. This is a disadvantage of using
Ecoflex 00-30 that can complicate implant fabrication as it imposes a limit on the
amount of working time from combining the two parts of the silicone elastomer to
casting and degassing the sample before it starts to cure. Other silicone candidates like
ExSil 100 or ExSil 50 (Gelest, Inc., Morrisville, PA, USA), whose curing time can be
highly controlled with temperature, have been identified and preliminary tests have
shown that CDDP25 and LAC50 composites can be manufactured using them in place
of Ecoflex 00-30. Further testing and development is warranted to confirm controlled,
sustained cisplatin release and cytotoxicity in vitro as well as tolerability and in vivo
functionality of these composites.
The mechanical properties of the LAC50 composites produced in this study,
measured both after production with no further processing and after a 42-day leaching
period in PBS that simulated a 6-week IP implantation, were found to fall within the
range of values typical of organs in the abdominal cavity. Histological examination of
CDDP25 disks implanted in vivo in the peritoneal cavity of healthy, immunocompetent
mice that can mount a foreign body response with subsequent fibrous capsule formation
showed minimal signs of fibrosis after 15 days of implantation. The overall body
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condition of the animals implanted with Ecoflex 00-30 disks or CDDP25 disks was good
and they were able to return to their pre-surgery weight soon after implantation,
suggesting that their overall health status was good while being implanted with the disks
(Figures 2.6A, 2.7A). These data combined provide evidence that the composite
implants developed in this study are mechanically well matched to the surrounding
tissues in the abdominal cavity and can be implanted safely from a mechanical
properties perspective. They can therefore form the basis for a peritoneal implant of
appropriate dimensions to achieve the desired cisplatin dose and surface area for drug
delivery for ovarian cancer patients with microscopic peritoneal metastases left behind
after surgical debulking.
The four different composite formulations developed were found to release
cisplatin in a controlled, sustained manner over a period greater than 100 days in vitro
under physiologic temperature and pressure. Their cisplatin release profiles are in
accordance with a matrix-type drug delivery system driven by drug dissolution and
diffusion through the pores generated throughout the polymer matrix by the leached
solid powder. A brief 24-hour burst period is followed by three distinct phases of near-
zero-order release for all formulations. All formulations released only a fraction of their
total payload after 109 days in vitro, indicating that they could sustain cisplatin release
for a longer period of time. The total duration of treatment for ovarian cancer patients
receiving IP chemotherapy is 18 weeks (6 chemotherapy cycles x 3
weeks/cycle). 18,23 ,136 Each cycle lasts 3 weeks because it includes a 2-week drug-free
break to allow the patient to recover from the severe toxicity and side effects caused by
the bolus maximum-tolerated-dose chemotherapy infusion. A treatment regimen like the
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one proposed in this work that relies on continuous low-dose chemotherapy instead of
periodic maximum-tolerated-dose chemotherapy would presumably last shorter than 18
weeks. The composites developed here are however expected to sustain treatment
over 18 weeks or even longer if necessary.
The CDDP25 formulation, selected for further testing and development based
on its in vitro cisplatin release rate, showed cytotoxic activity in vitro against both
cisplatin-sensitive and cisplatin-resistant human ovarian cancer cells. Its cytotoxic
activity was at least as effective as that of an equivalent cisplatin solution and no
cytotoxic effect could be attributed to the sacrificial lactose excipient or the Ecoflex 00-
30 matrix alone. The CDDP25 formulation was in fact found to be more effective against
the cisplatin-resistant SKOV3 cells than an equivalent cisplatin solution. This may be
attributed to the continuous release of freshly dissolved, active cisplatin from CDDP25
contrasted with the cisplatin degradation occurring over time in the equivalent cisplatin
solution. Degradation of cisplatin due to temperature, pH or exposure to light is an
important consideration that may affect a solution's therapeutic potency.17 118
CDDP25 disks were able to release cisplatin in vivo after IP implantation in
mice and they resulted in higher tissue platinum content at the 15-day time point in all
harvested abdominal organs compared to a single 4 mg/kg IP cisplatin injection. The
statistically significant higher platinum levels found in the liver, kidneys and spleen of
the mice implanted with CDDP25 disks along with the fact that cisplatin has known
toxicity against these organs warranted further confirmation that these elevated values
were not associated with organ toxicity. It was also important to assess whether the
cisplatin dose released by the CDDP25 disks in vivo was well tolerated overall. Neither
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the physical presence of the CDDP25 disks nor the cisplatin dose that they released in
vivo caused toxicity as tracked by weight loss, histologic examination of abdominal
organs or CBC values. H&E-stained slides of the liver, spleen, kidneys, small and large
intestine and bone marrow of the animals did not show any histologic abnormalities.
The white blood cell, lymphocyte, neutrophil, red blood cell and platelet counts of the
mice were all within normal values throughout the implantation period. These data taken
together provide evidence for the in vivo functionality of the CDDP25 disks in delivering
cisplatin in the peritoneal cavity at a dose that was well tolerated and at the same time
resulted in higher platinum concentration in key abdominal organs compared to a bolus
cisplatin IP injection. An implant releasing low-dose cisplatin continuously in the
peritoneal cavity can thus accomplish higher platinum levels in target organs compared
to bolus dosing without causing toxicity. These platinum levels however may be due to
tissue accumulation of both cisplatin and its inactive degradation products. A way to
differentiate between these sources of platinum in the tissue or an assessment of
antitumor efficacy in addition to platinum accumulation will help answer whether these
higher platinum levels seen with the CDDP25 implants translate into tumoritoxic
advantage. This platinum distribution study additionally did not differentiate between
tissue close to the edge of organs and deeper tissue when quantifying tissue platinum
concentration. The penetration depth of IP platinum chemotherapy is a cornerstone of
its benefit over systemic chemotherapy administration and various methods including
heat and pressure have been explored to enhance it further. 118,137-142 The size of tumors
left behind after cytoreductive debulking surgery in fact critically affects the outcome of
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IP chemotherapy in patients and so understanding how deep inside a tissue mass can
continuous low-dose cisplatin penetrate will be a critical next step. 1 ,18,2 3
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Chapter 3: Development of Spheroid-based Ovarian Cancer
Models to Capture the Impact of Residual Tumor Size on the
Effectiveness of Intraperitoneal Chemotherapy*
3.1 Introduction
Surgical tumor debulking is one of the most important components of treating advanced
ovarian cancer that has metastasized to the peritoneal cavity. The current standard of
care calls for optimal cytoreduction whenever possible leaving behind sub-centimeter
tumors. 14 ,6 8,6 9, 14 3-145 Residual tumor size affects tumor response to subsequent
chemotherapy particularly for IP administration but the mechanism that controls drug
transport into residual tumors is debated. Ovarian cancer tumor models with controlled
dimensions were developed in vitro using spheroids. They were then exposed to
different cisplatin dosing regimens mimicking intermittent high-dose and continuous low-
dose treatment in order to better understand how spheroid size affects response to the
drug. Small spheroids were found to respond the same way to intermittent high-dose
and continuous low-dose cisplatin. Large spheroids were found to shrink most
effectively after exposure to a continuous cisplatin regimen delivering the largest
cumulative dose. 83 These findings support the diffusion-controlled theory regarding drug
penetration into subcentimeter residual tumors and underscore the importance of
optimal surgical debulking for treating ovarian cancer patients with IP chemotherapy.
Continuous low-dose IP cisplatin has previously been shown to be as effective in
treating mice with human ovarian tumor xenografts as intermittent high-dose IP cisplatin
while causing less toxicity.45 Ovarian cancer mouse models based on spheroids were
* Parts of this chapter were reproduced or adapted from Tanenbaum and Mantzavinou et al.
(2017).7
92
piloted to attempt tighter control of tumor size at the start of treatment and more diffuse
dissemination of nodules throughout the peritoneal cavity in efforts to more closely
recapitulate the clinical appearance of advanced ovarian cancer after optimal surgical
cytoreduction. These models hold promise to more accurately assess the efficacy of
continuous low-dose vs. intermittent high-dose IP cisplatin as a follow-up to this work.
The in vitro and in vivo findings of this work illustrate the critical role that debulking
surgery plays in affecting the prognosis of ovarian cancer patients, the need to better
standardize the outcome of debulking surgery in terms of residual disease, the urgency
to develop animal models that more closely resemble patients after debulking surgery
when assessing the efficacy of new treatment regimens particularly for IP delivery and
the promise of adjuvant IP chemotherapy for superior outcomes in ovarian cancer
patients with microscopic residual tumors after surgery.
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3.2 Materials and Methods
3.2.1 Chemicals and materials
AggreWell 400 and AggreWell 800 24-well plates containing 1200 (AggreWell 400) or
300 (AggreWell 800) microwells per well with a 400-pm (AggreWell 400) or 800-pm
(AggreWell 800) microwell diameter were purchased from StemCell Technologies
(Vancouver, Canada). RPMI 1640 cell culture medium with no added L-glutamine,
0.25% trypsin-EDTA, FBS and 100x penicillin-streptomycin-glutamine were purchased
from Thermo Fisher Scientific (Cambridge, MA, USA). Pluronic F-127 was purchased
from Sigma-Aldrich (St. Louis, MO, USA). Sterile cell culture grade water, sterile
phosphate-buffered saline (PBS) and Becton-Dickinson ultra-fine U-100 insulin syringes
3/10 cc 31G were purchased from VWR International (Radnor, PA, USA). Medical
injection-grade cisplatin solution (100 mg/100 mL) for use in the spheroid cisplatin
exposure studies was purchased from McKesson Medical-Surgical (Richmond, VA,
USA). Sterile, non-tissue culture treated 24-well polystyrene plates were purchased
from Thermo Fisher Scientific (Waltham, MA, USA). Luciferin was purchased from
PerkinElmer (Waltham, MA, USA).
3.2.2 Cell culture
The UC1101 cell line expressing the firefly luciferase gene was provided by Dr. G. Scott
Rose (University of California, Irvine, CA, USA). The A2780 cell line expressing the
firefly luciferase gene was purchased from Sigma-Aldrich (St. Louis, MO, USA). Cells
were pathogen tested in 2015 by the Comparative Pathology Laboratory at MIT and in
2018 by the High-Throughput Screening Core at the MIT David H. Koch Institute for
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Integrative Cancer Research and tested negative for mycoplasma. Cells were grown as
monolayers at 370C with 5% CO2 using RPMI 1640 medium containing 10% FBS and
1% pen-strep-glut and were subcultured with 0.25% trypsin-EDTA at regular time
intervals to maintain cell densities below 80% confluence. Cell monolayers were
trypsinized at approximately 80% confluence for the creation of spheroids. Cells were
not used after passage number 13.
3.2.3 Spheroid formation
AggreWell 400 plates were used to generate (i) UC1101 spheroids of approximately
100- or 200- pm diameter comprising 100 or 2000 cells per microwell and (ii) A2780
spheroids of approximately 100-, 150-, 175- or 200-pm diameter comprising 100, 500,
1000 or 2000 cells per microwell for in the in vitro cisplatin exposure and shrinkage
evaluation studies. AggreWell 400 and AggreWell 800 plates were used to generate
UCl101 spheroids of approximately 190-, 200- or 300-pm diameter respectively
comprising 1250, 2000 or 10000 cells per microwell for the in vivo spheroid model pilot
studies. Each well of an AggreWell 400 or 800 plate was filled with 500 pL of 5% sterile
pluronic F-127 in cell culture-grade water to create a coating that prevents cell adhesion
to the microwell wall. Plates were centrifuged at 3500 RPM for 5 minutes to fill the
microwells within each well with the pluronic solution (5810R Centrifuge, Eppendorf,
Hamburg, Germany). Plates were examined under a microscope to confirm that no air
bubbles remained in the microwells. A second centrifugation step was carried out if air
bubbles were present in order to eliminate them. Plates with wells containing the
pluronic solution were subsequently incubated at room temperature for 30 minutes and
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then washed twice with sterile cell culture-grade water and twice with FBS-free cell
culture medium (500 pL per wash). The last culture medium wash was not removed
from the wells until immediately before adding the cell suspension for spheroid
formation. The cell suspension for spheroid formation was prepared in FBS-free cell
culture medium to prevent cell division overnight during spheroid formation and thus
achieve greater accuracy at estimating cell number per spheroid. To add the cell
suspension, each well was aspirated but not fully to prevent formation of air bubbles in
the microwells. 500 pL of homogeneously mixed cell suspension were added to each
well at a specific cell density to accomplish a desired spheroid diameter. Spheroids of
approximately 100-, 150-, 175-, 190-, 200- or 300-pm diameter comprising 100, 500,
1000, 1250, 2000 or 10000 cells per microwell translated to 1.2 x 105 , 6 x 105 , 1.2 x 106,
1.5 x 106, 2.4 x 106 or 3 x 106 cells per well respectively. Plates were then centrifuged at
1000 RPM for 5 minutes to distribute cells within the microwells and incubated at 370C
with 5% CO2 for 24 hours to allow the cells to form spheroids. Spheroids were imaged
in situ in the AggreWell plates using transmitted light microscopy (Invitrogen EVOS FL
Auto Cell Imaging System, Thermo Fisher Scientific).
3.2.4 Spheroid cisplatin treatment and shrinkage evaluation
Only spheroids measuring 100 or 200 pm in diameter (comprising approximately 100 or
2000 cells respectively) were used in the cisplatin treatment and shrinkage assessment
studies. Spheroids were harvested from AggreWell plates after formation and
transferred to non-tissue culture treated 24-well plates for cisplatin exposure. Spheroids
were harvested by adding 500 pL of culture media to each well of the AggreWell plate
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and using a 1000 pL pipet to gently pipet up and down 2-3 times and dislodge the
spheroids from the microwells. Each well was subsequently washed three times with an
additional 1000 pL of media per wash to collect remaining spheroids. Spheroids of the
same size were collected in a 50 mL conical tube for each cell line and allowed to settle
to the bottom of the tube. The FBS-free cell culture medium was aspirated taking care
to not aspirate any spheroids and complete cell culture medium was added to a volume
that diluted the original spheroid suspension to prevent well overpopulation and
minimize spheroid aggregation. The dilutions were as follows: (i) UC1101: 1:2 dilution for
100-pm spheroids and 1:4 dilution for 200-pm spheroids; (ii) A2780: 1:1 dilution for 100-
pm spheroids and 1:2 dilution for 200-pm spheroids. 1000 pL of the dilute suspension
were added to each well of the non-tissue culture treated 24-well plate.
Four cisplatin treatment conditions were applied to 100-pm and 200-pm
spheroids from each cell line by incubating them with cisplatin-containing media at
predetermined concentrations for specific amounts of time (Figure 3.1). The four
cisplatin treatment groups for UC1101 spheroids were: (i) Untreated control for 72 hours;
(ii) IP cisplatin (5 pg/mL) for 2 hours; (iii) Device Low DL cisplatin (0.14 pg/mL) for 72
hours; and (iv) Device High DH cisplatin (0.5 pg/mL) for 72 hours. The four treatment
groups for A2780 spheroids were: (i) Untreated control for 72 hours; (ii) IP cisplatin (10
pg/mL) for 2 hours; (iii) Device Low DL cisplatin (0.28 pg/mL) for 72 hours; and (iv)
Device High DH cisplatin (1.0 pg/mL) for 72 hours. The IP cisplatin concentrations for
each cell line were chosen based on prior in vitro cytotoxicity data using cell
monolayers.4 The DL cisplatin concentrations for each cell line were chosen to match
the total area under the concentration-time curve (AUC) of the IP concentrations
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(UC101: AUCL = 10 pg-hr/mL; A2780: AUCL = 20 pg-hr/mL). The DH cisplatin
concentrations were chosen to deliver a higher AUC than the IP dose (UC1101: AUCH =
36 pg-hr/mL; A2780: AUCH = 72 pg-hr/mL). Cisplatin dosing varied between the two cell
lines to account for previously observed cisplatin sensitivity differences between UC1101
and A2780 monolayers 45 Doses were additionally increased from those previously used
against monolayers to account for the increased chemoresistance reported with three-
dimensional ovarian cancer cell spheroids.85 -7 ,89 Fresh cisplatin solutions were
prepared and media changes in the spheroid plates were performed every 12 hours to
maintain cisplatin activity throughout the 72-hour treatment period. 20 Media changes
were performed in all four treatment groups to account for any handling-induced
damage to spheroids not attributed to cisplatin. Spheroids were imaged after 6, 24, 48,
and 72 hours of treatment and the lmageJ software was used to measure the length
and width of non-aggregated spheroids to calculate average spheroid diameter at each
time point. Unless noted otherwise, a total of fifteen spheroids were measured for each
spheroid size at each treatment condition and time point for each cell line to calculate
an average spheroid diameter.
3.2.5 In vivo spheroid model pilot studies
Female Nu/Nu immunodeficient mice (Charles River Laboratories, Wilmington, MA,
USA) were used for the in vivo spheroid pilot studies. Nu/Nu mice lack a thymus and
are therefore unable to produce T-cells making them appropriate for xenograft research.
The UC1101 cell line was used to generate spheroids as described previously.
The first pilot study compared orthotopic human ovarian cancer xenografts
98
generated by IP injection of 3 x 106 UCl101 cells as a suspension of 188-pm diameter
spheroids to xenografts generated by IP injection of 3 x 106 UC1101 cells as a free cell
suspension (n=3 mice per group). The second pilot study compared orthotopic human
ovarian cancer xenografts generated by IP injection of 3 x 106 UC1101 cells as a
suspension of 188-pm diameter spheroids to xenografts generated by IP injection of 3 x
106 UCl101 cells as a suspension of 301-pm diameter spheroids (n=6 mice per group).
For spheroid injections, spheroids were generated as described previously and allowed
to settle to the bottom of a 50 mL conical tube after collection from the AggreWell
plates. For free cell injections, UC1101 cells were grown as a monolayer, harvested in
50 mL conical tubes when they reached -80% confluence and centrifuged at 100 g for 5
minutes to create a pellet. The culture medium was aspirated and cold sterile PBS
(stored at 40C) was added to the spheroid or free cell suspension to create a cell
density of 3 x 106 UC1101 cells / mL of PBS. 1 mL of the spheroid or free cell
suspension was loaded into 1 cc syringes using 18G blunt tip needles to prevent
spheroid or cell shearing. The blunt tip needles were replaced with 25G or 21G bevel tip
needles for in vivo injection of 188-pm spheroids/free cells or 301-pm spheroids
respectively. Loaded syringes were stored in ice until injection. UC1101 cells grown as
monolayers were harvested to create spheroids over 24 hrs as well as prepare the free
cell injections for tumor inoculation. Mice receiving free cell injections were injected a
day prior to mice receiving spheroid injections as a result in order to use cells of the
same passage number in both groups. The rate of tumor uptake and distribution of
tumors throughout the mouse abdomen were evaluated noninvasively via
bioluminescence imaging (BLI) at regular time points after cell injection using the IVIS
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Spectrul Pre-Clinical Trial In Vivo Imaging System from PerkinElmer (PerkinElmer,
Waltham, MA, USA). Mice were injected intraperitoneally with 5 pL of 30 mg/mL luciferin
solution per g of body weight using BD ultra-fine U-100 insulin syringes and imaged 10
minutes after injection. Mice in the first study (188-pm spheroids vs. free cells) were
imaged using the two-dimensional modality of the imaging system. Mice in the second
study (188-pm spheroids vs. 301-pm spheroids) were imaged using both the two-
dimensional and the three-dimensional modality of the imaging system in an attempt to
evaluate the size and location of individual tumor nodules more accurately. Both studies
continued until all mice required euthanasia. Mice were weighed regularly to monitor
overall health and euthanized upon weight loss greater than 20% or poor body
condition. Euthanasia was carried out by carbon dioxide inhalation at a steadily
increasing flow rate to minimize distress. Tumors and any ascites were collected at
euthanasia and their mass was recorded as a direct measurement of tumor burden.
3.2.6 Statistical analysis
A one-way ANOVA with Tukey's multiple comparisons test (InStat GraphPad Software,
San Diego, CA, USA) was used to compare average spheroid diameter across
treatment groups for each cell line and each spheroid size at each time point.
Experiments were done in triplicate for each cell line. Reported results are expressed as
mean standard deviation from the mean. Differences with p-value < 0.05 were
considered to be statistically significant. Statistical significance is indicated as: ns p >=
0.05; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
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Figure 3.1: Experimental design for spheroid exposure to cisplatin in vitro. Adapted
original schematic by L. M. Tanenbaum.
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3.3 Results
3.3.1 Spheroid formation
The UC1101 and A2780 human ovarian cancer cell lines were able to form spheroids
after 24 hours of culture in AggreWell plates. Different spheroid sizes were formed by
adding different cell concentrations in each microwell of the plate (Figure 3.2). The cell
number - spheroid diameter range generated for UCl101 and A2780 cells is tabulated
in Table 3.1 along with data for 500 and 1000 UCI101 cells per microwell previously
collected by L.M. Tanenbaum.
Cells in Resulting average spheroid diameter
microwell (pm)
UCH101 A2780
100 87.8 10.9 91.8 6.5
500 154.2 4.1 137.3 4.3
1000 173.1 5.2 171.6 5.0
2000 205.7 9.7 197.7 7.1
Table 3.1: Average diameter of spheroids produced with various
numbers of cells for the human ovarian cancer cell lines UC1101
and A2780. Diameter is measured using the length and width of
each spheroid on ImageJ (n=10 spheroids per group). Data for
500 and 1000 UC1101 cells per microwell collected by L.M.
Tanenbaum and reproduced.46
The relationship between spheroid diameter D and cell number per spheroid N
previously described by Tanenbaum was confirmed by plotting spheroid diameter as a
function of the cube root of the number of cells in the microwell:
D oc N 1/3
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Both cell lines displayed a strong linear relationship with linear best-fit trendlines
through the data displaying R2 = 0.97 for UCH101 and R2 = 0.99 for A2780 (Fig. 3.2B,D).
The spheroid diameters generated by both cell lines in these studies are clinically
relevant because they are similar in size to typical multicellular aggregates present in
malignant ascites in vivo (30 - 200 pm) 1 46 and are comparable to the subcentimeter- to
submillimeter-sized tumor nodules left behind after optimal surgical cytoreduction.7 '68
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Figure 3.2: Relationship between cell number and spheroid size in
UCl101 and A2780 spheroids. (A) and (C): UCl101 and A2780
spheroids respectively grown with various cells per AggreWell
microwell ranging from 100 to 2000. Spheroid size increased with
increasing cell number and the spheroids of all sizes displayed a
high degree of sphericity and compactness. Scale bar is 400 pm.
500- and 1000-cell per spheroid data collected by L.M.
Tanenbaum and reproduced. (B) and (D): Average spheroid
diameter for UC1101 and A2780 cells respectively correlated
strongly to the cube root of the cell number for each spheroid size(n=10, R 2=0.97-0.99). Error bars represent standard deviation.
Adapted.83
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3.3.2 Spheroid cisplatin treatment and shrinkage evaluation
Cisplatin treatment of 200-pm spheroids was compared to the treatment of 100-pm
spheroids for both cell lines following the treatment regimen outlined in Figure 3.1.
Cisplatin works by crosslinking DNA during mitosis, interfering with cell division and
causing the cell to become apoptotic after failing to repair the damaged DNA. No
spheroid shrinkage is therefore expected until the amount of time the spheroid has been
exposed to cisplatin has allowed for cell divisions to occur and for affected cells to
become apoptotic. UC1101 cells divide approximately every 24 hours while A2780 cells
divide every 13-22 hours. Spheroid shrinkage started becoming apparent at 48 hours
after the start of cisplatin exposure for both cell lines (Figures 3.3A, D and 3.4A, D).
Average spheroid diameter over time is plotted in Figure 3.3B, E (100-pm spheroids)
and Figure 3.4B, E (200-pm spheroids).
Exposure to any cisplatin dosing regimen led to significantly smaller spheroid
diameters for both cell lines and both spheroid sizes compared to untreated spheroids
at the 72-hour time point (p < 0.0001, Figure 3.3 and 3.4 C, F). Both UCl101 and A2780
small spheroids shrunk similarly after exposure to the IP and DH or DL cisplatin regimen
(p > 0.05, Figure 3.3C, F). Both UC1101 and A2780 large spheroids shrunk significantly
more after exposure to the IP cisplatin regimen compared to the DL regimen with the
same AUC (p < 0.001 for UC1101 and p < 0.05 for A2780, Fig. 3.4C, F). Both UCI101
and A2780 large spheroids shrunk significantly more after exposure to the DH cisplatin
regimen with a higher AUC compared to the IP regimen (p < 0.01 for UC1101 and p <
0.001 for A2780, Fig. 3.4C, F). The DH dose, in addition to spheroid shrinkage,
markedly reduced A2780 spheroid density and spheroid border definition after 72 hours
(Figure 3.5). This was especially noticeable in large A2780 spheroids and so diameter
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quantification excluded cell debris around the spheroid. The visibly reduced spheroid
density of large A2780 spheroids in the DH group after 72 hours compared to the IP and
DL groups further emphasizes the improved efficacy of this treatment regimen. Average
spheroid diameter standard deviation for all treatment arms and both cell lines after 72
hours is listed in Table 2. The DH dosing regimen resulted in an additional reduction of
large spheroid diameter by 35.7 pm (UC1101) and 46.3 pm (A2780) compared to the IP
regimen translating to a reduction in spheroid volume by 41.0% and 64.4% respectively.
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Figure 3.3: Small spheroid response to cisplatin exposure.
Representative bright field images of small (A) UC1101 and (D) A2780
spheroids at regular time intervals (6, 24, 48, and 72 h) after the start of
treatment for all treatment groups (control, IP, device low, device high).
Small spheroids had a starting diameter of approximately 100 pm.
Scale bars are 400 pm. (B),(E): Average small spheroid diameter
throughout the 72- hour treatment period was quantified at regular
intervals for untreated control, IP, DL, and DH groups for each cell line.
(C),(F): Scatter plot of spheroid diameters after 72 h of treatment
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showing the mean for each treatment group for small UC1101 and
A2780 spheroids. All treated spheroids were significantly smaller than
untreated controls after 72 h (p < 0.0001). DL doses with the same AUC
as the IP group caused the same degree of shrinkage (p > 0.05), and
DH also matched the spheroid shrinkage of the IP group (p > 0.05).
Only significant comparisons are highlighted in the figure; all other
statistical comparisons among treatment groups were not significant (p
> 0.05). Reported results are expressed as mean standard deviation
of the mean and n = 15 spheroids for each group. Adapted.
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Figure 3.4: Large spheroid response to cisplatin exposure.
Representative bright field images of large (A) UC1101 and (D) A2780
spheroids at regular time intervals (6, 24, 48, and 72 h) after the start of
treatment for all treatment groups (control, IP, device low, device high).
Large spheroids had a starting diameter of approximately 200 pm.
Scale bars are 400 pm. (B),(E) Average large spheroid diameter
throughout the 72- hour treatment period was quantified at regular
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intervals for control, IP, device low and device high groups for each cell
line. (C),(F) Scatter plot of spheroid diameters after 72 h of treatment
showing the mean for each treatment group for large UC1101 and
A2780 spheroids. All treated spheroids were significantly smaller than
untreated controls after 72 h (p < 0.0001). DL doses with the same AUC
as the IP group caused less shrinkage than IP treatment in both cell
lines (p < 0.001 for UCl101 and p < 0.01 for A2780), but high device
doses caused more shrinkage than the IP regimen in both cell lines (p
< 0.01 for UCl101 and p < 0.05 for A2780). Only significant
comparisons are highlighted in the figure; all other statistical
comparisons among treatment groups were not significant (p > 0.05).
Reported results are expressed as mean standard deviation from the
mean and n = 15 spheroids for each group. Adapted. 3
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Figure 3.5: Effect of cisplatin exposure on spheroid compactness and
border definition. Representative bright field images of A2780 spheroids
after a 72-hr cisplatin exposure to either (A) the IP (10 pg/mL for 2hr
followed by cisplatin-free media) or (B) the DH (1.0 pg/mL for 72hr)
treatment regimen. Spheroid density and compactness are visibly
reduced in the DH-treated spheroid compared to the IP-treated one.
This is an edded indicator of the superior efficacy of this dosing
regimen against the A2780 lage spheroids beyond spheroid diameter.
Scale bar is 100 pm. Adapted. 3
Average spheroid diameter after 72 hours (pm)
UCI101 A2780
Treatment group 100 cells 2000 cells 100 cells 2000 cells
Untreated control 211.4 31.1 366.4 34.9 215.7 38.9 302.5 38.1
IP 122.8 20.8 221.3 27.0 107.3 23.2 147.3 31.7
DL 145.2 20.3 266.8 26.7 118.6 18.2 188.7 29.2
DH 132.9 21.6 185.6 24.3 95.7 17.8 112.8 18.8
Table 3.2: Average spheroid diameter standard deviation for both cell lines after
exposure to each type of treatment over a 72-hr period. Adapted. 3
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3.3.3 In vivo spheroid model pilot study 1: feasibility
The UC1101 cell line was selected to pilot an in vivo orthotopic human ovarian cancer
model based on injecting cell spheroids intraperitoneally and compare it to the model
previously used in this project that relied on IP inoculation with free UC1101 cells. The
goal of this work was to assess whether spheroids could offer a viable tumor inoculation
platform to replace free cell injections.
A spheroid-based in vivo model is of great interest to this work. Spheroids are
expected to seed the peritoneal cavity with disseminated tumors more readily than free
cells since they are (i) more robust due to their compactness 147 and extracellular matrix
formation8 2 (ii) more metastatically aggressive similar to multicellular aggregates
shedding from the primary tumor and circulating in the peritoneal fluid of
patients.85 ,86 ,88 ,89 Spheroids also offer the potential to control the size of seeded
peritoneal tumors since spheroid size can be accurately determined immediately prior to
injection and assuming that they remain relatively non-aggregated when flowing inside
the mouse peritoneal cavity and seeding it with tumors. UC1101 spheroids measuring
approximately 188 pm in diameter and comprising approximately 1250 cells each
resulted in an increase in bioluminescence signal faster than free cells when injected
intraperitoneally in Nu/Nu female mice (Figures 3.6 and 3.7). The bioluminescence flux
color map also suggested a more widely disseminated disease in the peritoneal cavity,
with hot spots of maximum flux (shown in red) appearing as high up in the abdomen as
the mouse diaphragm and as low down as the bladder (Figure 3.6).
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Figure 3.6: BLI flux sequence over 80 days for mice injected with UC1101 free cells or
spheroids. Mice received a 3 x 106 cell injection either as (A) a free cell suspension or (B) a
suspension of spheroids with diameter approximately measuring 186 pm. Mice injected with
spheroids developed BLI signal faster and appear to have more diffuse disease throughout
the peritoneal cavity compared to those injected with free cells. The color map range is 1e 7-
1e8 for all images until day 60 and range is otherwise noted under the image. With L.M.
Tanenbaum.
The average signal over the course of the study was plotted as total flux over time for
each group and the results are shown in Figure 3.7. The spheroid group consistently
had higher flux values compared to the free cell group especially taking into account the
fact that the mice in the spheroid group were imaged a day closer to inoculation day
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compared to the mice in the free cell group. The spheroid group also increased their
average flux signal more dramatically over the same amount of time compared to the
free cell group. The standard deviation from the mean for both groups was however
high especially on time points when flux was very high for some of the mice in each
group. This variability in the signal prevents any meaningful statistical conclusions to be
drawn from this pilot dataset in terms of differences in total flux at comparable time
points in the inoculation period.
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Figure 3.7: Bioluminescence flux over time for the free cell and spheroid
mouse groups. Flux values are plotted on a (A) linear and (B) logarithmic
scale. Arrows indicate days when mice with highest signal had to be
euthanized. The spheroid group had higher flux than the free cell group on
almost all imaged time points indicating faster tumor growth in these animals.
The study started with n=3 animals in each group and mice were euthanized
when they were moribund.
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3.3.5 In vivo spheroid model pilot study 2: optimization
The UCl101 cell line was used to generate an in vivo orthotopic human ovarian cancer
model in mice that more closely resembled residual tumors left behind in patients after
debulking surgery and to develop methods for noninvasive tumor tracking that would
enable use of this model to assess the effectiveness of continuous low-dose IP cisplatin
treatment in vivo. Two larger spheroid sizes were produced in an attempt to inoculate
mice with spheroids closer in size to the subcentimeter tumors commonly left behind
after optimal debulking. They comprised 10000 and 20000 cells per spheroid
respectively and were expected to have a diameter of approximately 300 and 400 pm
based on the diameter-cell number correlation established previously for the UC1101
cell line. Spheroid shape, border definition and robustness allowing removal from the
plates without disintegration were evaluated qualitatively based on spheroid microscopy
photos (Figure 3.8). Spheroids comprising 20000 cells each were not considered further
for in vivo injection because they more closely resembled cubes instead of spheres, had
poor border definition and disintegrated upon attempting to collect them from the plates.
Spheroids comprising 10000 cells each were more spherical and had an average
diameter of 341.8 9.8 pm (n=15 spheroids). Spheroid diameter after collection from
the plate (301.01 22.06 pm) was approximately 86% of the diameter measured while
in the plate suggesting that the spheroids experienced a limited degree of disintegration
during harvesting and were therefore viable for in vivo IP injection in mice. Two different
spheroid sizes were therefore injected intraperitoneally in mice for tumor inoculation:
spheroids measuring approximately 188 pm or 301 pm in diameter.
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Figure 3.8: Spheroid size scale-up for in vivo ovarian cancer model
development. (A) Representative images of UC1101 spheroids
comprising 1250, 10000 and 20000 cells each respectively. The
1250-cell spheroids with an average diameter of 188 pm displayed
the most sphericity and compactness. The 10000-cell spheroids
with an average diameter of 342 pm were spherical and compact.
The 20000-cell spheroids had a shape resembling a cube rather
than a sphere and were not compact enough to allow diameter
quantification and successful removal from the AggreWell plate.
Scale bar is 400 pm. (B) The UC1101 spheroid diameter-cube root
of cell number plot is updated to include measurements for the
10000-cell spheroids both before (blue) and after (red) collection
from the AggreWell plate. The 10000-cell spheroid diameter
maintained the strong linear correlation seen previously when
added to the plot (before-collection value, R2 =0.99).
The 301-pm spheroids were deemed problematic even prior to injection since
they were prone to settling to the bottom and along the walls of the loaded syringe and
required agitation to bring them back to suspension, which can presumably negatively
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affect spheroid integrity and lead to inadvertent spheroid aggregation due to contact. A
larger-gauge needle had to be used for IP injections of these larger spheroids to ensure
they would not shear during passage through the needle (needle inner diameter >
spheroid diameter). A 21G needle was selected as a compromise between spheroid
shearing risk and risk of adverse effects to the animal due to injection with a large-
gauge needle. The injection site did not appear to leak any spheroid suspension after
injection and no peritoneal fluid leakage-related infections were noted in any of the mice
but 5 of 6 mice in the group grew subcutaneous tumors at the injection site.
Three-dimensional reconstructions of the bioluminescence flux for all six mice in
each group on day 21 after spheroid injection are shown in Figure 3.9. This time point
was chosen because previous work with this animal model and UC1101 free cell
injections allowed a 21-day tumor inoculation period before the start of treatment. Both
spheroid groups show sources of bioluminescence signal suggestive of tumor nodules
in the mouse abdomen at this time point. The 301-pm spheroid group however appears
to have signal more localized near the site of injection (lower left quadrant of mouse
abdomen) compared to the 188-pm spheroid group. 4 out of 6 animals in the 188-pm
spheroid group and 3 out of 6 animals in the 301-pm spheroid group appear to have a
more dispersed distribution of signal sources in the abdomen. This may indicate a more
widespread metastatic pattern in the abdominal cavity similar to the microscopic
metastases remaining in patients after debulking surgery.
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Figure 3.9: Three-dimensional diffused luminescent imaging tomography reconstruction of
bioluminescent sources in mice 21 days after injection with UC1101 spheroids of different
sizes. Mice were injected with either (A) 301-pm or (B) 188-pm spheroids. The mouse is
positioned so that its ventral surface is facing up and the mouse surface has been
reconstructed using the IVIS software built-in tools. Flux cutoffs for the color map are 1 e1 e 7 .
More mice in the smaller spheroid group appear to have diffuse sources of bioluminescence
throughout their abdomen compared to the large-spheroid group relative to the injection site(lower left quadrant of the mouse abdomen).
The two-dimensional total flux at euthanasia is plotted as a function of total tumor
burden (solid peritoneal tumor, ascites and any subcutaneous tumors) for all animals in
Figure 3.10. Logarithmic trendlines have been added to both the 188-pm and the 301-
pm dataset. Neither trendline fit the data very well, with R2 = 0.53 for 188-pm spheroids
and R2 = 0.64 for 301-pm spheroids. This can be attributed to certain outliers -
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particularly mice with a large tumor burden. The larger size of tumors observed in
animals with increased tumor load can help explain the existence of these outliers.
Many of the tumors at this point have become necrotic, adding to the gross tumor mass
at euthanasia but not contributing to the flux since the cells in the necrotic tumor core
are not producing any bioluminescence. The luciferase reaction is oxygen-dependent,
so the varying degree of hypoxia within the tumor may also account for the inaccuracies
observed. 14 8 The presence of vasculature within these tumors can play a role in hypoxia
and necrosis as well as accessibility of deeper parts of the tumor for delivery of active
agents. 148 Larger tumors with inhomogeneous blood vessel presence within their mass
may not be accessible to the IP-injected luciferin that enters the systemic circulation.1 48
Diffusion of luciferin from the peritoneal cavity directly into tumors may additionally be
hindered in the case of larger tumors preventing live cells deeper into the tumor from
emitting a signal. The depth at which cancer cells lie within the mouse abdominal cavity
affects the intensity of the signal they emit - it was observed that a number of mice in
both spheroid groups had subcutaneous tumors at euthanasia that likely contributed a
bioluminescence signal that was greater in proportion to their mass compared to that of
tumors deeper inside the abdomen, whose signal may be dampened by surrounding
tissues.
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Figure 3.10: Bioluminescence of tumors in mice injected with 188-pm or
301-pm spheroids plotted as total flux over tumor mass measured at
necropsy following euthanasia. Flux is plotted on (A) a logarithmic or (B) alinear scale and data is fitted with (A) logarithmic or (B) linear best-fit
trendlines. The R2 values are given next to the trendlines. The flux-tumor
load data appear to be correlated although the correlation is not as good as
those commonly reported in the literature. Others like Black et al. havepointed out poor correlation between BLI and other measures of tumor like
MRI. BLI nevertheless remains a relevant noninvasive way of measuring
tumor burden progression in this model.
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3.4 Discussion
Multiple clinical trials and experience in the clinic have established that the success of
tumor debulking surgery in reaching optimal cytoreduction (leaving behind
subcentimeter tumors only) heavily influences the treatment outcome of advanced-
stage ovarian cancer patients. We have previously also shown that replacing maximum-
tolerated-dose intermittent cisplatin IP injections - akin to the infusions currently used in
the clinic - with continuous low-dose IP cisplatin delivered via fully implanted reservoir
devices can be as effective and less toxic in mouse models of ovarian cancer.45 The
total amount of cisplatin delivered by these devices however was 4.7 times that
delivered by the IP injections to accomplish a comparable extent of tumor kill. The effect
of tumor size on the efficacy of continuous IP cisplatin treatment has not yet been
established and it is a critical part of the puzzle when trying to determine the populations
of patients that may benefit the most from a continuous low-dose IP cisplatin regimen.
The optimal cisplatin dose of such a continuous regimen is also a key component of
developing a successful treatment alternative to the currently used periodic IP infusions.
In vitro and in vivo models of ovarian cancer that closely recapitulate the clinical
picture of an optimally debulked patient before the start of adjuvant chemotherapy
would ideally be used to establish this optimum continuous dose - one that maximizes
tumor kill while maintaining tolerable toxicity. The use of ovarian cancer cell spheroids
to explore the impact of tumor size on the tumoritoxic effectiveness of continuous low-
dose cisplatin was previously established in our lab by L.M. Tanenbaum and expanded
in this project.46 The work described here uses ovarian cancer cell spheroids from two
different cell lines as models of subcentimeter tumor nodules in vitro to demonstrate
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that: (i) smaller nodules are treated as effectively by continuous low-dose cisplatin as by
a brief bolus dose of cisplatin with the same AUC; and (ii) larger nodules require
exposure to continuous cisplatin at a dose delivering a larger AUC for effective
treatment. The work then proceeds to develop spheroid-based in vivo models of ovarian
cancer to demonstrate that: (iii) spheroids are a viable platform to inoculate in vivo
mouse models of ovarian cancer with precise control of nodule size on injection and
faster tumor growth compared to free cell injections; and (iv) spheroid-inoculated mouse
models exhibit a diffuse pattern of nodular disease throughout the abdomen but there
exists a limit to the starting size of spheroids that can successfully be injected
intraperitoneally to create such lesions.
The barrier of drug distribution into larger tumor nodules is a known hindrance to
effective treatment.1 48 It has been shown in vitro that tumor cell layers as thin as 200 pm
dramatically affect cisplatin penetration. 49 A low-dose cisplatin regimen further reduces
drug penetration into tumors since the cisplatin concentration gradient between the
surrounding fluid and the center of the tumor is smaller. This affects cisplatin diffusion
into the tumor. Continuous exposure to cisplatin can kill cells in each successive outer
layer of a spheroid but, as Tanenbaum points out, the surface-area-to-volume ratio of a
spheroid decreases with increasing spheroid radius and so a smaller proportion of cells
in the spheroid are exposed to cisplatin.46
Drug penetration into tumors is not the only mechanism limiting cisplatin cell kill.
Cisplatin effectively binds DNA within both actively dividing and non-dividing (quiescent)
cells but the apoptotic pathways ultimately leading to cell death are only activated as a
result of failed repair of this bound DNA during cell division. Quiescent cells will
127
therefore not be killed by cisplatin. Solid tumors are known to contain necrotic cores as
well as quiescent cells due to limited oxygen, nutrients and metabolites. Similar
chemical gradients (oxygen, nutrients, metabolites / catabolites) have been observed in
spheroids starting at approximately 200-pm diameters and necrotic cores have been
observed in spheroids with larger diameters (> 500pm)."''"' The spheroids used in this
work are too small to anticipate a necrotic core in vitro but smaller spheroids are
expected to contain fewer quiescent cells than larger spheroids and this may help
explain their more dramatic shrinkage in response to cisplatin exposure.46 Larger
spheroids are likely responding differently to continuous high-AUC cisplatin (DH)
compared to a brief bolus exposure to lower-AUC cisplatin (IP) primarily due to limited
drug penetration into the spheroid.
The in vitro portion of this work showed that continuous low-dose IP cisplatin can
effectively treat small tumors causing the same degree of shrinkage as an AUC-
matched brief IP bolus dose. This is not the case for larger tumors: continuous cisplatin
doses that result in a greater total AUC are needed in order to match or surpass
shrinkage by a brief IP bolus dose. These findings are in accordance with clinical data
showing improved IP chemotherapy outcomes in women with microscopic to no residual
tumors. These findings can also help shed some light on the results of the GOG 252
trial to date both in terms of a cisplatin dose reduction in the IP arm and in terms of the
variability in outcome of debulking surgery.
These in vitro findings emphasize the urgency to use animal models that are
clinically relevant and representative of optimally debulked patients to assess
continuous low-dose IP cisplatin regimens. Clinical relevance encompasses both the
128
size of tumor nodules in the models as well as their distribution throughout the
abdomen. Helland et al. attempted to perform cytoreductive surgery on mice bearing
orthotopic SKOV3 human ovarian cancer xenografts prior to start of a carboplatin-
paclitaxel combination IP chemotherapy and found that the group receiving surgery
followed by chemotherapy had the longest mean survival similar to clinical experience
with ovarian cancer patients. 80 The technical challenges associated with successfully
performing optimal cytoreduction on mice with no adverse survival outcomes make this
approach less attractive. Such an approach is additionally expected to maintain a
degree of subjectivity on determining surgical outcome that has been criticized in the
clinic and may help explain in part the findings to date of the GOG 252 trial - at least
until imaging tools that precisely guide lesion removal during debulking are readily
available. Spheroids have previously been used extensively as in vitro three-
dimensional models of cancer. Nishikawa et al. used spheroids to inoculate mice
intravenously with lung adenocarcinoma and found that spheroids were more effective
than a cell suspension at generating lung lesions and that smaller spheroids led to
greater tumor load than larger spheroids.152 The use of spheroids to inoculate mice
orthotopically with UC1101 xenografts was found to result in faster tumor growth and a
more widely distributed disease pattern compared to an equivalent inoculation with free
cells in suspension (Figure 3.6 and 3.7). This observation is in accordance with the
findings of Nishikawa et al. in their lung adenocarcinoma spheroid model.
The size of spheroids used for in vivo inoculation was varied as a next step in
developing this model in an attempt to get even closer to the clinical picture of an
optimally debulked patient. The 301-pm spheroids produced were at the limit of
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sphericity and compactness needed for spheroid size quantification and viable transfer
from the spheroid formation plate to syringes for in vivo injection. They were however
found to noticeably disintegrate upon agitation to mix the spheroid suspension in the
syringe immediately prior to injection. Their size posed a challenge for safe injection in
mice due to the large-gauge needle required. The large-gauge needle was additionally
found to likely promote spheroid suspension backflow into the subcutaneous space at
the injection site and thus cause growth of subcutaneous tumors that negatively affect
the orthotopic aspect of this model. The 188-pm spheroids were not only free of these
limitations but were also found to exhibit a relatively more dispersed nodule pattern
throughout the peritoneal cavity on BLI imaging (Figure 3.9B). The 188-pm spheroids
exhibited a greater degree of compactness and sphericity compared to the 301-pm
spheroids in vitro (Figure 3.8A) and can presumably sustain a greater amount of shear
during passage through the injection needle before breaking apart. They also exhibited
limited to no visible aggregation while resting in the syringe prior to injection and were
easily resuspended in the injection solution by gentle agitation of the syringe with no
disintegration observed by naked eye. These characteristics may help explain the
relatively more diffuse pattern of disease observed qualitatively in the three-dimensional
BLI sequence shown in Figure 3.9B (188-pm spheroids) compared to Figure 3.9A (301-
pm spheroids).
Both spheroid sizes resulted in a similar pattern of flux-tumor mass correlation at
euthanasia (Figure 3.10). The aggregates of either spheroid size that remained viable
and seeded the peritoneal cavity thus ultimately gave rise to tumors that grew to
comparable dimensions when the disease was allowed to reach advanced stage. These
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tumors likely suffered from similar limitations related to their necrotic core and other
considerations described previously that affect the flux-tumor mass correlation (R 2=0.51
and R 2=0.68 for linear-fit trendlines in the flux-tumor mass data of 188-pm and 301-pm
spheroids respectively, Figure 3.10A).
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Chapter 4: Material Optimization, Efficacy Pilot and Origami-
Inspired Proof-of-Concept Shapes for the In Vivo Translation of a
Composite Material for Intraperitoneal Cisplatin Delivery
4.1 Introduction
A CDDP25 composite material was previously developed as the basis of an implant for
sustained low-dose release of cisplatin in the peritoneal cavity for the treatment of
advanced ovarian cancer. A thinner version of this composite was developed, reducing
its thickness by more than 50% to a 0.4-0.45 mm thick sheet. The structural and
mechanical properties of this thinner CDDP25 material were examined and its similarity
to the previously developed thicker CDDP25 material was confirmed. Disks of various
diameters were cut out of the thinner sheet to serve as individual implants for use in
mice for intraperitoneal cisplatin delivery. The disks allowed modulation of the total
cisplatin release rate of the implant and behaved as expected when releasing cisplatin
in vitro. Disks measuring 1.0 cm, 1.5 cm or 2.0 cm in diameter were implanted
intraperitoneally in healthy mice in two dosing studies and their cisplatin dose
tolerability, biocompatibility and ability to deliver platinum effectively to tissues of interest
in the abdomen were assessed. The 1.5-cm diameter disks were deemed likely to
deliver the maximum tolerated cisplatin dose for this CDDP25 formulation and are good
candidates for implantation in mice bearing ovarian cancer xenografts for assessment of
their antitumor efficacy. An antitumor efficacy pilot was conducted in tandem with the
dosing studies using CDDP25 disks measuring 0.4 mm in thickness and 1.0 cm in
diameter or 1.0 mm in thickness and 0.5 cm or 0.8 cm in diameter. The pilot suffered
serious drawbacks related to an acquired bacterial infection and the number of animals
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used was too small to draw any statistically significant conclusions but a degree of
response to treatment was seen in all implant groups. Proof-of-concept origami-inspired
shapes were prototyped using the previously developed LAC50 formulation to assess
the feasibility of this approach for designing sheet-like implants that can be deployed
laparoscopically into the abdomen.
4.2 Materials and Methods
4.2.1 Chemicals and materials
Ecoflex 00-30 was purchased from Smooth-On Inc. (Macungie, PA, USA). Phosphate-
buffered saline (PBS) was purchased from VWR (Radnor, PA, USA).
Diethyldithiocarbamate trihydrate (DDTC), nickel (II) chloride, sodium hydroxide, high-
performance liquid chromatography (HPLC)-grade water, HPLC-grade methanol, 70%
nitric acid, cisplatin powder and lactose monohydrate powder were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Erbium 1,000 pg/mL standard solution was
purchased from Agilent Technologies (Santa Clara, CA, USA). Platinum 1,000 pg/mL
standard solution in nitric acid was purchased from Inorganic Ventures (Christiansburg,
VA, USA). Medical injection-grade cisplatin solution (100 mg/100 mL) for bolus
injections was purchased from McKesson Medical-Surgical (Richmond, VA, USA).
4.2.2 Composite material fabrication
A matrix-type cisplatin-eluting composite material formulation (CDDP25) was fabricated
as previously described by mixing cisplatin and lactose powders with Ecoflex 00-30
supersoft silicone elastomer. Ecoflex 00-30 was mixed with cisplatin powder and lactose
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monohydrate powder using a dual asymmetric centrifugal lab mixer (SpeedMixer,
Flacktek Inc., Landrum, SC, USA) to create a composition containing 25% Wcisplatin/wtotal
and 25% wiactose/wtotai. A mass of 1.0-1.5 g of the cisplatin-lactose-silicone mixture was
poured into a rectangular mold measuring 30 mm length by 70 mm width and 0.5 mm
depth that was machined in-house from Delrin black acetal using a micro CNC router
(Cameron Micro Drill Presses, Sonora, CA, USA). A razor blade was used to spread the
mixture evenly throughout the mold by sweeping the mixture along the mold length in
both directions. The mold was then placed in vacuum for 15 min to allow the mixture to
degas fully followed by overnight curing at room temperature and pressure. This yielded
composite material sheets measuring approximately 30 mm in length and 70 mm in
width and having a thickness of approximately 0.4-0.45 mm. Metal punches of various
diameters (1.0 cm, 1.5 cm, 2.0 cm) were used to punch out disks from the cured
material pieces for in vitro cisplatin release quantification and in vivo implantation in
mice. The resulting disks measured 1.0-2.0 cm in diameter and 0.4-0.45 mm in
thickness. All disks used for in vivo implantation were sterilized by ethylene oxide gas
and allowed to degas for 48 hours in a hood before use. An additional composite
formulation containing only lactose 50% w/wtotai (LAC50) was prepared to use for
mechanical testing, where material porosity was the critical parameter. The LAC50
formulation was prepared in the same way as the CDDP25 formulation except that dog
bone-shaped Delrin black acetal molds measuring 0.5 mm in depth were used for
casting the material into shapes appropriate for carrying out tensile testing. Cisplatin-
containing samples were kept away from light for all experiments.
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4.2.3 Miura v-pleat shape prototyping
Two-part molds were created for casting sheets of Ecoflex 00-30 and LAC50 to cure
with a partially pre-folded Miura v-pleat origami shape. The first Miura v-pleat origami
sheet proof-of-concept prototype was cast in a mold designed using SolidWorks
(Dassault Systemes, Velizy-Villacoublay, France) and machined out of a white Teflon
block in-house using a micro CNC router and the appropriate twist drill bit. The second
Miura v-pleat sheet prototype was intended to more closely resemble the dimensions of
an implant for human patients and was therefore cast in a mold designed using
SoldiWorks and 3D-printed using ABSplus proprietary thermoplastic material on a
Dimension Elite 3D printer with a 178-pm layer thickness (Stratasys, Eden Prairie, MN,
USA). The two molds were used to cast Ecoflex 00-30 and LAC50 Miura v-pleat sheets
following the same casting protocol previously described with the exception of filling the
mold bottom part with an excess of material and then firmly securing the top mold part
in place before degassing the closed mold in vacuum for 15 min.
4.2.4 Structural characterization
A razor was used to create lateral cross-sections of the CDDP25 sheet through the
sheet thickness. The cross-sections were examined by secondary and backscatter
scanning electron microscopy (SEM; 5600LV SEM) to study the composition of the
CDDP25 sheet and the topography of cisplatin and lactose crystals in the silicone matrix
and compare them to those of thicker CDDP25 samples prepared previously by manual
mixing and casting in different molds. A 10-pm gold-palladium coating was applied to
the cross-sections prior to SEM imaging to prevent charging of the sample.
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4.2.5 Mechanical characterization
Tensile testing of dog bone-shaped LAC50 samples was performed on an Instron 5943
testing machine with a 500 N load cell and steel grip platens. Specimens were
subjected to elongation at a rate of 15 mm/min until failure. Force was converted to
stress using the cross-sectional surface area of the sample and elongation was
converted to strain using the initial length of the sample. Stress-strain diagrams were
plotted and the modulus of elasticity, ultimate tensile stress and elongation at break
were calculated and compared to those of LAC50 samples with thickness 1-1.5 mm and
of representative tissues in the human abdominal cavity.
4.2.6 In vitro cisplatin release
CDDP25 disks measuring 0.4-0.45 mm in thickness and either (i) 0.5 cm, (ii) 1.0 cm or
(iii) 1.5 cm in diameter (Figure 2) were immersed in 50 mL of PBS in amber glass jars
and incubated at 370C on a shaker oscillating at 60 cycles/min to quantify the amount of
cisplatin released in vitro at regular intervals for a total period of 49 days. Each disk was
lodged within the turns of a thin stainless steel spring similar to the method described by
Keskar et al. (McMaster-Carr, Elmhurst, IL, USA) to prevent the disk from settling on the
bottom of the vial or floating to the top of the liquid.98 The disks were transferred to jars
containing fresh PBS at regular time intervals to maintain sink conditions for the
dissolution of lactose (lactose solubility in water = 100 mg/mL) and cisplatin (cisplatin
solubility in water = 2.53 mg/mL). The interval between PBS renewals was kept to 6
days or shorter to minimize cisplatin degradation. The PBS solution was sampled
frequently on the periods when the disks remained in the same jar by removing 1 mL of
PBS at regular time points. The amount of cisplatin present in the solution was
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measured at each prescribed time point by HPLC with a nickel (11) chloride internal
standard and the method described previously by our group.45
4.2.7 Surgical and euthanasia procedures for in vivo experiments
All listed procedures were in accordance with the Massachusetts Institute of Technology
Committee on Animal Care guidelines, as well as the NIH Guide for the Care and Use
of Laboratory Animals. Animal surgeries to implant CDDP25 disks were performed
within a sterile field and all surgical equipment was autoclaved. Inhalation anesthesia
was maintained throughout surgeries with isoflurane. Slow-release buprenorphine was
used as pre- and post-surgical analgesia per recommendation by the animal care
committee. The incision site was sterilized with iodine and isopropyl alcohol. A small
abdominal incision of about 5 mm was made through the skin and peritoneum to implant
the disks. The disks were rolled up for placement inside the abdomen. The disks once
implanted were unfolded flat and allowed to freely move within the peritoneal cavity.
Mice were weighed regularly to monitor overall health and euthanized upon weight loss
greater than 20% or poor body condition. Euthanasia was carried out by carbon dioxide
inhalation at a steadily increasing flow rate to minimize distress.
4.2.8 Inductively coupled plasma mass spectroscopy protocol for platinum
quantification in tissue and blood serum
The platinum concentration in blood serum ultrafiltrate and nitric acid-digested mouse
tissue was measured by inductively coupled plasma mass spectroscopy (ICP-MS) on
an Agilent 7900 ICP-MS (Agilent, Santa Clara, CA, USA). Samples were serially diluted
to a final dilution of 10- using 2% nitric acid before ICP-MS measurement. An internal
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erbium standard was used to monitor the performance of the ICP-MS run for any drift
and the bounds for rejecting readings were defined at +/- 20% of the erbium internal
standard recovery. A platinum calibration curve was prepared using eight platinum
concentrations ranging from 0 to 500 ppb to convert the ICP-MS platinum-to-erbium
count ratio to a platinum concentration for each sample. The platinum calibration curved
was a straight line through the origin with R 2 = 0.9999. The platinum concentration
values obtained for each sample were multiplied by the dilution factor used when
preparing the sample to obtain the platinum concentration in the original sample. The
calculated platinum concentration for blood serum ultrafiltrate samples was used to
express the serum platinum content in pg Pt / L serum. The calculated platinum
concentration for digested tissue samples was multiplied by the sample volume after
acid digestion to obtain the total platinum mass in each sample. This total platinum
mass was then divided by the tissue mass in each tube to obtain a normalized pg Pt / g
tissue content for each sample.
4.2.9 In vivo CDDP25 implant dosing studies
The in vivo tolerability and platinum delivery of three CDDP25 disk sizes with thickness
of 0.4-0.45 mm and either (i) 1.0-cm diameter, (ii) 1.5-cm diameter or (iii) 2.0-cm
diameter were assessed over six weeks in tumor-free mice and compared to those of
weekly 4 mg/kg intraperitoneal (IP) cisplatin injections. The different CDDP25 disk sizes
were evaluated as a way to escalate the cisplatin dose delivered by the CDDP25
implant and so identify a maximum tolerated dose (MTD) for treatment with the implant.
All chemicals and materials for the in vivo portions of these studies were sterile and
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maintained under sterile conditions. Two separate dosing studies were carried out: the
first compared CDDP25 disks of 1.5-cm or 2.0-cm diameter to weekly 4 mg/kg IP
cisplatin injections. The second compared CDDP25 disks of 1.0-cm diameter to weekly
4 mg/kg IP cisplatin injections. The two studies were performed on different dates and
different batches of mice were used so IP cisplatin injection groups were included in
both studies to provide an unbiased comparison to the CDDP25 implant treatment
groups. Female Nu/Nu athymic mice bearing no tumors and weighing 20-25 g were
used in both studies (Charles River Laboratories, Wilmington, MA, USA) because they
are well-suited for growth of human tumor xenografts due to their deficient immune
system and are expected to serve as the animal model for antitumor efficacy studies
using the CDDP25 material. Blood was sampled via the saphenous vein of all mice prior
to the start of the experiment to obtain baseline complete blood count (CBC) values with
auto differential. The mice in the first dosing study were allocated in four different
treatment groups: (1a) IP implantation of a single CDDP25 2.0-cm diameter disk (n=3
mice); (2a) IP implantation of a single CDDP25 1.5-cm diameter disk (n=3 mice); or (3a)
IP administration of weekly 4 mg/kg IP cisplatin injections (six total injections, n=3). The
mice in the second dosing study were allocated in two different treatment groups: (1b)
IP implantation of a single CDDP25 1.0-cm diameter disk (n=3 mice); or (2b) IP
administration of weekly 4 mg/kg IP cisplatin injections (six total injections, n=3). Sterile
CDDP25 disks were incubated in 50 mL of PBS at 370C on a shaker oscillating at 60
cycles/min for 24-48 hours prior to implantation to eliminate their cisplatin burst. The
disks were then implanted intraperitoneally in the mice of groups 1a, 2a and 1b. The
mice of groups 3a and 2b received a 4 mg/kg IP cisplatin injection at the same time as
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the implantation surgery given as a 1 mL injection using 0.9% w/v saline as a diluent
and injected via a 28G needle. All mice in the first study were euthanized 42 days after
the start of treatment or whenever their body condition required euthanasia, whichever
came first. Mice in group 1 b in the second study were euthanized 42 days after the start
of treatment and mice in group 2b in the second study were euthanized 48 hours after
administration of their 6th cisplatin injection to capture any cisplatin toxicity before they
had time to recover. The liver, spleen, kidneys, stomach, sections of the small and large
intestine, ovaries, uterus, femurs, implant with any surrounding fibrous capsule and fat
pad tissue - if present - of the euthanized mice were harvested. The implant and any
associated capsule were placed intact in 10% neutral buffered formalin immediately
after harvesting and processed for histological analysis. All harvested tissues with the
exception of the femurs were cut in half using a razor blade. One half of each tissue
was processed for histological analysis to assess toxicity and the other half was
processed for platinum quantification as an indirect measurement of the in vivo cisplatin
dosing capability of the different-size CDDP25 disks and 4 mg/kg IP injections. The
femurs were entirely processed for histological analysis.
4.2.10 CDDP25 implant tolerability evaluation - in vivo dosing studies
Approximately 100 pL of blood were collected weekly from all mice in both dosing
studies by saphenous vein puncture for CBC with auto differential unless if their body
condition made them unfit for safe blood collection. Blood was also collected from all
mice at euthanasia by cardiac puncture for CBC with auto differential and serum
platinum quantification. Blood samples for CBC with auto differential were collected in
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EDTA-coated 100 pL microvettes (Sarstedt, Numbrecht, Germany) as per manufacturer
instructions to prevent clotting and were processed on a Hemavet 950FS Auto Blood
Analyzer (Drew Scientific, Miami Lakes, FL, USA) within 24 hrs after collection.
Samples that were not processed immediately after collection were stored in the
refrigerator to maintain sample integrity. The tissue halves for histological analysis with
the exception of the femurs were placed in 10% neutral buffered formalin immediately
after harvesting and allowed to fix for 48-72 hours. The femurs were placed in Bouin's
solution and allowed to decalcify for at least two weeks and until they could be bent by
applying a small amount of force to each end of the bone. The fixed tissues with the
exception of the femurs were sectioned with a razor blade and half of each sample was
placed in histology cassettes. The femurs were placed in histology cassettes without
any sectioning. The implants were carefully sectioned with a razor blade along their axis
to ensure any fibrous capsule remained on the sample and placed in histology
cassettes such that the implant cross-section and capsule would be visible on the
paraffin section. Care was taken to ensure that all five liver lobes and half of each
kidney as well as different representative sections of the small and large intestines were
included in the respective cassette. The cassettes were placed in 70% ethanol followed
by paraffin embedding and hematoxylin & eosin (H&E) staining of slides for pathology
review with a veterinary pathologist consultant at the Hope Babette Tang Koch Institute
Histology Core.
141
4.2.11 CDDP25 implant platinum delivery to systemic circulation and tissues - in
vivo dosing studies
Blood samples for serum platinum quantification were collected on euthanasia in 1.1 mL
Z-Gel microtubes (Sarstedt, NUmbrecht, Germany) containing serum gel with clotting
activator and were centrifuged at 13,000 g for 5 minutes. The serum was collected
following blood centrifugation and ultrafiltered using an Amicon Ultra-0.5 mL centrifugal
filter (MilliporeSigma, Burlington, MA, USA) as per manufacturer instructions to collect
both the serum ultrafiltrate and the serum concentrate. Serum ultrafiltrate and
concentrate samples were stored at -800C until further processing. The serum
ultrafiltrate is free of proteins, primarily albumin, and therefore does not contain protein-
bound cisplatin that is no longer therapeutic. The platinum levels in serum ultrafiltrate
were measured by ICP-MS using the method described previously. The tissue halves
for platinum quantification were collected in Eppendorf tubes on euthanasia and placed
immediately on dry ice followed by storage at -80*C until further processing. To quantify
the amount of platinum in the harvested tissues, the organs were homogenized using a
Bertin Precellys CK14 soft tissue homogenization kit (VWR, Radnor, PA, USA) and
digested using 70% nitric acid. Briefly, each organ was weighed and then divided into
pieces weighing at most 200 mg. Each piece was placed in a tissue homogenization
tube containing inert 1.4 mm zirconium oxide beads and 1 mL of RIPA lysis and
extraction buffer (Invitrogen, Carlsbad, CA, USA) was added. The tubes were placed in
a Precellys 24 homogenizer (Bertin, Montigny le Bretonneux, France) and the samples
were homogenized at 6,000 RPM for 4 x 20 s cycles. The tubes were then centrifuged
at 10,000 g for 10 min to remove any foam buildup and placed uncapped on a
thermoblock at 950C for at least 48 hours until all the supernatant had evaporated. The
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lysed tissue pellets were digested by adding 1 mL of 70% nitric acid to each tube,
loosely capping it and placing it in the hood on a hot plate at 550C for 24 hours. The
platinum concentration of the digested samples was quantified by ICP-MS using the
protocol described previously.
4.2.12 In vivo CDDP25 antitumor efficacy pilot
The in vivo antitumor efficacy of three different CDDP25 disk types was evaluated in a
small pilot study using female athymic Nu/Nu mice weighing 20-25g (Charles River
Laboratories, Wilmington, MA, USA) and bearing UCI101 human ovarian cancer
orthotopic xenografts. All chemicals and materials for the in vivo portion of the efficacy
pilot were sterile and maintained under sterile conditions. The antitumor efficacy pilot
occurred in parallel with the thin CDDP25 dosing studies and so the three different
CDDP25 disk types evaluated were chosen based on data that had been collected
previously in the project. The three disk types evaluated were: (i) 0.5-cm diameter, -1.0-
mm thickness (n=6); (ii) 0.8-cm diameter, -1.0-mm thickness (n=6); and (iii) 1.0-cm
diameter, -0.4-mm thickness (n=5). Disk type (i) represented the original CDDP25
composite material and thickness previously evaluated over a 15-day platinum
distribution and toxicity study in vivo in mice (Chapter 1). Disk type (iii) represented the
1.0-cm (i.e. 'small') thin implant used in the thin CDDP25 dosing studies that had been
well tolerated in vivo at the point of starting the efficacy pilot. Disk type (ii) was chosen
as an intermediate dose between the expected dose by disk type (i) and that expected
by disk type (iii). The remaining three treatment groups in the efficacy pilot were: (iv)
mice receiving 6 weekly 4 mg/kg IP cisplatin injections (n=5); (v) mice receiving 6
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weekly 10 mg/kg IP cisplatin injections (n=6); and (vi) untreated control mice (n=5). The
IP injection dose used in group (v) was selected because it was calculated to be the
mouse equivalent to the recommended dose used in ovarian cancer care for IP cisplatin
infusions (100 mg/M 2). The IP injection dose used in group (iv) was selected because it
had previously been used in this project and had been found to effectively treat tumors
without causing intolerable toxicity.45 Animals were weighed multiple times every week
following inoculation with tumor cells and throughout the duration of the pilot as a
marker of their overall health status. Methods for tumor cell inoculation and noninvasive
tumor monitoring by BLI are described in greater detail in Chapter 2. Briefly, all mice
were inoculated with 3 x 106 UC1101 cells / mouse injected intraperitoneally as a free
cell suspension in 1 mL of cold PBS using a 26G needle. The UCl101 cells used in this
study bear the luciferase gene and so all mice were imaged with BLI twice weekly as a
noninvasive measure of their tumor load starting one day after tumor cell inoculation
and throughout the duration of the study following the protocol described in Chapter 2.
The mice were imaged both on the dorsal and on the ventral side to ensure that the
maximum bioluminescence intensity was captured at each time point in case of uneven
tumor growth. There was BLI signal variability across animals on each imaging time
point that is expected given the variable rate of tumor rejection and growth in vivo. BLI
signal on day 23 after tumor cell inoculation was used to randomize animal assignment
to the six different treatment groups. Treatment with either IP implantation of a CDDP25
disk or administration of weekly IP cisplatin injections was started for mice in groups (i)-
(v). The duration of the efficacy pilot was 41 days to allow administration of 6 weekly
cisplatin injections bringing the total duration of the efficacy pilot to 64 days. Mice were
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euthanized either on day 64 or whenever their body condition required euthanasia.
Methods for blood sampling for CBC and platinum quantification in serum as well as for
organ harvesting for histology and platinum quantification in tissues are described in
greater detail in Chapter 1 and earlier in Chapter 3. Briefly, blood was sampled from the
saphenous vein of all mice before the start of treatment to establish a baseline CBC and
then again on week 2 and 5 after the start of treatment. Blood was sampled from the
facial vein of all mice on week 3 after the start of treatment and the serum was
separated, filtered and stored at -80*C for future systemic platinum level quantification
by ICP-MS. The liver, kidneys, spleen, stomach, small and large intestine, ovaries and
uterus and femurs of each mouse were harvested at euthanasia and prepared as
described previously for platinum quantification by ICP-MS and histologic evaluation of
toxicity. The implants of mice in groups (i)-(iii) were collected along with any surrounding
fibrous capsule and prepared for histologic evaluation. All visible solid tumors and any
ascites were collected from each mouse and weighed to quantify the tumor mass at
euthanasia. Methods for in vitro cisplatin release from CDDP25 are described in detail
in Chapter 1 and earlier in Chapter 3. Briefly, extra CDDP25 disks that were prepared
as backup but not implanted in animals were placed in PBS at 370C on a shaker
oscillating at 60 RPM to quantify their cisplatin release profile over 42 days. This release
profile served as an indirect measurement of the expected in vivo cisplatin release
profile of the CDDP25 disks used in this pilot.
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4.2.13 Data analysis
All data are expressed as a mean +/- standard deviation. All error bars represent
standard deviations from the mean. All samples were examined in triplicate unless if
otherwise noted. The GraphPad Prism software was used for all statistical analyses
(GraphPad Software, CA, USA). Tissue platinum content values were compared for
each organ across treatment groups in the two thin CDDP25 dosing studies using a
one-way ANOVA with Tukey's multiple comparisons test. Tumor mass values at
euthanasia were compared across treatment groups in the antitumor efficacy pilot using
a one-way ANOVA with Tukey's multiple comparisons test. Differences with p-value <
0.05 were considered to be statistically significant. Statistical significance is indicated
as: ns p >= 0.05; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
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4.3 Results
4.3.1 Structural characterization
Secondary electron SEM imaging of the thin (-0.4 mm) CDDP25 sheet cross-section
was performed to assess its topography and compare it to that of the thicker (-1.5 mm)
CDDP25 composite material developed previously. Two distinct phases were seen in
the thin sheet similar to what was previously seen in the thicker composite, with the
minor phase similarly appearing as crystals of various shapes and sizes dispersed
homogeneously within a flat-appearing major phase across the height of the cross-
section (Figure 4.1A-B). Backscatter electron SEM imaging of the thin CDDP25 sheet
cross-section was performed to assess its composition and confirmed the presence of
brighter and darker crystals across the silicone matrix thickness attributed to cisplatin
and lactose respectively and appearing homogeneously distributed throughout the
thickness (Figure 4.1C-D).
B
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Figure 4.1: SEM images of thin CDDP25 cross-sections. (A)-(B) secondary electron SEM
images of cross-sections of (A) thin CDDP25 sheet and (B) thicker CDDP25 disk; (C)-(D)
backscatter SEM images (C) thin CDDP25 sheet and (D) thicker CDDP25 disk. The cross-
sections are oriented such that the top surface of the cast sample is at the top of the SEM
image and the bottom surface that is in contact with the mold is at the bottom. A uniform
distribution of crystals throughout the Ecoflex 00-30 matrix is seen in both thin and thick
CDDP25 cross-sections. Cisplatin crystals are expected to appear brighter in the backscatter
electron SEM than lactose crystals because of the heavier Pt nuclei that more effectively
scatter electrons compared to low-atomic-number elements. Scale bars are 100 pm.
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4.3.2 Mechanical characterization
LAC50 dog bone-shaped samples with thickness measuring 0.4-0.45 mm underwent
tension testing to evaluate their elastic modulus, ultimate tensile strength and elongation
at break and compare them to the values previously calculated for thicker LAC50
samples measuring 1-1.5 mm in thickness. The thicker LAC50 material had been
deemed appropriate for peritoneal implantation based on its mechanical performance
compared to the properties of representative tissues in the abdomen. This mechanical
characterization of the thinner LAC50 composite was similarly used as a metric its
mechanical appropriateness for intraperitoneal placement. The complete results are
shown in Table 4.1.
Material Elastic modulus Ultimate tensile Elongation at(MPa) strength (MPa) break (%)
LAC50 thin 0.186 0.277 454
LAC50 thick 0.226 0.356 590
Table 4.1: Mechanical properties of thin LAC50 samples (0.4-0.45 mm thickness)
compared to thick LAC50 samples previously developed (1-1.5 mm thickness). The
thinner version of the LAC50 composite is almost 18% less stiff, 22% less strong and
23% less stretchy than the thicker version previously developed. Values are the mean of
three measurements from identical samples
The elastic modulus of the thin LAC50 material was 18% lower than that of the thicker
material (0.186 MPa compared to 0.226 MPa respectively). The elastic modulus is a
material property so no difference in its value would be expected with sample dimension
changes for the same material. The difference observed here /is relatively small but not
negligible. This difference could be the result of batch-to-batch manufacturing variability
since the thicker samples were made and evaluated previously. It could also be the
result of defects in the composite structure made more prominent in the thinner
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material. The ultimate tensile strength of the thinner LAC50 material was found to be
almost 80% of the value calculated for the thicker samples (0.277 MPa compared to
0.356 MPa respectively) meaning that the thinner material is approximately 20% less
strong than its thicker counterpart. The thin LAC50 elongation at break finally was found
to be approximately 77% of the value calculated for the thicker LAC50 samples (454%
compared to 590% respectively) making it slightly less stretchy. The differences in these
mechanical properties between the two thickness versions of LAC50 were relatively
small. The thinner material was still within the same value ranges as those previously
considered for relevance to tissues found in the abdominal cavity like the liver, stomach
and intestines suggesting that it would be safe for peritoneal placement. Further
assessment of the response of both LAC50 thicknesses to forces specifically
experienced during laparoscopic placement, removal and more extreme manipulation is
necessary to ensure implantation safety and should be carried out as a next step in
material development.
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4.3.3 In vitro cisplatin release of thin CDDP25
The thickness and diameter of the three CDDP25 disk sizes used for the in vitro release
studies are shown in Figure 4.2. The cisplatin release profile of the three CDDP25 disk
sizes over the 49-day in vitro release period is shown in Figure 4.3 as a rate per day (A)
and per hour (B). The shape of the release profiles suggests three discrete phases with
different rates of release occurring during the same time intervals for all three
diameters. The difference in release rate between phases becomes more prominent as
disk diameter increases. Linear best-fit trendlines were added to each phase and their
slopes used to calculate a weighted average cisplatin release rate taking into account
the relative duration of each phase. This weighted average was used as an estimate of
a zero-order constant release rate for each disk size for the entire 49-day in vitro
release period.
1.5-cm 0.4-0.45 mm
disk
1.0-cm 0.4-0.45 mm
disk 1.0 cmdisk .2
0.5-cm 0.4-0.45 mm
disk -0.5 cm
Figure 4.2: Schematic representation of the three thin CDDP25 disk sizes used for in vitro
release studies. The schematic indicates average thickness and diameter values.
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Figure 4.3: /n vitro cisplatin release for the 0.5-cm, 1.0-cm and 1.5-cm diameter CDDP25 thin
disks over a 49-day period. Time on the x-axis is measured in (A) days or (B) hours. Error
bars represent standard deviation from the mean.
The in vitro cisplatin release rate for each disk size normalized by the average
surface area for release of the sample is plotted in Figure 4.4 as a function of time
expressed in hours. The premise behind prototyping a thinner version of the previously
developed CDDP25 composite material and using disk surface area to modify cisplatin
release rate was the assumption that this new, thinner material will behave similarly to
the thicker version of CDDP25 characterized previously. This implies that the thin CDDP
material must have a surface area-normalized release rate that is similar to the one
calculated for the thick CDDP25 composite (0.773-0.780 pg/cm 2/hr calculated using
linear best-fit trendlines or weighted average of release rates in each of three distinct
phases respectively). An average release rate of 0.777 pg/cm 2/hr can be assumed for
the thick CDDP25 formulation as the middle value of this range. The normalized release
rates for each disk size and their performance against the thick CDDP25 average
normalized release rate are found in Table 4.2. The 0.5-cm and 1.0-cm disk sizes were
closest to the expected release rate (0.656 pg/cm 2/hr and 0.657 pg/cm 2/hr compared to
0.777 pg/cm 2/hr) at 84% and 85% of the expected value respectively. The 1.5-cm disk
size was the least close (0.579 pg/cm 2/hr compared to 0.777 pg/cm 2/hr) at 75% of the
expected value. The normalized release rates were nevertheless overall close to their
expected values. These findings illustrate that the CDDP25 formulation is consistently
releasing cisplatin in a predictable manner. The findings also illustrate that the CDDP25
formulation can be scaled both in terms of thickness - which is very important for
designing a laparoscopically deployable implant - and in terms of surface area for
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release - which provides a way to modulate the cisplatin dose that can be delivered
from an implant made out of CDDP25 without altering the formulation itself.
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Figure 4.4: In vitro cisplatin release normalized to disk surface area for the 0.5-cm, 1 .0-cm
and 1.5-cm diameter CDDP25 thin disks over a 49-day period. Time on the x-axis is given in
hours. The surface area-normalized release profiles were expected to be very similar for all
three disk sizes since they comprise the same material. The data are in good accordance with
this expectation although there exists some variability in the release profiles that can likely be
attributed to human error during manufacturing or cisplatin quantification. The normalized
release rates should be close to the normalized in vitro cisplatin release rate previously
calculated for the CDDP25 thicker version of the composite (0.773-0.780 pg/cm 2/hr). Taking
0.777 pg/cm 2/hr as the average thick CDDP25 release rate, the release rate of the 0.5-cm
and 1.0-cm disks (0.656 and 0.657 pg/cm 2/hr respectively) were 84 and 85% of the expected
value respectively The release rate of the 1.5-cm disk (0.579 pg/cm 2/hr) was 75% of the
expected value. Values in the plot are the mean of results from identical samples (sample
number indicated in graph label). Error bars correspond to standard deviation from the mean.
The initial 24-hr burst was not taken into account in calculating in vitro release
rates as it was eliminated for all disk sizes after 24 hours. The initial 24-hour burst could
similarly be eliminated in the actual clinical embodiment of these composite materials
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for an intraperitoneal implant, for instance by pre-treating the implant before placement
in the patient.
Disk diameter
(cm)
Expected in vitro
release rate
(ii /day)
Actual average in
vitro release rate
(u /dav)
Proportion of
expected rate
achieved (%)
0.5 8.6 7.2 84
1.0 31.7 26.9 85
1.5 70.1 52.5 75
Table 4.2: In vitro cisplatin release rate estimation for thin CDDP25 disks of various
diameters. A constant in vitro release rate for each disk size was estimated over the 49-
day period using the duration-weighted average of the slopes of the linear best-fit
trendlines through each phase for each size. This rate is compared to the expected release
rate based on the disk surface area and normalized release rate of the thicker CDDP25
composite previously developed. The three disk sizes overall performed reasonably well
with the worst performing one (1.5 cm) still achieving 75% of its expected release rate.
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4.3.4 In vivo dosing studies with CDDP25 implants
The first dosing study focused on mice implanted with medium (1.5-cm diameter, n=3
mice) or large (2.0-cm diameter, n=2 mice) CDDP25 disks while the second dosing
study focused on mice implanted with small (1.0-cm diameter, n=3 mice) CDDP25 disks
(Figure 4.5). The first dosing study lasted 42 days to allow administration of 6 weekly IP
cisplatin injections to the injection-treated group and a full week of recovery after the 6th
injection. The IP injection group in the second dosing study was euthanized on day 37,
48 hours after receiving their 6 th injection to collect data on acute toxicity before the
mice had a chance to recover and also quantify tissue platinum levels in the first two
days after an injection.
Large 0.4-0.45 mm
implant 2.0 cm
Medium 0.4-0.45 mm
implant
Small 0.4-0.45 mm
implant
Figure 4.5: Schematic representation of the three CDDP25 disk sizes used for the two in vivo
dose escalation studies. The schematic indicates average thickness and diameter values.
The large and medium implants were used in the first study while the small implant was used
in the second study.
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Expected in vitro cisplatin release rates for each implant size on a daily and
weekly basis are given in Table 4.3 along with an average weekly cisplatin dose
administered by a 4 mg/kg IP injection to an average-sized mouse weighing 22.5 g.
These values allow a comparison of the total weekly cisplatin dose administered with
the different treatments, although the implant values are estimates based on in vitro
release data and not on actual in vivo release data. It is therefore expected that the
cisplatin dose values for all implant groups are likely to be lower in vivo than the
estimates in Table 4.3. Many factors can affect implant release inside the peritoneal
cavity including: (i) implant contact with connective tissues like fat that may affect the
implant surface area available for cisplatin release; (ii) any fibrotic response to the
implant that may encase it in a fibrous sheath affecting cisplatin transport through it and
to the surrounding peritoneal cavity; and (iii) the protein-rich environment of the
peritoneal fluid compared to PBS used for in vitro release. The table values however still
provide a means of comparison of estimated weekly doses for each treatment as a
ballpark.
Dosing Implant Estimated in vitro Ratio to weekly 4
Study diameter release rate mg/kg IP cisplatin
(cm) (pg/week) injection
2 1.0 182.2 2.0
1 1.5 397.2 4.4
1 2.0 695.9 7.7
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Table 4.3: Comparison of the estimated weekly cisplatin dose released by each
implant size used in the two dose escalation studies to the amount of cisplatin
delivered once weekly by a 4 mg/kg IP injection. An average mouse mass of 22.5
g was used for calculating the IP injection dose administered since the mice used
in these two studies weighed 20-25 g. The estimated weekly cisplatin dose
released by the implants is calculated based on a 15.13 pg/cm 2/day average
cisplatin release rate calculated from multiple in vitro release studies of various
sample diameters. The actual in vivo cisplatin dose achieved with each implant
size has not yet been quantified so this is providing an estimate that is expected
to be higher than what can actually be accomplished in vivo due to any fibrosis of
the implant, contact with tissues like the fat pad obstructing release from parts of
its surface and the higher protein content of the peritoneal fluid compared to PBS.
The amount of platinum (Pt) present in different tissues of the peritoneal cavity was
quantified for the small- and medium-implant and IP injection groups and is shown in
Figure 4.6A. The large-implant group was not included in the analysis because the
animals had to be euthanized just 3 days after implantation due to toxicity. The medium
implant achieved a higher concentration of Pt in all tissues examined compared to either
the small implant or to six 4 mg/kg IP cisplatin injections at the 42-day time point. The
difference between the medium implant and the six injections was statistically significant
for the liver (p = 0.0008), kidney (p = 0.0095), small intestine (p = 0.0007) and large
intestine (p = 0.0143). The medium CDDP25 implant, even though releasing cisplatin
continuously at a much lower dose than that achieved instantaneously by each 4 mg/kg
IP injection, is able to accomplish more Pt delivery to key tissues of interest in the
abdominal cavity that are frequently sites of metastasis in ovarian cancer. The medium
implant was expected to deliver a total cisplatin dose 4.4X larger than the total dose
delivered by the IP cisplatin injections and so this may in part explain the difference in
Pt content seen in the tissues. The small implant on the other hand achieved a lower Pt
content in all organs compared to either the medium implant or the 6 injections at the
42-day time point even though it is expected to release a total cisplatin dose that is 2.OX
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larger than the total injection dose. The difference between the small and medium
implant was statistically significant for the liver (p < 0.0001), the spleen (p = 0.0097), the
kidney (p = 0.0020), the small intestine (p = 0.0001) and the large intestine (p = 0.0017).
There was no statistical significant difference between the small implant and the IP
injection group at the 42-day time point.
The amount of Pt in blood serum ultrafiltrate from the small- and medium-implant
mice and corresponding IP injection mice measured by ICP-MS is plotted on a
logarithmic scale in Figure 4.6B. Three different time points were sampled in the IP
injection group, at 2 hours, 48 hours and 7 days after the 6th cisplatin injection (blue
squares). The 2-hr and 48-hr samples come from a different batch of animals than the
7-day samples (IP injection group of second and first dose escalation study
respectively). The Pt content values in the IP injection group illustrate a spike in serum
Pt content reaching 583 pg/L 2 hours after injection and dropping to approximately 11
pg/L 7 days later. The small-implant group time points all correspond to the intended
euthanasia point 42 days after surgical implantation and illustrate a serum Pt content of
approximately 19 pg/L. The medium-implant group contains two Pt serum values, one
from the two mice euthanized on the intended date at 42 days after implantation (-66.5
pg/L) and one from the single mouse that had to be euthanized early 10 days after
implantation (-163 pg/L). The serum Pt value of the medium-implant mouse that had to
be euthanized is more than twice the value of the other two mice in the same group that
survived. This can be explained by revisiting the in vitro release profile of the medium
implants shown in Figure 4.3. The profile displayed a faster release phase in the first
two weeks that then dropped to a lower release rate for more than 20 days and
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appeared to accelerate again on day 37. The medium-implant mouse euthanized early
may have still been experiencing the steep accelerated release of those first few days,
which may in part explain its demise and also the elevated Pt serum value. It could be
plausible that the medium implant assigned to this mouse released cisplatin at an even
faster rate than that expected due to sample-to-sample variability. This possibility was
ruled out by resuming in vitro cisplatin release for this implant after it was explanted
from the euthanized mouse and comparing the profile to that of an extra medium
implant from the same batch that had been prepared as a backup for this study. The
release profile for these two medium implants is plotted in Figure 4.6C and shows a
similar release profile for the two samples. The Pt serum levels measured for the two
implant groups were all detectable but well below the maximum Pt serum level
measured for the IP injection groups, with the maximum Pt serum level measured in an
implant-bearing mouse being less than 30% of the maximum Pt serum level measured
in IP-injected mice (162.96 pg/L vs. 582.87 pg/L respectively).
The fact that a higher total cisplatin dose can be delivered with a CDDP25
implant compared to periodic bolus IP injections raises a critical question regarding the
tolerability and toxicity of such an implant. Answering this question is key to assessing
the potential of this continuous low-dose approach for optimizing maximum tolerated
dosing. The weights, CBC and histology of harvested tissues were all evaluated for the
two dosing studies to determine whether the dose delivered by each implant size was
toxic to the mice.
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Figure 4.6: Platinum quantification and cisplatin release results from the two thin CDDP25 in
vivo dosing studies. (A) Box-and-whiskers plots of the average normalized tissue platinum (Pt)
content in ppm for the small- and medium-implant and IP injection groups quantified at
euthanasia. The IP injection mice in study 1 were euthanized 7 days after the 6th injection while
the IP injection mice in study 2 were euthanized 48 hours after the 6th injection. The ends of the
box are the upper and lower quartiles of the data, the lines outside the box indicate the highest
and lowest values and the median is marked by the vertical line inside the box. The medium-
implant group had higher normalized Pt content in all organs compared to the IP injection and
small-implant groups. The difference between the medium implant and six injections was
statistically significant for the liver, kidneys, small intestine and large intestine when compared
with a one-way ANOVA. The difference between the medium implant and the small implant was
statistically significant for all organs except for the stomach and the reproductive system
(ovaries, uterus). There was no statistically significant difference between the small implant
group and the six IP injections. These data support the hypothesis that the medium CDDP25
implant, even though releasing cisplatin continuously at a much lower dose than that achieved
instantaneously by each 4 mg/kg IP injection, is able to achieve more Pt delivery to key tissues
of interest in the abdominal cavity. The medium implant was expected to deliver a total cisplatin
dose 4.4X that delivered by the 6 combined IP cisplatin injections and so this may in part
explain the difference in Pt content seen with this data. (B) Blood serum ultrafiltrate Pt levels in
samples from mice implanted with a small or medium implant or receiving weekly 4 mg/kg IP
cisplatin injections. The time since administration of treatment is measured starting on surgery
day for implant-bearing mice and starting on the day of the last injection for injection-treated
mice. The number of animals sampled at each point is indicated above the data point. Both
small and medium implants resulted in detectable Pt levels in the serum that were nevertheless
orders of magnitude lower than the maximum Pt serum level in the IP injection group, measured
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2hr after injection. Not enough blood could be collected by the large-implant mice at euthanasia
for serum ultrafiltration and isolation of unbound cisplatin for quantification by ICP-MS. (C) In
vitro cisplatin release was tracked for an extra medium implant produced with those implanted in
mice but not used in vivo (red squares) as well as the medium implant explanted from the
mouse that had to be euthanized early 10 days after implantation (red triangles). Both release
profiles were similar to that expected from other medium-implant in vitro release studies and the
original release studies of the CDDP25 formulation using thicker samples. This confirmed that
the implants were behaving as expected in terms of cisplatin release, to help address the cause
behind the early demise of a medium-implant mouse.
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4.3.5 CDDP25 implant tolerability evaluation - in vivo dosing study 1
Animal survival for the first dosing study is plotted in Figure 4.7A. The mice implanted
with large disks (large-implant) had to be euthanized 3 days after undergoing surgery
for disk implantation because of poor body condition (signs of respiratory distress). One
of the mice implanted with medium disks (medium-implant) had to be euthanized on day
10 after surgery because of exceeding 20% weight loss despite supportive measures
even though it was alert and behaviorally otherwise appeared healthy. The remaining
two medium-implant mice and three IP-injection mice were followed over the intended
42-day (6-week) period.
Average animal weights tracked over the study duration are plotted in Figure
4.7B. The mice receiving a weekly 4 mg/kg IP injection of cisplatin (blue rectangles)
exhibited weight fluctuations that aligned with their injection schedule: their weight
dropped visibly soon after receiving an injection and eventually started recovering only
to plummet again with the next injection. They appeared to stabilize at a weight that was
approximately 90% of their original pre-treatment weight by the 5th injection although the
standard deviation of the weight measurements is high and increasing over time,
suggesting significant animal variability within the group. The two remaining medium-
implant mice also experienced a marked drop in their weight after surgery that
eventually brought them down to approximately 80% of their pre-treatment weight. The
two mice remained stable at this reduced weight but were alert and responsive
throughout the 42-day study despite their weight loss.
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Figure 4.7: Tolerability of the thin CDDP25 implants in the first dosing study. (A) Survival
plot and (B) average animal weight plot for the three treatment groups in the first dose
escalation study. Large-implant animals had to be euthanized three days after the start of
treatment due to toxicity and poor body condition. One of the medium-implant mice also
had to be euthanized early at ten days after the start of treatment because of rapid weight
loss that did not recover even though it appeared otherwise healthy. The mice receiving a
weekly 4 mg/kg IP cisplatin injection displayed a seesaw weight loss pattern matching their
injection schedule, with each injection resulting in a weight plummet and an eventual
recovery to about 90% of their pre-treatment weight and stabilization after the last injection.
165
10C
75-
50-
25-
NO
0
n
A
120-
1001
80-
60-
40-
20-
-- ------
-U-
Co,
.60
~0
a)
N
0
V)
III
-4
0
r)
The standard deviation from the mean weight in this group was however quite large
indicating that some animals dropped a lot more weight with each injection while others
tolerated the treatment better. The medium-implant mice experienced a weight loss
following surgery that reached approximately 20% of their pre-surgery weight and
remained relatively stable around the 80% weight value throughout the rest of the
treatment period. The standard deviation from the mean weight in the medium-implant
group was much smaller compared to the IP injection group, suggesting that these mice
more consistently responded to treatment with the medium implant in terms of weight
fluctuation. The values plotted are the mean weight of the mice in each group surviving at
each time point and the error bars correspond to standard deviation from the mean. The
dashed line indicates the 20% weight loss point that is commonly used as a criterion for
euthanasia alongside the rest of the clinical picture of the animal.
The average CBC values at euthanasia for all treatment groups in the study are
plotted in Figure 4.8. Dashed lines have been added to indicate normal range bounds
for each cell type. All values were within normal bounds for all treatment groups with the
lymphocyte count (Figure 4.8C) being borderline low for large-implant mice and the
platelet count for similarly being borderline low IP-injection and large-implant mice
(Figure 4.8E), which suggests the possible start of bone marrow depletion due to the
cisplatin dose received.
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Figure 4.8: Plots of the average cell density of different blood
cell populations for each of the three treatment groups in the
first thin CDDP25 dosing study. The populations assessed are:(A) white blood cells, (B) neutrophils, (C) lymphocytes, (D) red
blood cells and (E) platelets. Values were obtained by CBC
with auto-differential from samples collected at euthanasia. All
values were within normal bounds for all groups with the
exception of lymphocyte counts for the large-implant group
(borderline low). Lymphocyte counts were at the lower end of
the normal range for all three groups but the Nu/Nu mice lack a
thymus and display reduced lymphocyte counts in general.
The platelet counts for the mice receiving weekly 4mg/kg IP
injections and those with a large implant were also at the lower
end of the normal range, suggesting platelet depletion possibly
as a result of the cisplatin dose given. Platelet counts are an
important indicator in cancer treatment since patients will be
taken off chemotherapy when their platelets drop to
dangerously low numbers and put them at risk for
uncontrollable bleeding. The fact that the platelet counts for the
medium-implant mice are the highest in this group suggests
that this treatment is best tolerated from that safety
perspective. It is important to note that the medium-implant
mouse that required euthanasia early due to rapid weight loss
had an elevated red blood cell count of 10.58 M cells / pL(upper normal bound is 9.42 M cells / pL) suggesting that it
was dehydrated and this may have caused its rapid weight
loss. Dashed lines indicate normal value bounds.
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Histologic examination of the liver, kidneys, spleen, small and large intestine and
explanted implant - for implant treatment groups - of the mice in this study showed
extensive kidney and gut damage in large-implant mice (Figure 4.9A) and no fibrotic
response to the implant as well as minimal tissue toxicity in medium-implant mice
(Figure 4.9B). This included the medium-implant mouse that had to be euthanized early
10 days after surgical implantation. This mouse suffered rapid dehydration whose cause
could not be identified on necropsy. The in vitro cisplatin release profile of an extra
medium implant prepared for this study but not implanted in an animal displayed very
rapid release on days 7-9 (Figure 4.6C). It is possible that the health deterioration of the
animal leading to its euthanasia was the result of a similar faster cisplatin release
happening in those first 10 days that this particular mouse tolerated less well than the
two that survived the entire 42-day study period. The large implants explanted from the
two mice in this study were not submitted for histology because they were removed
after only three days of implantation and were saved instead for future cisplatin in vitro
release studies and cisplatin quantification analysis.
The weight, CBC and histologic findings taken together indicate that the large
implant (2.0-cm diameter) caused intolerable toxicity due to its cisplatin release rate and
that the medium implant (1.5-cm diameter) resulted in borderline tolerable toxicity and
therefore may be indicative of the maximum tolerated dose for the cisplatin-eluting
CDDP25 composite material.
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Figure 4.9: Representative histology with H&E staining from mice implanted with thin CDDP25
disks in the first dosing study. Mice received (A) large or (B) medium implants. (A) Clockwise
from top left: kidney, spleen, small intestine and colon sections. There was marked tubular
epithelium apoptosis and protein accumulation (arrows) in the renal cortex and a lot of apoptosis
in the spleen. Paneth cells in the small intestine had very red granules and an abnormally large
number of them had released their granules out of the cytoplasm (star). There were apoptotic
cells near the base of the villi (arrows). The colon displayed an uneven crypt border and
apoptotic cells (arrows) as well. (B) Clockwise from top left: implant, kidney, spleen and small
intestine cross sections. No fibrosis or other signs of an inflammatory response were visible in
the implant histology. The kidney showed no signs of acute damage but a small amount of
tubular regeneration was evident. The spleen and small intestine both appeared normal.
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4.3.6 CDDP25 implant tolerability evaluation - in vivo dosing study 2
Animal survival for the second dose escalation study is plotted in Figure 4.1OA. All mice
survived and were followed over the intended treatment period (37 days to include 48
hours after the 6 h injection for the IP injection group and 42 days for the small-implant
group).
Average animal weights tracked over the study duration are plotted in Figure
4.10B. The mice receiving a weekly 4 mg/kg IP injection of cisplatin (blue rectangles)
again exhibit weight fluctuations that align with their injection schedule: their weight
drops visibly soon after receiving an injection and eventually starts recovering only to
plummet again with the next injection. They lost 20% of their weight following the first
injection to recover almost fully by day 21. They then experienced consistent weight
loss until their euthanasia on day 37 at which point they had reached almost 70% of
their pre-treatment weight. These mice appear to have tolerated the weekly IP cisplatin
injection regimen less well than the equivalent IP injection group in the first dosing study
(Figure 4.7B). The small-implant mice lost approximately 20% of their pre-surgery
weight by the first week after implantation but had returned to almost 95% of their pre-
surgery weight by day 28 of the study. The error bars in the small-implant group were
smaller than those in the weekly IP injection group similarly to what was observed in the
first in vivo dosing study of the thin CDDP25 material suggestive of less animal-to-
animal variability in tolerating this dosing regimen.
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Figure 4.10: Tolerability of the thin CDDP25 implants in the second dosing study. (A)
Survival plot and (B) average animal weight plot for the two treatment groups in the
second dosing study. All mice survived to the intended euthanasia time point (48
hours after the 6th injection for IP injection mice and 42 days after implantation for
small-implant mice). The mice receiving a weekly 4 mg/kg IP cisplatin injection (blue
squares) displayed a seesaw weight loss pattern matching their injection schedule,
with each injection resulting in a weight plummet. These animals experienced a more
dramatic weight loss compared to the same treatment group in the first dose
escalation study, losing more than 80% of their weight after the first injection,
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recovering slightly and eventually undergoing weight loss without recovery after the
5th injection that brought them well below the 20% weight loss cutoff commonly used
as an indicator for euthanasia. The small-implant mice (red circles) experienced
weight loss following surgery that reached approximately 20% of their pre-surgery
weight, remained relatively stable at this reduced weight until approximately 14 days
after implantation and then recovered to almost 95% of their pre-surgery weight byday 28. The values plotted are the mean weight of the mice in each group surviving at
each time point and the error bars correspond to standard deviation from the mean.
The average CBC values at euthanasia for both treatment groups in the study
are plotted in Figure 4.11. Dashed lines have been added to indicate normal range
bounds for each cell type. All values were within normal bounds for all treatment groups
with the exception of the platelet count (Figure 4.11 E) being low for IP-injection mice,
which is reasonable given their weight loss and suggests toxicity to the bone marrow
likely as a result of the repeated cisplatin injections.
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Figure 4.11: Plots of the average cell density of different blood cell
populations for each of the two treatment groups in the second thin
CDDP25 dosing study. The populations assessed are: (A) white blood
cells, (B) neutrophils, (C) lymphocytes, (D) red blood cells and (E)
platelets. Values were obtained by CBC with auto-differential from
samples collected at euthanasia. All values were within normal bounds
for all groups with the exception of platelet counts for the IP injection
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group that were low. Dashed lines indicate normal value bounds.
Histologic examination of the liver, kidneys, spleen, small and large intestine of
the mice in this study showed no signs of toxicity in either treatment group. The
explanted implants of the small-implant mice showed however a greater fibrotic
response to the implants compared to the medium-implant mice in the first dosing study
(Figure 4.12). A more extensive amount of inflammation and deposition of fibrous tissue
were noted in these histologic sections. The small implants were found to be more
mobile inside the abdomen after implantation compared to the medium implants: two of
the three implants had migrated to distant locations from the site of placement on
surgery, one being found at the back of the animal pushing against its spine and the
other enveloping one of the liver lobes. Only one small implant was found close to the
site of placement on surgery. All three medium implants were found near the site of
placement on surgery for comparison. This implant migration in vivo displayed by the
small-implant group may help explain the more extensive inflammatory response and
fibrosis caused by these implants as a result of movement of the implants inside the
abdomen and subsequent tissue irritation. The small implant that had enveloped a liver
lobe was found to have created a thin layer of inflammatory fibrotic tissue at the
boundary between the implant and the liver but no tissue damage further inside the liver
was noted. This suggests that the cisplatin dose delivered by the small implants was not
in itself toxic.
The small-implant mice in this second dosing study tested positive by
polymerase chain reaction for corynebacterium bovis (C. bovis), a pathogenic bacterium
that causes scaly skin lesions in mice and is highly contagious. It is possible that any
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bacteria that crossed to the mouse systemic circulation localized themselves to the
implant forming a biofilm and exacerbated any inflammatory response already mounting
against it.
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Figure 4.12: Representative histology with H&E staining of explanted small implants and any
surrounding fibrotic response. Clockwise from top left: cross-section of a small implant after
explantation; fibrotic tissue from all three small-implant mice. The first and second fibrotic tissuepanels at the top right and bottom right respectively show the response to the small implant that
migrated to the back and the implant that enveloped a liver lobe respectively. The last fibrotic
tissue panel at bottom left shows the response to the small implant that stayed close to the site
of placement at surgery. The fibrotic response was least pronounced for the implant that did not
migrate far from the site of placement at surgery, suggesting that implant movement within the
abdominal cavity may be problematic for implant tolerability and functionality.
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The weight and CBC findings taken together suggest that the small implant was
well tolerated by the animals in terms of systemic toxicity while the 4 mg/kg IP injections
led to toxicity that met the requirements for animal euthanasia before the end of the
study. The histologic findings regarding abdominal organs similarly suggest that neither
treatment arm caused organ toxicity. The fibrotic response to the small implants seen
on histology was however more pronounced than that seen with medium implants or
with the thicker CDDP25 material previously assessed in vivo. This pronounced fibrotic
response may have been related to the C. bovis skin infection diagnosed by PCR in
these animals but may also have been the result of increased implant mobility inside the
abdominal cavity. The smaller size of the implants compared to the medium- and large-
implant sizes allowed them to migrate away from the site of implantation and may have
led to increased tissue irritation and foreign object response by the mouse immune
system.
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4.3.7 In vivo antitumor efficacy pilot
Multiple animals (9 out of 34) in different treatment groups of the efficacy pilot randomly
selected for screening tested positive by PCR for C. bovis bacterial infection. This
bacterium is highly contagious and the animals were housed in different cages before
being assigned to treatment groups so it is highly unlikely that any mice were not
infected by C. bovis. This bacterium has been associated with suppressed growth of
implanted tumors, changes in immune cell activity (especially affecting natural killer
cells) and increased toxicity of chemotherapeutic agents.153 Mice that were implanted
with CDDP25 disks were additionally found to have a 60% incidence of abscesses at
the site of subcutaneous analgesia injection on their neck, often resulting in significant
swelling and purulent discharge. These abscesses had not been observed previously in
animals that had not tested positive for C. bovis. The infected abscesses are likely
linked to this bacterial infection after consultation with the veterinarians of the MIT
Division of Comparative Medicine. The C. bovis and abscess findings are expected to
have affected the outcome of the efficacy pilot and so analysis of the harvested tissues
and blood serum filtrate samples were halted in light of these findings. Average in vitro
cisplatin release rates and their comparison to expected values for each sample type
are tabulated in Table 4.4. The in vitro cisplatin release profile, animal survival, animal
weight and bioluminescence normalized to the start of treatment and the tumor mass at
euthanasia were averaged within each treatment group and are plotted in Figure 4.13.
Linear best-fit trendlines for each of the three periods of near-zero-order release
evident in the Figure 4.13A release profiles for each disk type (period 1: day 1-6, period
2: day 7-30, period 3: day 31-42) were used to calculate a weighted average in vitro
cisplatin release rate over the 42-day period. The values are compared to those
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expected based on previous in vitro release studies in Table 4.4. A lower average in
vitro cisplatin release rate and larger-than-anticipated variability were observed in the in
vitro cisplatin release profile of all three CDDP25 disk types (Table 4.4, Figure 4.13A)
based on the in vitro cisplatin release data previously exhibited by CDDP25 samples
(Chapters 2 and 4). All three disk types had a cisplatin release profile that accelerated
after day 30 and was less linear than expected. Possible reasons for the lower cisplatin
release rate, larger variability and less linear release include inconsistencies with the
batch of Ecoflex 00-30 used for these implants as well as a different cisplatin crystal
size distribution compared to previous vials of cisplatin powder used in CDDP25
manufacturing. The size of drug crystals affects drug release kinetics from silicone
matrices as described by Golomb et al. and can either accelerate or decelerate release
depending on the matrix and its preparation.115 Better control of cisplatin and lactose
crystal size during composite manufacturing is needed moving forward to ensure such
discrepancies are addressed.
Animal survival in the efficacy pilot is plotted in Figure 4.13B. Multiple animals
had to be euthanized before the end of study leaving three mice in the 0.5 cm group (i),
one mouse in the 0.8 cm group (ii), four mice in the 1.0 cm group (iii), five mice in the 4
mg/kg IP injection group (iv), three mice in the 10 mg/kg IP injection group (v) and three
mice in the untreated control group (vi) by day 41. All but the three mice of group (v)
were euthanized due to excessive tumor burden. The three mice of group (v) were
euthanized due to excessive weight loss and poor body condition associated with their
cisplatin injections.
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Disk Disk In vitro Proportion of expected in
diameter thickness release rate vitro release rate
(cm) (mm) (pg/day) achieved (%)
0.5 1.0 8.48 83
0.8 1.0 17.87 76
1.0 0.4 25.15 87
Table 4.4: Comparison of the weighted average daily cisplatin dose released in
vitro by each disk type used in the efficacy pilot to the expected daily in vitro
release from previous studies. All disk types released cisplatin at a lower rate
than expected (76-87% of expected). All disk types displayed greater standard
deviation than that seen in previous in vitro release studies. These discrepancies
may be the result of CDDP25 composite manufacturing for this particular batch
and specifically cisplatin crystal size distribution.
Mouse weights plotted in Figure 4.13C normalized to the value at the start of
treatment further illustrate the toxicity of the 10 mg/kg weekly IP injections given to
group (v). A dashed line has been added as a visual guide to mark the point of 20%
weight loss commonly used as a criterion for animal euthanasia due to poor body
condition. The animals in group (v) reached this degree of weight loss by day 11 of
treatment following two weekly injections. Their weight continued to drop reaching less
than 70% of its initial value by day 35 of treatment. Special permission was obtained
from the veterinarians to allow continuation of the study in this treatment group until day
41.
There was large variability in bioluminescence across all mice in this pilot study
before the start of any treatment, as seen by the large standard deviation error bars in
the BLI plot (Figure 4.13D). This suggests that some animals were less likely to reject
the xenografts and showed a faster tumor growth rate compared to others. The number
of mice in this pilot was small and so all animals were randomized to treatment groups
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even though previous experience with this animal model suggested that those with a
lower BLI signal (<1 E8) were at risk for xenograft rejection.
The average BLI in each treatment group plotted in Figure 4.13D suggests tumor
response to treatment for all five cisplatin treatment groups. The normalized BLI signal
is lower after CDDP25 disk implantation in groups (i) and (ii) compared to the untreated
control group (vi). This pattern continues until the euthanasia of two untreated control
mice that had high tumor burden and did not recover from isoflurane anesthesia on day
4.14. The BLI signal at later time points is affected by successive animal euthanasias in
groups (i), (ii) and (vi) and it becomes hard to make across-group comparisons using
the average BLI signal of the remaining mice. The normalized BLI signal is lower after
CDDP25 disk implantation in group (iii) compared to the untreated control group (vi) as
well and this trend continues until the end of the study on day 41. Only one animal was
euthanized early in group (iii) making the BLI signal series more representative of the
true average tumor response to treatment throughout the 41-day pilot. Both IP injection
groups (iv) and (v) reduced their BLI signal by day 41 to < 5% of its value at the start of
treatment. These groups responded the best to treatment as tracked noninvasively by
BLI.
Tumor mass at euthanasia is plotted in Figure 4.13E as box-and-whiskers plots
from the minimum to the maximum value and showing all points. Multiple mice had
tumors that developed both an intraperitoneal and a subcutaneous portion, penetrating
the abdominal wall. Only intraperitoneal tumors and ascites were weighed and included
in this quantification. A one-way ANOVA with Tukey's multiple comparisons test was
used to compare the average tumor mass of each treatment group to the others. The
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only statistically significant differences were between the 0.8-cm diameter disk (group
(ii)) and the 4 mg/kg and 10 mg/kg weekly IP cisplatin injection regimens (groups (iv)
and (v) ) with p-values of 0.0260 and 0.0177 respectively. The large variability in tumor
rejection and growth between animals resulted in lack of any significant difference
between the two extreme control groups: group (v) receiving 10 mg/kg IP cisplatin
injections equivalent to the current standard of care and group (vi) receiving no
treatment. The fact that the two extreme controls (clinically-treated and entirely
untreated) did not have a statistically significant difference in tumor mass at euthanasia
means that the results of this efficacy pilot are not reliable. Better approaches to the
mouse model used and the tumor burden cutoff applied for treatment group
randomization should be implemented in the next efficacy studies to avoid such an
issue.
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Figure 4.13: Antitumor efficacy pilot study results. (A) In vitro cisplatin release profile of extra
CDDP25 disks prepared for the efficacy pilot but not implanted in mice. This in vitro release
study was carried out over a 42-day time period to get an indirect metric of expected
cisplatin release from the CDDP25 disks actually implanted in mice. All three CDDP25 disk
types displayed relatively large standard deviations compared to previous studies. All three
disk types released cisplatin at a rate slower than the one expected (83%, 76% and 87%
respectively) and displayed a less linear release profile. (B) Animal survival is plotted for the
six treatment groups. Multiple animals had to be euthanized before the 41-day intended final
time point because of poor body condition either due to tumor load or, in the case of group
(v) receiving 10 mg/kg weekly IP cisplatin injections, due to weight loss caused by cisplatin
toxicity. (C) Average mouse weights normalized to the value at the start of treatment plotted
for each of the six groups in the pilot. Groups (i)-(iii) lost weight immediately after surgical
implantation of their CDDP25 disks but recovered within a week. Notable in this plot is the
dramatic weight loss of group (v) animals receiving the mouse-scaled equivalent dose to IP
cisplatin infusions given in the clinic. (D) BLI signal normalized to the value at the start of
treatment is plotted as an average value for each treatment group at each imaging time
point. Mice implanted with 1.0 cm-diameter 0.4 mm-thickness disks had the least increased
BLI signal (the other two disk-implanted groups (i) and (ii) had lost most mice with high tumor
burden before day 41). The two IP injection groups (iv) and (v) showed the most effective
BLI signal reduction to less than 5% of its value at the start of treatment. (E) Tumor mass at
euthanasia averaged for each treatment group and plotted as a box-and-whiskers plot. The
ends of the box are the upper and lower quartiles of the data, the lines outside the box
indicate the highest and lowest values and the median is marked by the vertical line inside
the box. All individual data points are additionally shown. There was no statistically
significant difference in average tumor mass between the two IP injection-treated groups
and the untreated controls, suggesting that the findings of this pilot are unreliable since
these were the two extreme control conditions. This lack of statistical significance is likely
due to the large degree of variability in xenograft rejection and tumor growth between
animals and the small n in each group. Values are plotted as means unless otherwise
indicated and error bars show standard deviation from the mean.
4.3.8 Miura v-pleat origami prototypes
The Ecoflex 00-30 and LAC50 Miura v-pleat sheets cast using the machined Teflon
mold measured approximately 44 mm in length by 44 mm in width. The individual pleat
features on the partially pre-folded sheets measured approximately 2.5 mm in
depth/height, 4 mm in width, 2 mm in length and 1 mm in thickness. The Ecoflex 00-30
and LAC50 Miura v-pleat sheets cast using the 3D-printed ABSplus mold measured
approximately 70 mm in length by 70 mm in width. The individual pleat features on the
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partially pre-folded sheets measured approximately 10 mm in depth/height, 8 mm in
width, 4 mm in length and 1.5 mm in thickness (Figure 4.14). The prototypes did not
exhibit any signs of air entrapment or other casting defects visible to the naked eye. No
mechanical characterization of the origami prototypes was performed since they were
intended for proof-of-concept demonstration of the feasibility of using an origami fold to
drive collapse of a large thin composite sheet into a shape that can fit through
laparoscopic tools and then be opened up once inside the body. The prototypes created
were too thick to allow them to pass through laparoscopic tools at their compressed
state but the work described in this chapter developing a thinner CDDP25 formulation
can readily be translated to casting origami sheets that are thinner and/or have other
optimized dimensions. These sheets will ultimately be required to reach a collapsed size
that will allow them to be easily passed through a trocar with maximum diameter of 12
mm.
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Figure 4.14: Miura v-pleat origami sheet prototypes. The prototypes are
made of Ecoflex 00-30 alone (left) or LAC50 (right). The prototypes were
cast using a (A)-(B) machined Teflon and (C)-(D) 3D-printed ABSplus two-
part mold. Scale bar 10 mm. (C)-(D): Application of force along the length or
width of (C) Ecoflex 00-30 or (D) LAC50 origami prototypes allows
compression to a smaller size to fit through a more narrow incision than the
actual sheet dimensions. A US penny has been added for scale.
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4.4 Discussion
The CDDP25 formulation developed previously for controlled, low-dose near-zero-order
release of cisplatin over a prolonged period of time was optimized in this work to
develop a material that is thinner and is a more viable candidate to create a
laparoscopically deployable implant for IP cisplatin delivery. The material thickness was
reduced by almost two thirds of its original value to 0.4-0.45 mm. This reduced-
thickness material allowed dose escalation studies to be performed because it made
implantation of much larger-diameter samples possible through a small incision on the
mouse abdomen to minimize invasiveness of the surgery. The thinner disk-shaped
samples can be easily rolled up for placement into the mouse abdomen through a small
incision compared to the thicker ones. They can then be unrolled into their original
dimensions once inside the abdomen. Thinner samples will have a lower bending
stiffness since they will have a lower area moment of inertia /c. The /c of a rectangle with
height h and width b when attempting to bend it about its centroid is expressed by:
I bhC 12
The height is raised to the third power in this expression, so any increase in sample
thickness will dramatically increase 1,. The reduction in bending stiffness as a result of
reducing the sample thickness is also expected to be beneficial for the safety of an
implanted sample in vivo. A less rigid implant will more readily take on the shape of the
space around it and is less likely to irritate the organs and tissues surrounding it
compared to a more rigid implant.
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Reducing the thickness of a composite elastomeric material can affect many of
the properties influencing its behavior as a drug-eluting system in vivo. The
manufacturing process for the material may have to change leading to better or worse
performance in terms of defects in the structure. The composite comprises a silicone
matrix impregnated with crystals of lactose and cisplatin. Confirmation of a
homogeneous distribution of solid excipients in the silicone matrix is necessary to
ensure that the material has not fundamentally changed due to this new manufacturing
process. Reducing material thickness can additionally make it more prone to contain
defects caused by crystal impregnation that can lead to failure under tension. A
reduction in the material thickness under the disk sample preparation methods
employed in this work - using a punch to cut out individual samples from a larger sheet
of material - affects the surface area of the sides of a disk that was directly cut out from
a bigger piece. This side surface area is likely to contain more exposed lactose and
cisplatin crystals compared to the flat top and bottom surfaces that were in contact with
the mold or the atmosphere during curing. A reduction in sample thickness will reduce
this surface area and is likely to affect the release of lactose and cisplatin from the
sample. The impact of such a change in release from the sides to the overall release
profile of the sample will depend on the contribution of release from the sides to the
overall release from the entire sample.
The structure, mechanical properties and in vitro release of this new CDDP25
thickness were assessed in order to compare them to those of the previously developed
thiciser CDDP25 formulation and confirm its appropriateness for manufacturing an IP
implant. Secondary and backscatter electron SEM confirmed that this new thickness
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contained uniformly distributed cisplatin and lactose crystals impregnated in the silicone
matrix similar to what was observed in the thicker CDDP25 formulation (Figure 4.1).
Mechanical characterization of the thin material revealed that its elastic modulus,
ultimate tensile strength and elongation at break were all almost 80% of the values
calculated for the thicker formulation and still well within ranges making them safe for
presence inside the abdomen (Table 4.1). Evaluation of either formulation under
mechanical tests simulating laparoscopic implantation and removal is outstanding and
should be carried out as a next step to confirm safety for implantation in patients from a
mechanical standpoint. The average in vitro cisplatin release rate of three different disk
diameters cut out from the thinner CDDP25 formulation was close to the expected value
with deviation increasing with increasing disk diameter. This trend is reasonable since
sources of deviation, manufacturing or others, from the calculated surface area-
normalized cisplatin release rate are expected for any sample batch. Such deviation will
be amplified with increasing surface area of a sample. The surface area-normalized
release rate displayed by all three disk sizes is plotted in Figure 4.4 and is in good
agreement with the expected surface area-normalized release rate based on the thicker
CDDP25 formulation. These findings confirmed that the thin CDDP25 formulation is
releasing cisplatin as expected.
Thin CDDP25 disk sizes of different diameters were manufactured and implanted
in the peritoneal cavity of mice to assess the toxicity of the cisplatin dose they delivered,
the overall material biocompatibility and the concentration of platinum in tissues of the
abdominal cavity accomplished by the disks as an indirect measure of their in vivo
cisplatin release capacity. The two dose escalation studies performed compared weekly
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4 mg/kg IP cisplatin injections - a regimen previously used in this project and found to
be well tolerated in vivo - to 1.0-cm, 1.5-cm and 2.0-cm diameter disks expected to
release cisplatin at a total dose that as 2.OX, 4.4X and 7.7X that of the injections
respectively. The 2.0-cm disks were deemed too toxic for in vivo implantation most likely
on the basis of their cisplatin release rate considering the acuteness of the toxicity that
required euthanasia 3 days after implantation. The 1.5-cm disks were tolerated by two
of the three mice and the cause leading to the toxicity that eliminated the third mouse
has not yet been determined although it may be related to a more rapid cisplatin release
observed on days 7-9 in this implant batch. The 1.0-cm disks appeared to be well
tolerated in terms of animal weight, CBC and abdominal organ histology but were found
to cause a more pronounced inflammatory foreign body response compared to the 1.5-
cm disks and to the thicker CDDP25 formulation previously evaluated in vivo. This
pronounced foreign body response may be associated with the increased mobility of
1.0-cm disks within the abdominal cavity observed in vivo and may point to a design
component that must be optimized in the final implant dimensions selected for in vivo
antitumor efficacy evaluation. The 1.5-cm disks may be considered representative of the
maximum tolerated dose for this cisplatin-eluting material based on weight, CBC and
histologic assessment and point to an implant size that may be most promising for
future efficacy studies based also on the fibrotic response it induces.
The efficacy pilot study conducted using 1.0-cm disks of 0.4-mm thickness
('small implants' from the second dosing study described in this chapter) as well as 0.5-
cm and 0.8-cm disks of 1.0-mm thickness suffered from critical drawbacks that
compromised its outcome. Multiple animals in the study tested positive for a bacterial
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infection that has been found to affect tumor growth, response to chemotherapeutics
and immune cell populations. Animals receiving surgical implantation of CDDP25 disks
additionally suffered large and infected abscesses at the site of subcutaneous analgesia
infection at a very high incidence never observed before when performing such
surgeries. These abscesses may likely be connected to the bacterial infection and may
have further affected immune response to the xenografts inoculated in these animals as
well as the administered cisplatin chemotherapy. A small number of mice were used in
each treatment group and large variability in xenograft rejection and tumor growth were
observed across the board. This led to lack of statistical significance in tumor mass
difference between the two extreme controls (untreated vs. clinical standard of care
equivalent) at euthanasia and further cast doubt to the validity of data from this pilot.
Key takeaways were nevertheless obtained from this study: (1) a response to treatment
was seen in all CDDP25 disk groups albeit transient in the two groups receiving the
lowest continuous cisplatin dose; (2) 1.0-mm thick CDDP25 disks were primarily found
embedded in the mouse fat pad near the bottom of the pelvis while 0.4-mm thin
CDDP25 disks remained closer to the site of implantation; (3) xenograft rejection and
tumor growth variability should be taken into account more conservatively moving
forward, potentially using a BLI signal cutoff as an inclusion criterion for treatment group
assignment; (4) diligent testing of animals upon arrival for infection with pathogens like
C. bovis that can affect study outcomes should be performed to the extent possible
every time; and (5) modifications in tumor inoculation technique should be carried out to
prevent growth of subcutaneous lesions and only generate intraperitoneal tumors in
mice. Next iterations of the efficacy study will involve only the thinner version of the
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CDDP25 composite and will explore delivery of higher continuous cisplatin doses while
targeting points (1) through (5) above.
The implant envisioned to deliver IP cisplatin to treat peritoneal metastasis in
ovarian cancer patients must be able to expose as large a surface area as possible
inside the abdomen to drug while allowing placement and removal via minimally
invasive surgery to reduce postoperative complications and recovery time. Minimally
invasive surgery, also known as laparoscopy, employs tools known as trocars to
introduce and remove items intra-abdominally. Trocars exist in various diameters
ranging from 2 to 12 mm. 15 4 Risk of complications both peri- and post-operatively such
as tissue injury or herniation of the bowel or fat increases with increasing incision site. 154
It is desired therefore to design an implant that can fit through as small a laparoscopic
incision as possible. The maximum trocar diameter is however assumed to be the upper
bound to design a laparoscopically deployable implant since the implant must also
optimize for maximal surface area of exposure to the drug. The Miura v-pleat origami
tessellation was used to drive the shape of an Ecoflex 00-30 or LAC50 sheet by casting
it in molds with three-dimensional features. The goal was to allow folding down of the
origami sheet by pressing along either its length or width and so reduce that dimension
to allow passing through a narrow opening. The origami sheets created with this
approach maintain a partially folded shape even at their relaxed state and this is
suboptimal in terms of implantation safety. The existence of peaks and troughs along
the surface of the origami sheets can lead to accumulation of tissue or fluid in those
features that may eventually cause infection inside the abdomen. The silicone-based
composite materials developed in this work to deliver cisplatin are soft and stretchy and
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so are challenging to fold down in a straightforward and repeatable manner without
having some degree of pre-folding in their shape. Optimization of the dimensions of the
Miura v-pleat shape used to produce the proof-of-concept prototypes shown in Figure
4.14 as well as reduction of the cast origami sheet to one third - one half of its current
thickness are two starting points to enable creation of origami sheets that are more
likely to fit through laparoscopic tools. Other origami tessellations such as a single v-
pleat can be explored in case they are better suited to create sheets that can fit through
a trocar. It is also important to note that the material developed in this work swells when
immersed in an aqueous medium as part of its cisplatin and lactose release process.
The degree of swelling was not quantified in this work but is an important next quantity
to understand since it will impact the feasibility of laparoscopic removal of a composite
implant at the end of the treatment period using a trocar.
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Chapter 5: Assessment of Technology Adoption Potential in Low-
and Middle-Income Countries
5.1 Introduction
Gynecologic and gastrointestinal cancers, affecting more than 2 million patients and
killing more than 1 million patients in low- and middle-income countries (LMICs)
annually, metastasize intraperitoneally with a very poor prognosis. IP chemotherapy can
increase survival but is not an option in LMICs because of its high cost, complicated
technology and debilitating toxicity. The sustained-release implants for IP delivery of
cisplatin described in this work are well suited for use in resource-constrained
environments. They are made of readily accessible materials, deliver off-patent
chemotherapy at low doses to reduce side effects and do not require repeat visits to the
hospital beyond placement and removal. They hold promise for improving accessibility,
cost effectiveness and tolerability of IP chemotherapy particularly in LMICs. A clinician
survey deployed across India reveals eagerness for early adoption of new technologies
and dosing regimens to treat peritoneal metastasis and shows potential for utilization of
the sustained-release implants developed in this project.
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5.2 Materials and Methods
5.2.1 Online clinician survey
Exemption from institutional board review was granted by the MIT Committee on the
Use of Humans as Experimental Subjects (COUHES) to the survey protocol. The
Qualtrics platform was used to create an online survey targeted at healthcare providers
in India. The survey was designed to be adaptable to participant input and direct
participants to different question blocks depending on their answers. The survey
response duration was kept to < 5 min in order to maximize successful completion.
Question content focused on five key areas: (i) participant background, affiliation and
experience caring for cancer patients; (ii) incidence and management of peritoneal
metastasis; (iii) use and challenges of IP chemotherapy both catheter-based and
HIPEC/PIPAC; (iv) use of metronomic chemotherapy particularly for patients with
peritoneal metastasis; and (v) outlook on adopting new technologies for IP
chemotherapy. The survey collected data in an anonymous fashion but allowed
participants to provide their email address for follow-up if desired. Participants were
informed of the purpose of the survey and potential use of their responses for
presentations in scientific meetings, conferences and publications via an introductory
consent section before starting the survey. Participants had the option of opting out of
the survey at any point during its completion.
5.2.2 Survey dissemination
The clinician database of the National Cancer Grid of India was used to disseminate the
survey electronically. Access to the database was given by the National Cancer Grid
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Director. Clinicians were contacted via electronic messages containing a link to the
anonymous survey.
5.2.3 Data representation and analysis
Data from survey participants were exported as .csv files from the Qualtrics platform
and further analyzed and represented graphically. Incomplete, duplicate or invalid
responses were removed prior to further analysis.
5.3 Results
5.3.1 Participant background, affiliation and cancer care experience
The clinician survey has collected responses from 40 participants to date representing
10 specialties and 35 hospitals across India (Figure 5.1A-B). The hospitals affiliated with
the survey responders represent both public (35%) and private (65%) institutions and
are mostly tertiary centers (94%) with a small number of secondary centers (6%)
(Figure 5.1C-D).
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Figure 5.1: Responder location, background, specialty and affiliation results
of the Indian clinician survey to date. (A) Map representing the locations of
hospital affiliations of survey responders to date. The locations include major
urban centers like Mumbai and New Delhi as well as remote locations like
the Andaman and Nicobar Islands and Assam. (B) Responders to date
represent 10 specialties and all provide care to patients with cancer. (C)-(D)
The hospitals affiliated with the survey responders represent both public
(35%) and private (65%) institutions and are almost entirely tertiary centers
(94%) with a few responses originating from secondary centers (6%).
5.3.2 Incidence and management of peritoneal metastasis
More than three quarters of responders reported the incidence of peritoneal metastasis
among the cancer patients they treated to be between 1 % and 25% and more than 90%
of responders placed that number between 1% and 50% (Figure 2A). This number is
lower than what would be expected based on the incidence of peritoneal metastasis at
advanced stages of disease and the proportion of patients diagnosed late according to
epidemiological data from India. This discrepancy may be related to the fact that
responders belong to 10 specialties many of which treat multiple types of cancer (e.g.
surgical oncology, medical oncology, radiation oncology). These specialists provide
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Hospital type
incidence estimates taking into consideration their entire cancer patient pool. Many of
their patients would face a very low probability of peritoneal metastasis given the origin
and type of their cancer therefore skewing the peritoneal metastasis incidence
estimates to lower numbers.
The percentage of cancer patients with peritoneal metastasis that undergo
surgical debulking was reported to be between 1% and 25% by almost half of the
survey responders (Figure 5.2B). Surgical debulking is a cornerstone. of advanced
ovarian cancer treatment but is less commonly used to treat other malignancies with
peritoneal involvement. This low percentage is not surprising since the survey did not
differentiate between patients with peritoneal metastasis of ovarian origin and others.
Surgical debulking will also not be performed if the procedure is not deemed to be
beneficial to the patient either because their disease is too advanced or because they
should first undergo neoadjuvant chemotherapy to shrink down their tumors. These
considerations of peritoneal metastasis care are reflected in the survey responses: the
main reason for not performing surgical debulking cited in the survey was patient
eligibility (24%) followed by cost (15%), lack of trained staff (13%) and resources (13%)
and lack of benefit to the patient (12%) (Figure 5.2C).
Cancer patients with peritoneal metastasis
Everyone 3%
76-99% 3%
51-75% 3%
26-50% 14%
1-25% 77%
None 3%
A
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Cancer patients with peritoneal metastasis who
undergo surgical tumor debulking
Everyone 0%
76-99% 6%
51-75% 15%
26-50% 21%
1-25% 47%
None 12%
B
Reasons for not performing surgical debulking
Patient not eligible 24%
cost 15%
Lack of appropriately trained staff 13%
Lack of infrastructure/resources 13%
No therapeutic or palliative benefit 12%
Physician preference 10%
Patient preference 9%
Additional risk for anesthesia and recovery 1 %
Neoadjuvant chemo + interval cytoreduction 1 %
C
Figure 5.2: Incidence and management of peritoneal metastasis in India. (A) Incidence of
peritoneal metastasis among cancer patients seen by responders. More than three quarters
of responders reported this value to lie between 1% and 25% of patients. This low number
may be explained by the fact that many responders represent specialties treating patients
with various types of cancer, many of whom face a very low probability of developing
peritoneal metastasis. (B) Proportion of patients with peritoneal metastasis undergoing
surgical tumor debulking. Almost half of survey responders reported this number to lie
between 1 % and 25% of patients and the reasons for not performing surgical debulking
ranked in (C) may help shed some light to this low number. Lack of patient eligibility for
debulking (24%) and no benefit from the surgery (12%) are both common reasons to not
perform debulking in the US as well while cost (15%) and access to trained staff (13%) and
resources (13%) are likely reasons more applicable to the LMIC setting.
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5.3.3 Use and challenges of IP chemotherapy
The majority of responders (74%) reported being familiar with IP chemotherapy but
described limited use of this route of administration (Figure 5.3A, B). More than half
(54%) reported not using IP chemotherapy at all with peritoneal metastasis patients
while almost all remaining responders (42%) reported using IP chemotherapy only with
1-25% of their peritoneal metastasis patients (Figure 5.3B). IP chemotherapy when
used is overwhelmingly performed in the operating room as HIPEC (73%) while only
27% of responders indicated using traditional catheter-and-port IP chemotherapy
administration (Figure 5.3C). They cited the reasons for not performing catheter-and-
port IP chemotherapy as primarily lack of infrastructure and resources (72%) and lack of
appropriately trained nursing staff (59%) while cost (48%), infections (38%) and catheter
or port complications (31%) and loss to follow-up (24%) were also ranked high. They
also pointed to the importance of surgical debulking, citing it as the fifth reason for not
performing catheter-and-port IP chemotherapy.
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Figure 5.3: Use and challenges of IP chemotherapy in India. (A) Almost three quarters(77%) of survey responders described being familiar with IP chemotherapy but (B) more
than half (54%) reported not giving it to any peritoneal metastasis patients. Most of the
remaining responders (42%) reported giving IP chemotherapy to 1-25% of peritoneal
metastasis patients. (C) When given, IP chemotherapy is overwhelmingly HIPEC (73%) and
only 27% of responders reported using catheter-and-port IP chemotherapy for theirpatients. (D) Responders rank lack of infrastructure and resources (72%), lack of
appropriately trained nurses (59%) and cost (48%) as the top three reasons for notperforming catheter-and-port IP chemotherapy. Infections (38%) and catheter or port
complications (31%) are also cited as important reasons for lack of use of this IP
chemotherapy modality.
5.3.4 Use of metronomic chemotherapy
Metronomic or dose-dense chemotherapy is an attractive approach for cancer treatment
in LMICs because it leads to fewer side effects for patients who cannot afford being
unable to earn a livelihood during their treatment. This dosing regimen is similar in
principle to the sustained low-dose chemotherapy administration described in this
project. Use of metronomic chemotherapy is therefore promising for adoption of a
sustained low-dose chemotherapy regimen.
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Almost all survey responders (92%) reported being familiar with metronomic
chemotherapy (Figure 5.4A) and described some use of this dosing regimen to treat
peritoneal metastasis. Almost half of responders (42%) specifically reported using
metronomic chemotherapy to treat 1-25% of their peritoneal metastasis patients.
Physicians familiar with metronomic chemotherapy
92% EYes ENo
A
Cancer patients with peritoneal metastasis on
metronomic chemotherapy
51-75% -4%
26-50%
1-25%
None
0%
42%
54%
B
Figure 5.4: Use of metronomic chemotherapy against peritoneal metastasis in India. (A)
Almost all responders indicated familiarity with metronomic chemotherapy. (B) Some use of
metronomic chemotherapy in peritoneal metastasis treatment was reported with 42% of
survey responders indicating that they use it for 1-25% of their peritoneal metastasis
patients.
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5.3.5 Outlook on adopting new technologies for IP chemotherapy
The responses regarding adoption of a new technology for IP chemotherapy were
overwhelmingly positive. More than half of responders (56%) would definitely try a new
technology whereas another 33% would probably try it. The remaining 11 % indicated
ambiguity about trying a new technology for IP chemotherapy and there were no
negative responses.
Would you try a new technology for IP chemotherapy?
Definitely yes 56%
Probably yes 33%
Might or might not 11%
Definitely not 0%
Probably not 0%
Figure 5.5: Adoption of new technologies for IP chemotherapy in India. More than half of
responders (56%) would definitely try a new technology for IP chemotherapy while more
than 30% would probably try it. The remaining 11% were ambiguous. This outlook is
promising for use of the sustained-release chemotherapy implants developed in this project.
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5.4 Discussion
Low-income countries face 56% of the global disease burden while accounting for only
2% of global health spending according to the World Bank. 1 55 Cancer care in resource-
constrained settings in particular suffers from a tremendous mismatch between supply
of trained personnel and resources and demand for services by a growing population of
cancer patients. Approximately 70% of deaths from cancer occur in LMICs according to
the World Health Organization.1 56 The majority of patients in LMICs lack healthcare
insurance and are expected to pay out of pocket for medical costs. Costs of care as well
as missed wages and travel expenses to seek specialized treatment in major urban
centers can have a major financial impact on families. Close to 100 million people are
being pushed into extreme poverty annually because of out-of-pocket healthcare
expenses according to a 2017 joint report by the World Health Organization and the
World Bank.1 57 These financial and access considerations underline the importance of
solutions that improve accessibility and cost-effectiveness of healthcare options for
patients in resource-constrained settings. The sustained-release chemotherapy
implants for treatment of peritoneal metastasis described in this thesis are well suited
for improving cancer care in LMICs. They can give patients the freedom to receive a
single implantation procedure and avoid follow-up care often requiring extensive travel,
while experiencing reduced toxicity that may allow them to still participate in the
workforce. They also give clinicians the freedom to control treatment in their setting and
not rely on patient follow-up to complete treatment courses.
India is particularly unique and well positioned for adoption of this proposed
technology. It has the clinician expertise and resources required for deployment of this
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technology in specialized cancer hospitals across the country and is a setting with a
long tradition of pioneering medical innovations to improve access to better
healthcare. 158 '1 59
The clinician survey deployed via the National Cancer Grid network led to accrual
of cancer care information relevant to this project from across the country. Responses
reflected care in public and private hospitals in many Indian states but came almost
entirely from specialized cancer centers. This is not surprising as cancer cases are
referred to specialty hospitals and clinics by primary and secondary care providers.
Multiple physician specialties involved in treating cancer patients were represented in
the survey allowing it to capture a more complete spectrum of cancer care across the
country. The survey was at the same time designed to pose peritoneal metastasis-
specific questions only to responders treating this patient population and so paint a
more detailed picture of this area of cancer care in the Indian setting.
The survey revealed that the decision to not perform surgical debulking in India is
driven by factors both resource-agnostic (patient ineligibility, no therapeutic or palliative
benefit) and specific to limited-resource environments (lack of access to expertise and
resources, cost). It is known that surgical debulking of patients with peritoneally
metastasized ovarian cancer prior to start of IP chemotherapy is critical for optimal
treatment outcome. Surgical debulking will likely be of similar importance if the implant
described in this thesis is used to treat patients with peritoneal metastasis of non-
ovarian origin with sustained low-dose local chemotherapy. The advanced ovarian
cancer patient population seen by Indian clinicians could be the focus of a follow-up
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survey attempting to quantify the frequency and quality of surgical debulking in these
patients.
The use of IP chemotherapy by Indian clinicians was found to mirror the situation
in the US and other high-resource countries. Catheter-and-port IP chemotherapy faces
poor clinical adoption and hospitals are building up capacity to perform new IP
techniques like HIPEC and PIPAC that are still under active research and
development.14 2 The reasons for not performing catheter-and-port IP chemotherapy in
India also capture the access and financing obstacles faced by patients in LMICs: lack
of expertise, resources and infrastructure as well as high cost are the top three reasons
on the list.
Indian physicians are not only adopting cutting-edge experimental IP
chemotherapy techniques like HIPEC and PIPAC but also making use of alternative
dosing regimens to minimize patient toxicity and increase adherence to treatment. More
than 90% of survey responders indicated awareness about metronomic chemotherapy.
Use of this regimen for peritoneal metastasis treatment was reported by 42% of
responders who indicated using metronomic chemotherapy in 1-25% of their peritoneal
metastasis patients. Use of metronomic chemotherapy in cancer care generally and in
peritoneal metastasis management specifically is very encouraging for adoption of the
sustained-release chemotherapy implant described in this project because its dosing
regimen is based on similar principles of toxicity minimization and drug-free period
reduction.
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Chapter 6: Conclusions and Future Work
6.1 Composite Material Development and Evaluation
The composite material developed in this thesis can form the basis for a cisplatin-eluting
implant that can be safe for IP placement and effective in releasing cisplatin in the
peritoneal cavity. The mechanical properties of CDDP25 make it well suited for creating
implants shaped like large thin sheets that can be folded down for placement inside the
patient's peritoneal cavity and still maximize surface area for drug release in vivo. This
work is still preliminary but the findings are promising for the creation of an implant for
continuous low-dose IP cisplatin delivery to treat residual tumors in ovarian cancer
patients following optimal surgical debulking. This implant can be used as a platform to
treat patients with peritoneal metastasis of different origin (gastrointestinal, primary
peritoneal etc.) and to incorporate other chemotherapeutic agents already established
or as those become available. Chemotherapeutics like carboplatin, gemcitabine,
topotecan and possibly mitomycin are already established attractive possible
candidates to attempt incorporating into the composite. Future work should focus on
such expansion of incorporated agents to make these implants true platforms for
sustained low-dose IP chemotherapy.
6.2 Spheroid-based Ovarian Cancer Models
The in vitro component of this section helps shed light to the question of the mechanism
controlling drug distribution into tumors following IP administration of chemotherapy.
The findings described in this thesis support the hypothesis that intratumoral drug
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distribution in nodules without access to vasculature is diffusion-controlled and that
continuous low-dose IP cisplatin treatment would be most effective againts microscopic
tumors.
The in vivo findings of this work taken together demonstrate that an in vivo
human ovarian cancer orthotopix xenograft model based on injection of size-controlled
multicellular spheroids is a viable approach to accelerate tumor growth and achieve
more widely distributed disease in mice. There exists an upper limit to the size of
spheroids that can be successfully injected in mice for practical and safety
considerations but smaller spheroids in fact appear to result in more diffuse disease and
fewer off-site lesions compared to larger spheroids.
This work paves the way for development of a robust animal model to evaluate
continuous low-dose IP chemotherapy developed at optimal doses in clinically relevant
preclinical models of ovarian cancer that capture the debulked subcentimeter disease in
patients. The next step in developing these models is to more systematically
characterize the size and distribution of tumor nodules over time after spheroid injection
and use the information to determine the appropriate time point for start of continuous
low-dose treatment using cisplatin-eluting IP implants such that it captures this
subcentimeter diffuse disease.
Another component of developing this spheroid in vivo model approach is to
attempt establishing a spheroid model in immunocompetent animals bearing mouse-
derived ovarian tumors. The immune system is hypothesized to play a critical role in the
antitumor outcome of sustained low-dose chemotherapy. It is important to reveal any
antitumor immunomodulatory effect of sustained low-dose chemotherapy and so work
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to harness it alongside the cytotoxic capacity of the chemotherapeutic agent. '460 A pilot
study pioneering the use of mouse-derived MOC-1 ovarian cancer cells to create
orthotopic allografts in immunocompetent C57BL/6 wildtype mice revealed challenges in
in vitro spheroid formation with these cells as well as difficulties in successfuly
inoculating mice with MOC-1 tumors. Studies exploring optimization of MOC-1 spheroid
formation by co-culturing MOC-1 cells with mouse fibroblasts to promote ECM
production or including matrigel in the spheroid formation process in order to promote
cell aggregation into spheroids are planned and underway.
6.3 Composite Material Optimization for In Vivo Use, Dosing Studies and
Efficacy Pilot
The behavior of the thinner CDDP25 formulation considered on the basis of structure,
mechanical properties, cisplatin release and biocompatibility was well predicted by the
previously developed thick CDDP25 formulation. This behavior makes the thinner
composite material well suited for in vivo IP implantation to deliver cisplatin as a
chemotherapeutic agent regimen against peritoneal metastases of ovarian cancer. The
thinner formulation allows straightforward dose calibration by modifying its surface area
for release and enables implantation through a small abdominal incision in mice to
minimize surgical trauma and complications. Preliminary antitumor efficacy findings
from a study that suffered serious drawbacks nonetheless support the hypothesis that
the thinner CDDP25 formulation is better suited for in vivo tumor treatment. The proof-
of-concept origami sheet prototypes created out of Ecoflex 00-30 or LAC50 illustrated
the potential of this approach to create deployable structures that can be folded down
and introduced to the peritoneal cavity through a laparoscopic trocar and opened up
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once inside the abdomen. Further shape design optimization and research into
appropriate origami tessellations to reach the desired minimum dimension that would
allow introduction through a 12-mm trocar are needed. A full mechanical
characterization of the material both as a sheet and in its final three-dimensional shape
as an implant is needed to ensure safety for laparoscopic implantation, manipulation, in
vivo presence and removal. Testing criteria applied to indwelling catheters and other
peritoneal implants can be used to ensure the developed materials and implants can
withstand the expected forces with safety for the patient. Assessment of the tolerability
and functionality of large-scale implants sized for human patients can be carried out in
large animals such as pigs as a next step closer to a patient clinical trial. A patient trial
comparing dose-dense to high-dose intermittent IP/IV therapy in ovarian cancer as
described by Tanenbaum will also help promote clinical translation of these implants.46
6.4 Potential for Technology Adoption in LMICs
The critical role of accessibility and cost-effectiveness in providing treatment to patients
and the overwhelmingly positive attitude toward adoption of new technologies for IP
chemotherapy and of different dosing regimens (e.g. metronomic therapy) are very
encouraging for the future of this work in the LMIC setting. Collaboration with centers
currently performing cutting-edge IP chemotherapy treatments like HIPEC or PIPAC can
help reveal potential synergies between those treatments and the proposed implant or
otherwise help shape the implant use scenario in a resource-constrained setting.
Adoption of the technology described in this thesis by physicians in LMICs like India can
affect the life of millions of cancer patients in the developing world.
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Appendix
A.1 Indian Clinician Survey
Tata Project IP Chemotherapy Survey
Start of Block:- Background lnf
Info: This survey is part of an MIT research project. It should take
minutes to complete.
approximately 5
Your decision to complete this survey is voluntary and you may stop at any time. This is
an anonymous survey, unless if you choose to share your email with us. The results of
the research may be presented at scientific meetings or published in scientific journals.
Clicking on the 'SUBMIT' button at the end of this survey indicates that you are at least
18 years of age and agree to complete this survey voluntarily.
*
1 What is your primary hospital/clinic affiliation?
please answer NA)
Please also indicate location. (If none,
*N
1 b What is your email address? (Optional)
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2 What best describes your role?
Physician (1)
Other healthcare provider (nurse, nurse assistant etc.) (2)
Other: please specify (3)
3 Are you involved in the care of cancer patients?
O Yes (1)
o No (2)
End of Block: Background Info
Start of Blockl: 0!hysiciarfs
1.1 What is your specialty?
End of Biock: Physicians
Start of Block: Physicians with cancer patients
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2.1 Approximately what percentage of your cancer patients suffer from peritoneal
metastasis?
0 None (1)
( 1-25% (2)
0 26-50% (3)
051-75% (4)
0 76-99% (5)
Everyone (6)
2.2 Are you familiar with intraperitoneal (IP) chemotherapy, either given through a
catheter into the patient's abdomen every few weeks or done during surgery as HIPEC?
0 Yes (1)
0 No (2)
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2.2.1 In your opinion, what are the chief challenges with performing catheter-and-port
intraperitoneal (IP) chemotherapy? (You can select more than one)
EDLack of appropriate infrastructure/hospital resources (1)
E: Lack of appropriately trained nursing staff (2)
E Cost (3)
E Patient not eligible for IP chemotherapy (age, health status) (4)
ESuboptimal or no surgical debulking (5)
ECatheter or port complications (6)
EDDrug toxicity (7)
ELoss to follow-up or poor patient adherence (12)
E Infection risk due to poor catheter or port maintenance (8)
EPhysician preference (9)
EDPatient preference (10)
E Other: please specify (11)
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2.2.2 Would you consider trying a new technology to deliver IP chemotherapy using an
implant that reduces toxicity and side effects for patients, is less complicated and
requires fewer resources?
O Definitely yes (1)
o Probably yes (2)
0 Might or might not (3)
0 Probably not (4)
o Definitely not (5)
2.3 Are you familiar with metronomic chemotherapy, given at a lower dose more
frequently to reduce toxicity and improve patient adherence to the treatment?
O Yes (1)
o No (2)
End of Biock: Physicians with cancer patients
Start of Block: Physicians with peritoneal metastasis patients
3.1 Approximately what portion of your patients with peritoneal metastasis undergo
surgical tumor debulking?
o None (1)
o 1-25% (2)
o 26-50% (3)
C 51-75% (4)
o 76-99% (5)
o Everyone (6)
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3.2 In your opinion, what are the chief reasons why surgical debulking will not be
performed on a patient with peritoneal metastasis? (You can select more than one)
QCost (1)
L Lack of appropriate infrastructure/hospital resources (2)
L Lack of appropriately trained staff (3)
0DNo therapeutic or palliative benefit (4)
EPatient not eligible (5)
0 Patient preference (6)
LPhysician preference (7)
Other: please specify (8)
3.3 Approximately how many of your patients with peritoneal metastasis undergo
chemotherapy?
26-50% 51-75% 76-99% Everyone
None (1) 1-25% (2) (3(4(5(6(3) (4) ()(6)
Chemotherapy
before surgical
debulking (1)000
Chemotherapy
after surgical 0 0 0 0 0 0debulking (2)
Chemotherapy
without
surgical 0 0 0 0 0 0
debulking (3)
End of Block: Physicians with peritoneal metastasis patients
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I
Display This Question:.
If Are you familiar with intraperitoneal (IP) chemotherapy, either given through a catheter into the
Yes
4.1 Approximately how many of your patients with peritoneal metastasis receive any
kind of intraperitoneal (IP) chemotherapy while under your care (incl. HIPEC, IP/lV
combo etc.)?
None (1)
1-25% (2)
O 26-50% (5)
051-75% (6)
0 76-99% (7)
C Everyone (8)
Display This Question:
If Approximately how many of your patients with peritoneal metastasis receive any kind of intrape
=1-25%
Or Approximately how many of your patients with peritoneal metastasis receive any kind ofintraperit... = 26-50%
Or Approximately how many of your patients with peritoneal metastasis receive any kind ofintraperit... = 51-75%
Or Approximately how many of your patients with peritoneal metastasis receive any kind ofin trap erit... = 76-99%
Or Approximately how many of your patients with peritoneal metastasis receive any kind ofintraperit... = Everyone
4.2 What is the most common type of IP chemotherapy that these patients receive?
) catheter-and-port IP infusions (1)
0 HIPEC (2)
Other: please specify (3)
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4.3 Approximately what percentage of patients with peritoneal metastasis get treated
with metronomic chemotherapy?
o None (1)
o 1-25% (2)
o 26-50% (3)
051-75% (4)
0 76-99% (5)
0 Everyone (6)
End of Block: Physicians with peritoneal metastasis patients + chemotherapy
Start of Block: Other healthcare providers
5.1 Approximately what portion of the cancer patients you care for receive
chemotherapy?
0 None (1)
0 1-25% (2)
0 26-50% (3)
0 51-75% (4)
0 76-99% (5)
0 Everyone (6)
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5.2 Are you familiar with intraperitoneal (IP) chemotherapy, either given through a
catheter into the patient's abdomen every few weeks or done during surgery as HIPEC
to treat peritoneal metastasis?
Yes (1)
C No (2)
5.3 Are you familiar with metronomic chemotherapy, given at a lower dose more
frequently to reduce toxicity and improve patient adherence to the treatment?
Yes (1)
0 No (2)
5.3.1 In your opinion, how frequently is metronomic chemotherapy used to treat the
cancer patients you care for?
o Never (1)
o Rarely (2)
Sometimes (3)
Often (4)
( Always (5)
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5.4 Approximately how many of the cancer patients you care for receive any kind of IP
chemotherapy while under your care (incl. HIPEC, IP/IV combo etc.)?
o None (1)
o 1-25% (2)
o 26-50% (5)
o 51-75% (6)
o 76-99% (7)
0 Everyone (8)
5.4.1 What is the most common type of IP chemotherapy that these patients receive?
o catheter-and-port IP infusions (1)
o HIPEC (2)
0 Other: please specify (3)
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5.5 In your opinion, what are the chief challenges with performing catheter-and-
port intraperitoneal (IP) chemotherapy? (You can select more than one)
LiLack of appropriate infrastructure/hospital resources (1)
0 Lack of appropriately trained nursing staff (2)
Li Cost (3)
D Patient not eligible for IP chemotherapy (age, health status) (4)
,-Suboptimal or no surgical debulking (5)
LiCatheter or port complications (6)
L Drug toxicity (7)
LLoss to follow-up or poor patient adherence (12)
LInfection risk due to poor catheter or port maintenance (8)
LPhysician preference (9)
L Patient preference (10)
LOther: please specify (11)
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5.6 Would you consider trying a new technology to deliver IP chemotherapy using an
implant that reduces toxicity and side effects for patients, is less complicated and
requires fewer resources?
O Definitely yes (1)
o Probably yes (2)
o Might or might not (3)
o Probably not (4)
o Definitely not (5)
End of Block: Other healthcare providers
Start of Block: Other
6.1 Are you familiar with intraperitoneal (IP) chemotherapy, either given through a
catheter into the patient's abdomen every few weeks or done in the OR as HIPEC?
O Yes (1)
0 No (2)
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6.1.1 In your opinion, what are the chief challenges with performing catheter-and-
port intraperitoneal (IP) chemotherapy? (You can select more than one)
0 Lack of appropriate infrastructure/hospital resources (1)
E Lack of appropriately trained nursing staff (2)
ECost (3)
Patient not eligible for IP chemotherapy (age, health status) (4)
OSuboptimal or no surgical debulking (5)
tm Catheter or port complications (6)
L Drug toxicity (7)
ELoss to follow-up or poor patient adherence (12)
EInfection risk due to poor catheter or port maintenance (8)
EPhysician preference (9)
E Patient preference (10)
EOther: please specify (11)
6.2 Are you familiar with metronomic chemotherapy, given at a lower dose more
frequently to reduce toxicity and improve patient adherence to the treatment?
O Yes (1)
0 No (2)
239
6.2.1 In your opinion, how frequently is metronomic chemotherapy used to treat cancer
patients?
o Never (1)
o Rarely (2)
o Sometimes (3)
o Often (4)
o Always (5)
End of Block: Other
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